US20170029457A1 - Methods for the synthesis of functionalized nucleic acids - Google Patents
Methods for the synthesis of functionalized nucleic acids Download PDFInfo
- Publication number
- US20170029457A1 US20170029457A1 US15/222,910 US201615222910A US2017029457A1 US 20170029457 A1 US20170029457 A1 US 20170029457A1 US 201615222910 A US201615222910 A US 201615222910A US 2017029457 A1 US2017029457 A1 US 2017029457A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- aryl
- alkenyl
- alkynyl
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [3*]C1[C@H]([BaH])O[C@H](C[W]P([H])(=[W])[W][C@@H]2C([3*])[C@H]([BaH])O[C@@H]2C[4*])[C@@H]1O[5*] Chemical compound [3*]C1[C@H]([BaH])O[C@H](C[W]P([H])(=[W])[W][C@@H]2C([3*])[C@H]([BaH])O[C@@H]2C[4*])[C@@H]1O[5*] 0.000 description 36
- YGRSKOVOWODMDN-COUSVAMISA-N CC/C=C\CS.CCC(C)(C)CCS.CCC1=C(C(=O)S)C=CC=C1.CCC1=C(CC(=O)S)C=CC=C1.CCC1=C(CCS)C=CC=C1.CCC1=C(CS)C=CC=C1.CCCC(C)(C)CCS.CCCC(C)(C)CS.CCCCCS Chemical compound CC/C=C\CS.CCC(C)(C)CCS.CCC1=C(C(=O)S)C=CC=C1.CCC1=C(CC(=O)S)C=CC=C1.CCC1=C(CCS)C=CC=C1.CCC1=C(CS)C=CC=C1.CCCC(C)(C)CCS.CCCC(C)(C)CS.CCCCCS YGRSKOVOWODMDN-COUSVAMISA-N 0.000 description 4
- NXNDHQCXKPYVTO-FGSKAQBVSA-N C.CS(=O)(=O)SC/C=C\CSS(C)(=O)=O.CS(=O)(=O)SCCSS(C)(=O)=O.CS(=O)(=O)SCSS(C)(=O)=O Chemical compound C.CS(=O)(=O)SC/C=C\CSS(C)(=O)=O.CS(=O)(=O)SCCSS(C)(=O)=O.CS(=O)(=O)SCSS(C)(=O)=O NXNDHQCXKPYVTO-FGSKAQBVSA-N 0.000 description 3
- DEEUTQILNXEHLR-UHFFFAOYSA-M CCCN(C)(C)C.CCCN(C)C.CCCN1CCCC1C(=O)OC.CCCN1CCN(C)CC1.CCCN1CCOCC1.[Cl-] Chemical compound CCCN(C)(C)C.CCCN(C)C.CCCN1CCCC1C(=O)OC.CCCN1CCN(C)CC1.CCCN1CCOCC1.[Cl-] DEEUTQILNXEHLR-UHFFFAOYSA-M 0.000 description 3
- QCNBIIZXNXUOGB-UHFFFAOYSA-N C.CC(=O)OCC1OC(C)C(OC(C)=O)C(C)C1C.CCCN(C)C.CCCN1CCCC1.CCCN1CCCC1C(=O)OC.CCCN1CCN(C)CC1.CCCN1CCOCC1.CCC[N+](C)(C)C Chemical compound C.CC(=O)OCC1OC(C)C(OC(C)=O)C(C)C1C.CCCN(C)C.CCCN1CCCC1.CCCN1CCCC1C(=O)OC.CCCN1CCN(C)CC1.CCCN1CCOCC1.CCC[N+](C)(C)C QCNBIIZXNXUOGB-UHFFFAOYSA-N 0.000 description 2
- DEEUTQILNXEHLR-UHFFFAOYSA-N CCCN(C)(C)C.CCCN(C)C.CCCN1CCCC1C(=O)OC.CCCN1CCN(C)CC1.CCCN1CCOCC1.Cl Chemical compound CCCN(C)(C)C.CCCN(C)C.CCCN1CCCC1C(=O)OC.CCCN1CCN(C)CC1.CCCN1CCOCC1.Cl DEEUTQILNXEHLR-UHFFFAOYSA-N 0.000 description 2
- VCACEYDQKGNVAF-ITCIDZDISA-N [H][P@@](=O)(OC[C@H]1O[C@@H](N2C=NC3=C2N=CN=C3NC(=O)COC2=CC=CC=C2)CC1O[P@]([H])(=O)OC[C@H]1O[C@@H](N2C=NC3=C2N=C(NC(=O)COC2=CC=CC=C2)N=C3OCCC#N)CC1O[P@]([H])(=O)OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(=O)C(=O)NC)OC1C[C@H](N2C=CC(NC(C)=O)=NC2=O)O[C@@H]1CO Chemical compound [H][P@@](=O)(OC[C@H]1O[C@@H](N2C=NC3=C2N=CN=C3NC(=O)COC2=CC=CC=C2)CC1O[P@]([H])(=O)OC[C@H]1O[C@@H](N2C=NC3=C2N=C(NC(=O)COC2=CC=CC=C2)N=C3OCCC#N)CC1O[P@]([H])(=O)OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(=O)C(=O)NC)OC1C[C@H](N2C=CC(NC(C)=O)=NC2=O)O[C@@H]1CO VCACEYDQKGNVAF-ITCIDZDISA-N 0.000 description 2
- HWSDILYZOYLQMG-FOWGLRFMSA-N BrCBr.BrCCBr.CC(C)(C)C(=O)OC1=C(COS(C)(=O)=O)C=CC=C1.CC(C)(C)C(=O)OCCl.CCC1=C(COS(C)(=O)=O)C=CC=C1.OCC1=C(CO)C=CC=C1.OCC1=C(O)C=CC=C1.[3H]C(S)CC1=C(CC)C=CC=C1.[3H]C(S)CC1=C(OC(=O)C(C)(C)C)C=CC=C1.[3H]SCCC([3H])S.[3H]SCCCC([3H])S.[3H]SCCCSSCCN1CCOCC1.[3H]SCCOC(=O)C(C)(C)C Chemical compound BrCBr.BrCCBr.CC(C)(C)C(=O)OC1=C(COS(C)(=O)=O)C=CC=C1.CC(C)(C)C(=O)OCCl.CCC1=C(COS(C)(=O)=O)C=CC=C1.OCC1=C(CO)C=CC=C1.OCC1=C(O)C=CC=C1.[3H]C(S)CC1=C(CC)C=CC=C1.[3H]C(S)CC1=C(OC(=O)C(C)(C)C)C=CC=C1.[3H]SCCC([3H])S.[3H]SCCCC([3H])S.[3H]SCCCSSCCN1CCOCC1.[3H]SCCOC(=O)C(C)(C)C HWSDILYZOYLQMG-FOWGLRFMSA-N 0.000 description 1
- COHBPXFGRFRWFH-DMDZFWCPSA-J BrCCN12CCC(CC1)CC2.CC(C)(CO)CO.CC(C)(CO[Si](C)(C)C)CSC(=O)CCN1CCOCC1.CCC1=C(COS(C)(=O)=O)C=CC=C1.CN(C)(C)CCBr.COC(=O)CCBr.COC(=O)CCl.NCC1=C(CO)C=CC=C1.O=C(S)CCN1CCOCC1.[3H]C(S)CC1=C(CC)C=CC=C1.[3H]SCCC(=O)OC.[3H]SCCCC(=O)OC.[3H]SCCCN(C)(C)C.[3H]SCCCN12CCC(CC1)CC2.[Br-].[Br-].[Br-].[Br-] Chemical compound BrCCN12CCC(CC1)CC2.CC(C)(CO)CO.CC(C)(CO[Si](C)(C)C)CSC(=O)CCN1CCOCC1.CCC1=C(COS(C)(=O)=O)C=CC=C1.CN(C)(C)CCBr.COC(=O)CCBr.COC(=O)CCl.NCC1=C(CO)C=CC=C1.O=C(S)CCN1CCOCC1.[3H]C(S)CC1=C(CC)C=CC=C1.[3H]SCCC(=O)OC.[3H]SCCCC(=O)OC.[3H]SCCCN(C)(C)C.[3H]SCCCN12CCC(CC1)CC2.[Br-].[Br-].[Br-].[Br-] COHBPXFGRFRWFH-DMDZFWCPSA-J 0.000 description 1
- IVDUPGCHCWNMLI-UHFFFAOYSA-N C.C.C.C.C=CCC(C)(C)C.C=CCOC(=O)C(C)(C)C.C=CCOC=O.CB=O.CC(=O)C(C)(C)C.CC(C)(C)C(=O)OCC1=CC=CC=C1.CC(C)(C)C(C)(C)C.CC(C)(C)C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.CC(C)(C)CC1=CC=C(CO)C=C1.CC(C)(C)CC1=CC=CC=C1.CC(C)(C)OC(=O)C(C)(C)C.CC(C)C.CC(C)C(=O)OCC1C2=CC=CC=C2C2=C1C=CC=C2.CC(C)C(=O)OCC[Si](C)(C)C.CC(C)[Si](C)(C)C(C)(C)C.COC1=CC=C(C)C=C1.C[SiH](C)C(C)(C)C.O=COCC1=CC=CC=C1 Chemical compound C.C.C.C.C=CCC(C)(C)C.C=CCOC(=O)C(C)(C)C.C=CCOC=O.CB=O.CC(=O)C(C)(C)C.CC(C)(C)C(=O)OCC1=CC=CC=C1.CC(C)(C)C(C)(C)C.CC(C)(C)C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.CC(C)(C)CC1=CC=C(CO)C=C1.CC(C)(C)CC1=CC=CC=C1.CC(C)(C)OC(=O)C(C)(C)C.CC(C)C.CC(C)C(=O)OCC1C2=CC=CC=C2C2=C1C=CC=C2.CC(C)C(=O)OCC[Si](C)(C)C.CC(C)[Si](C)(C)C(C)(C)C.COC1=CC=C(C)C=C1.C[SiH](C)C(C)(C)C.O=COCC1=CC=CC=C1 IVDUPGCHCWNMLI-UHFFFAOYSA-N 0.000 description 1
- NMBQMKYEBIZWFM-UHFFFAOYSA-N C.CC(=O)OCC1OC(S)C(OC(C)=O)C(C)C1C.CCCN(C)C.CCCN1CCCC1.CCCN1CCCC1C(=O)OC.CCCN1CCN(C)CC1.CCCN1CCOCC1.CCC[N+](C)(C)C Chemical compound C.CC(=O)OCC1OC(S)C(OC(C)=O)C(C)C1C.CCCN(C)C.CCCN1CCCC1.CCCN1CCCC1C(=O)OC.CCCN1CCN(C)CC1.CCCN1CCOCC1.CCC[N+](C)(C)C NMBQMKYEBIZWFM-UHFFFAOYSA-N 0.000 description 1
- AFKZSWHIFFAIJV-HEZSDDSDSA-N C.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)SC.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OP(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)O[Si](C)(C)C.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1O[PH](=O)OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1.O=C(B=S)C(F)(F)F Chemical compound C.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)SC.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OP(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)O[Si](C)(C)C.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1O[PH](=O)OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1.O=C(B=S)C(F)(F)F AFKZSWHIFFAIJV-HEZSDDSDSA-N 0.000 description 1
- KZRBJZMDAKJUOE-UHFFFAOYSA-N C1=CC2=C(C=C1)CC=C2.C1=CC2=C(C=C1)N=CC2.C1=CC2=C(C=C1)N=CC=N2.C1=CC2=C(C=C1)OC=N2.C1=CC2=C(C=C1)SC=C2.C1=CC2=C(C=CS2)S1.C1=CC=C2N=C3C=CC=CC3=CC2=C1.C1=CC=NC=C1.C1=CC=NC=C1.C1=CCC=C1.C1=CCC=C1.C1=CN=CC1.C1=CN=CC1.C1=CN=CC=N1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CN=NC=C1.C1=COC=C1.C1=COC=C1.C1=COC=N1.C1=CSC=C1.C1=CSC=C1.C1=CSC=N1.C1=NC=NC2=C1CC=N2 Chemical compound C1=CC2=C(C=C1)CC=C2.C1=CC2=C(C=C1)N=CC2.C1=CC2=C(C=C1)N=CC=N2.C1=CC2=C(C=C1)OC=N2.C1=CC2=C(C=C1)SC=C2.C1=CC2=C(C=CS2)S1.C1=CC=C2N=C3C=CC=CC3=CC2=C1.C1=CC=NC=C1.C1=CC=NC=C1.C1=CCC=C1.C1=CCC=C1.C1=CN=CC1.C1=CN=CC1.C1=CN=CC=N1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CN=NC=C1.C1=COC=C1.C1=COC=C1.C1=COC=N1.C1=CSC=C1.C1=CSC=C1.C1=CSC=N1.C1=NC=NC2=C1CC=N2 KZRBJZMDAKJUOE-UHFFFAOYSA-N 0.000 description 1
- NDNZXKFGUGLUTC-UHFFFAOYSA-N C1=CC=C2OCCOC2=C1.C1=CCCC1.C1=CCCCC1.C1=COC=CC1.C1=CSC=CC1.C1=NCCC1.C1=NCCO1.C1CC2CCC1O2.C1CCCC1.C1CCCCC1.C1CCN2CCCCC2C1.C1CCNC1.C1CCNCC1.C1CCOC1.C1CCOC1.C1CCOCC1.C1CCSC1.C1CN2CCC1NC2.C1CO1.C1COCCN1.C1CSCCS1.O=C1CCCC1.O=C1CCCC1.O=C1CCCC1.O=C1CCCN1.O=C1CCCO1.O=C1NCCCO1.O=S1(=O)CCCC1.O=S1(=O)CCCCCN1 Chemical compound C1=CC=C2OCCOC2=C1.C1=CCCC1.C1=CCCCC1.C1=COC=CC1.C1=CSC=CC1.C1=NCCC1.C1=NCCO1.C1CC2CCC1O2.C1CCCC1.C1CCCCC1.C1CCN2CCCCC2C1.C1CCNC1.C1CCNCC1.C1CCOC1.C1CCOC1.C1CCOCC1.C1CCSC1.C1CN2CCC1NC2.C1CO1.C1COCCN1.C1CSCCS1.O=C1CCCC1.O=C1CCCC1.O=C1CCCC1.O=C1CCCN1.O=C1CCCO1.O=C1NCCCO1.O=S1(=O)CCCC1.O=S1(=O)CCCCCN1 NDNZXKFGUGLUTC-UHFFFAOYSA-N 0.000 description 1
- KBOOOMNZWNSARF-WVNXDIGBSA-N C1=CSC=C1.C=C(SC(=C)C(C)C)C1=CC=C(C2=CC=CS2)S1.C=CC1=CSC(C2=CC=C(C(C)C)S2)=C1C=C.CC(C)C1=C2C=C3C=CC=N4CCCC(=C34)C2=OC(=O)=C1.CC(C)C1=CC=C(/C=C/C2=CC=CC=C2)C=C1.CC(C)C1=CC=C(C2=CC=C(C3=CC=CC=C3)C=C2)C=C1.CC(C)C1=CC=C(CCNC(=O)CCCC(=O)NC2=CC=C(/C=C/C3=CC=CC=C3)C=C2)C=C1.CC(C)N1C(=O)NC(=O)C2=C1C=C1C=CC=CC1=C2.CC(C)N1C(=O)NC(=O)C2=C1C=CC=C2.CC(C)N1C(=O)NC(=O)C2=C1N=CC=N2.CC(C)N1C=CN2C(=O)NC(=O)NC21.CN1=C(=O)C=NC2=C1NC(N)NC2=O Chemical compound C1=CSC=C1.C=C(SC(=C)C(C)C)C1=CC=C(C2=CC=CS2)S1.C=CC1=CSC(C2=CC=C(C(C)C)S2)=C1C=C.CC(C)C1=C2C=C3C=CC=N4CCCC(=C34)C2=OC(=O)=C1.CC(C)C1=CC=C(/C=C/C2=CC=CC=C2)C=C1.CC(C)C1=CC=C(C2=CC=C(C3=CC=CC=C3)C=C2)C=C1.CC(C)C1=CC=C(CCNC(=O)CCCC(=O)NC2=CC=C(/C=C/C3=CC=CC=C3)C=C2)C=C1.CC(C)N1C(=O)NC(=O)C2=C1C=C1C=CC=CC1=C2.CC(C)N1C(=O)NC(=O)C2=C1C=CC=C2.CC(C)N1C(=O)NC(=O)C2=C1N=CC=N2.CC(C)N1C=CN2C(=O)NC(=O)NC21.CN1=C(=O)C=NC2=C1NC(N)NC2=O KBOOOMNZWNSARF-WVNXDIGBSA-N 0.000 description 1
- AITJTWGANNPGBY-ACNVFJPWSA-N C1C2CC1C2.C1C2CC3CC1CC(C2)C3.C1CC1.C1CC2CC(C1)C2.C1CC2CC1C2.C1CC2CCC1C2.C1CC2CCC1CC2.C1CCC1.C1CCC2(CC1)CCCCC2.C1CCCC1.C1CCCCC1.C1CCCCCC1.C1CCCCCCC1.[H][C@@]12CCCC[C@]1([H])CC2.[H][C@@]12CCC[C@]1([H])C2.[H][C@@]12CC[C@]1([H])C2.[H][C@]12CCCC[C@@]1([H])CCCC2.[H][C@]12CCCC[C@@]1([H])CCCC2.[H][C@]12CCC[C@@]1([H])CCC2 Chemical compound C1C2CC1C2.C1C2CC3CC1CC(C2)C3.C1CC1.C1CC2CC(C1)C2.C1CC2CC1C2.C1CC2CCC1C2.C1CC2CCC1CC2.C1CCC1.C1CCC2(CC1)CCCCC2.C1CCCC1.C1CCCCC1.C1CCCCCC1.C1CCCCCCC1.[H][C@@]12CCCC[C@]1([H])CC2.[H][C@@]12CCC[C@]1([H])C2.[H][C@@]12CC[C@]1([H])C2.[H][C@]12CCCC[C@@]1([H])CCCC2.[H][C@]12CCCC[C@@]1([H])CCCC2.[H][C@]12CCC[C@@]1([H])CCC2 AITJTWGANNPGBY-ACNVFJPWSA-N 0.000 description 1
- CUHNLYBJZVGELA-COUSVAMISA-N C=C(S)CC1=C(CC)C=CC=C1.CC/C=C\CS.CCC(C)(C)CCS.CCC1=C(C(=O)S)C=CC=C1.CCC1=C(CCS)C=CC=C1.CCC1=C(CS)C=CC=C1.CCCC(C)(C)CCS.CCCC(C)(C)CS.CCCCCS Chemical compound C=C(S)CC1=C(CC)C=CC=C1.CC/C=C\CS.CCC(C)(C)CCS.CCC1=C(C(=O)S)C=CC=C1.CCC1=C(CCS)C=CC=C1.CCC1=C(CS)C=CC=C1.CCCC(C)(C)CCS.CCCC(C)(C)CS.CCCCCS CUHNLYBJZVGELA-COUSVAMISA-N 0.000 description 1
- NVIDYLJZLPMYKF-UHFFFAOYSA-L C=CC(F)(F)F.CCC(=O)OC.CCC(C)(C)CCSC(=O)CCN1CCOCC1.CCC(C)(C)CSC(=O)CCN1CCOCC1.CCC1=C(CNC(C)=O)C=CC=C1.CCC1=C(COC(=O)C(C)(C)C)C=CC=C1.CCC1=C(OC(=O)C(C)(C)C)C=CC=C1.CCCC(=O)OC.CCCN(C)(C)C.CCCN12CCC(CC1)CC2.CCCSSCCN1CCOCC1.CCOC(=O)C(C)(C)C.CCOC(=O)OC(C)C.[Br-].[Br-] Chemical compound C=CC(F)(F)F.CCC(=O)OC.CCC(C)(C)CCSC(=O)CCN1CCOCC1.CCC(C)(C)CSC(=O)CCN1CCOCC1.CCC1=C(CNC(C)=O)C=CC=C1.CCC1=C(COC(=O)C(C)(C)C)C=CC=C1.CCC1=C(OC(=O)C(C)(C)C)C=CC=C1.CCCC(=O)OC.CCCN(C)(C)C.CCCN12CCC(CC1)CC2.CCCSSCCN1CCOCC1.CCOC(=O)C(C)(C)C.CCOC(=O)OC(C)C.[Br-].[Br-] NVIDYLJZLPMYKF-UHFFFAOYSA-L 0.000 description 1
- JLNGIFPJGMMLRK-YFFKFFCBSA-N CC(=O)NC1C(S)OC(CO)C(O)C1O.CC(=O)NC1C(SSC/C=C\CSP(=O)(OC[C@H]2O[C@@H](N3C=C(C)C(=O)NC3=O)CC2O)OC2C[C@H](N3C=C(C)C(=O)NC3=O)O[C@@H]2CO)OC(CO)C(O)C1O.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)SC/C=C\CSSC1OC(CO)C(O)C(O)C1NC(C)=O.[3H]SCC/C=C\CSP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)OC1C[C@H](N2C=C(C)C(=O)NC2=O)O[C@@H]1CC Chemical compound CC(=O)NC1C(S)OC(CO)C(O)C1O.CC(=O)NC1C(SSC/C=C\CSP(=O)(OC[C@H]2O[C@@H](N3C=C(C)C(=O)NC3=O)CC2O)OC2C[C@H](N3C=C(C)C(=O)NC3=O)O[C@@H]2CO)OC(CO)C(O)C1O.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)SC/C=C\CSSC1OC(CO)C(O)C(O)C1NC(C)=O.[3H]SCC/C=C\CSP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)OC1C[C@H](N2C=C(C)C(=O)NC2=O)O[C@@H]1CC JLNGIFPJGMMLRK-YFFKFFCBSA-N 0.000 description 1
- VCHPJRCUOYPJQZ-QTTLQANQSA-N CC(=O)OCC1O[C@@H](S)C(OC(C)=O)[C@@H](C)[C@@H]1C.CC/C=C\COC(=O)C(C)(C)C.CC/C=C\COS(C)(=O)=O.OC/C=C\CO.SCCN1CCOCC1.[3H]C(S)C/C=C\CSS[C@@H]1OC(COC(C)=O)[C@@H](C)[C@H](C)C1OC(C)=O.[3H]SCC/C=C\CC([3H])S.[3H]SCC/C=C\COC(=O)C(C)(C)C.[3H]SCC/C=C\CSSCCN1CCOCC1.[3H]SCCCO.[3H]SCCCOC(=O)C(C)(C)C Chemical compound CC(=O)OCC1O[C@@H](S)C(OC(C)=O)[C@@H](C)[C@@H]1C.CC/C=C\COC(=O)C(C)(C)C.CC/C=C\COS(C)(=O)=O.OC/C=C\CO.SCCN1CCOCC1.[3H]C(S)C/C=C\CSS[C@@H]1OC(COC(C)=O)[C@@H](C)[C@H](C)C1OC(C)=O.[3H]SCC/C=C\CC([3H])S.[3H]SCC/C=C\COC(=O)C(C)(C)C.[3H]SCC/C=C\CSSCCN1CCOCC1.[3H]SCCCO.[3H]SCCCOC(=O)C(C)(C)C VCHPJRCUOYPJQZ-QTTLQANQSA-N 0.000 description 1
- MRNQIZKZCVIIAW-UHFFFAOYSA-N CC(C)(CCS)CC[IH]SCc1c(CSC(c2ccccc2CI)=O)cccc1 Chemical compound CC(C)(CCS)CC[IH]SCc1c(CSC(c2ccccc2CI)=O)cccc1 MRNQIZKZCVIIAW-UHFFFAOYSA-N 0.000 description 1
- IJSXPFMSPAXZDN-OUKFUNFYSA-N CC(C)(CO)CCO.CC(C)OC(=O)OCCl.CC1=CC=C(S(=O)(=O)OCC(C)(C)CSC(=O)CCN2CCOCC2)C=C1.CSS(=O)(=O)C1=CC=C(C)C=C1.CSS(C)(=O)=O.[3H]C(S)CC(C)(C)CSC(=O)CCN1CCOCC1.[3H]CC(C)(C)CCC.[3H]CC(C)(C)CCSC(=O)CCN1CCOCC1.[3H]S.[3H]S.[3H]SCCOC(=O)OC(C)C Chemical compound CC(C)(CO)CCO.CC(C)OC(=O)OCCl.CC1=CC=C(S(=O)(=O)OCC(C)(C)CSC(=O)CCN2CCOCC2)C=C1.CSS(=O)(=O)C1=CC=C(C)C=C1.CSS(C)(=O)=O.[3H]C(S)CC(C)(C)CSC(=O)CCN1CCOCC1.[3H]CC(C)(C)CCC.[3H]CC(C)(C)CCSC(=O)CCN1CCOCC1.[3H]S.[3H]S.[3H]SCCOC(=O)OC(C)C IJSXPFMSPAXZDN-OUKFUNFYSA-N 0.000 description 1
- ZFWHWDDMKOVBOO-HWNLDUAHSA-N CC(C)/C1=C2\C=C/C(=C/C3=N/C(=C(/C4=CC=CC=C4)C4=CC=C(/C=C5/C=CC1=N5)N4)C=C3)N2 Chemical compound CC(C)/C1=C2\C=C/C(=C/C3=N/C(=C(/C4=CC=CC=C4)C4=CC=C(/C=C5/C=CC1=N5)N4)C=C3)N2 ZFWHWDDMKOVBOO-HWNLDUAHSA-N 0.000 description 1
- FAYXIKUSZGSNAT-MEXJYRITSA-N CC(C)/N=C(\N)C(C)C.CC(C)/N=C(\O)C(C)C.CC(C)C.CC(C)C.CC(C)C(=N)O.CC(C)C(N)=O.CC(C)C1=NN=NC1.CC(C)C1=NN=NN1.CC(C)C1=NNN=N1.CC(C)C1=NNN=N1.CC(C)NC(=N)C(C)C.O=C1C=CC=CN1.OC1=NC=CC=C1.[H]/C(=C(/O)C(C)C)C(C)C.[H]C([H])(C(=O)C(C)C)C(C)C.[H]N(C(=O)C(C)C)C(C)C.[H]N1C(C(C)C)=CN=C1C(C)C.[H]N1C=NC(C(C)C)=C1 Chemical compound CC(C)/N=C(\N)C(C)C.CC(C)/N=C(\O)C(C)C.CC(C)C.CC(C)C.CC(C)C(=N)O.CC(C)C(N)=O.CC(C)C1=NN=NC1.CC(C)C1=NN=NN1.CC(C)C1=NNN=N1.CC(C)C1=NNN=N1.CC(C)NC(=N)C(C)C.O=C1C=CC=CN1.OC1=NC=CC=C1.[H]/C(=C(/O)C(C)C)C(C)C.[H]C([H])(C(=O)C(C)C)C(C)C.[H]N(C(=O)C(C)C)C(C)C.[H]N1C(C(C)C)=CN=C1C(C)C.[H]N1C=NC(C(C)C)=C1 FAYXIKUSZGSNAT-MEXJYRITSA-N 0.000 description 1
- LEBJYINPEKDJHN-UHFFFAOYSA-N CC(C)C1=C2/C=C\C3=C4C(=CC=C3)C=CC(=C24)C=C1.CC(C)C1=C2C=CC=CC2=C2/C=C\C=C/C2=C1.CC(C)C1=C2C=CC=CC2=CC=C1.CC(C)C1=CC2=CC=CC=C2C=C1.CC(C)C1=CC=CC=C1.CC(C)C1C=NC=N1.CC(C)N1C=CC([N+](=O)[O-])=C1.CC(C)N1C=CC=C1 Chemical compound CC(C)C1=C2/C=C\C3=C4C(=CC=C3)C=CC(=C24)C=C1.CC(C)C1=C2C=CC=CC2=C2/C=C\C=C/C2=C1.CC(C)C1=C2C=CC=CC2=CC=C1.CC(C)C1=CC2=CC=CC=C2C=C1.CC(C)C1=CC=CC=C1.CC(C)C1C=NC=N1.CC(C)N1C=CC([N+](=O)[O-])=C1.CC(C)N1C=CC=C1 LEBJYINPEKDJHN-UHFFFAOYSA-N 0.000 description 1
- KTWNSMPNMTZXAZ-UHFFFAOYSA-N CC(C)C1=CC2=C(C=C1)NC(=O)NC2=O.CC(C)C1=CC2=CC3=C(C=C2C=C1)NC(=O)NC3=O.CC(C)C1=CC2=CC3C(=O)N=C(N)N=C3C=C2C=C1.CC(C)N1C=CC2=C1C=CC1=C(N)NC(=O)N=C12.CC(C)N1C=CC2=C1C=CC1=CN=C(N)N=C=12.CC(C)N1C=NC2=C1C=C1N=C(N)N=C(=O)C1=C2.CC(C)N1C=NC2=C1C=C1N=CN=C(N)C1=C2.CC1=CC(C(C)C)=CC2=C1NC(=O)N=C2N.CC1=CC2=C(NC(=O)N=C2N)C(C(C)C)=C1.CC1=CC2=C(NC(=O)NC2=O)C(C(C)C)=C1 Chemical compound CC(C)C1=CC2=C(C=C1)NC(=O)NC2=O.CC(C)C1=CC2=CC3=C(C=C2C=C1)NC(=O)NC3=O.CC(C)C1=CC2=CC3C(=O)N=C(N)N=C3C=C2C=C1.CC(C)N1C=CC2=C1C=CC1=C(N)NC(=O)N=C12.CC(C)N1C=CC2=C1C=CC1=CN=C(N)N=C=12.CC(C)N1C=NC2=C1C=C1N=C(N)N=C(=O)C1=C2.CC(C)N1C=NC2=C1C=C1N=CN=C(N)C1=C2.CC1=CC(C(C)C)=CC2=C1NC(=O)N=C2N.CC1=CC2=C(NC(=O)N=C2N)C(C(C)C)=C1.CC1=CC2=C(NC(=O)NC2=O)C(C(C)C)=C1 KTWNSMPNMTZXAZ-UHFFFAOYSA-N 0.000 description 1
- PZDJRJUEIVPNMU-UHFFFAOYSA-N CC(C)COC1OC([BaH])C(O)C(O)C1OP(C)(=O)OC(C)C.CC(C)COC1OC([BaH])C(O)C(O)C1OP(C)(=O)OC(C)C.CC(C)COC1OC([BaH])CC(O)C1OP(C)(=O)OC(C)C.[H]OC1C(O)C([BaH])OC(OCC(C)C)C1OP(C)(=O)OC(C)C.[H]OC1CC(C)OC(OCC(C)C)C1OP(C)(=O)OC(C)C Chemical compound CC(C)COC1OC([BaH])C(O)C(O)C1OP(C)(=O)OC(C)C.CC(C)COC1OC([BaH])C(O)C(O)C1OP(C)(=O)OC(C)C.CC(C)COC1OC([BaH])CC(O)C1OP(C)(=O)OC(C)C.[H]OC1C(O)C([BaH])OC(OCC(C)C)C1OP(C)(=O)OC(C)C.[H]OC1CC(C)OC(OCC(C)C)C1OP(C)(=O)OC(C)C PZDJRJUEIVPNMU-UHFFFAOYSA-N 0.000 description 1
- ZIMBPJNUHUZKBP-UHFFFAOYSA-N CC(C)OC(C[BaH])COP(C)(=O)OC(C[BaH])COP(C)(=O)OC(C)C Chemical compound CC(C)OC(C[BaH])COP(C)(=O)OC(C[BaH])COP(C)(=O)OC(C)C ZIMBPJNUHUZKBP-UHFFFAOYSA-N 0.000 description 1
- QGOKWHVTMYHNDX-UHFFFAOYSA-N CC(C)OC1CCC([BaH])C(O)C1OP(C)(=O)OC(C)C.CC(C)OC1CCC([BaH])C(O)C1OP(C)(=O)OC(C)C.CC(C)OC1CCC([BaH])C(OP(C)(=O)OC(C)C)C1O.CC(C)OC1CCC([BaH])C(OP(C)(=O)OC(C)C)C1O.CC(C)OC1CCC([BaH])C(OP(C)(=O)OC(C)C)C1O.CC(C)OC1CCC([BaH])C1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])C(O)C(O)C1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])C(O)C(O)C1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])CC(O)C1OP(C)(=O)OC(C)C.[H]OC1C(O)C([BaH])CC(COC(C)C)C1OP(C)(=O)OC(C)C.[H]OC1C(OC(C)C)CCC([BaH])C1OP(C)(=O)OC(C)C.[H]OC1CC([BaH])CC(COC(C)C)C1OP(C)(=O)OC(C)C Chemical compound CC(C)OC1CCC([BaH])C(O)C1OP(C)(=O)OC(C)C.CC(C)OC1CCC([BaH])C(O)C1OP(C)(=O)OC(C)C.CC(C)OC1CCC([BaH])C(OP(C)(=O)OC(C)C)C1O.CC(C)OC1CCC([BaH])C(OP(C)(=O)OC(C)C)C1O.CC(C)OC1CCC([BaH])C(OP(C)(=O)OC(C)C)C1O.CC(C)OC1CCC([BaH])C1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])C(O)C(O)C1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])C(O)C(O)C1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])CC(O)C1OP(C)(=O)OC(C)C.[H]OC1C(O)C([BaH])CC(COC(C)C)C1OP(C)(=O)OC(C)C.[H]OC1C(OC(C)C)CCC([BaH])C1OP(C)(=O)OC(C)C.[H]OC1CC([BaH])CC(COC(C)C)C1OP(C)(=O)OC(C)C QGOKWHVTMYHNDX-UHFFFAOYSA-N 0.000 description 1
- ZATWMXKSVOIIOF-UHFFFAOYSA-N CC(C)OC1CCC([BaH])C(OP(C)(=O)OC(C)C)C1.CC(C)OC1CCC([BaH])C(OP(C)(=O)OC(C)C)C1.CC(C)OC1CCC([BaH])C1OP(C)(=O)OC(C)C.CC(C)OC1CCC([BaH])CC1OP(C)(=O)OC(C)C.CC(C)OC1CCC([BaH])CC1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])C(O)CC1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])C(O)CC1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])CC(O)C1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])CCC1OP(C)(=O)OC(C)C.[H]OC1CC(C)CC(COC(C)C)C1OP(C)(=O)OC(C)C Chemical compound CC(C)OC1CCC([BaH])C(OP(C)(=O)OC(C)C)C1.CC(C)OC1CCC([BaH])C(OP(C)(=O)OC(C)C)C1.CC(C)OC1CCC([BaH])C1OP(C)(=O)OC(C)C.CC(C)OC1CCC([BaH])CC1OP(C)(=O)OC(C)C.CC(C)OC1CCC([BaH])CC1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])C(O)CC1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])C(O)CC1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])CC(O)C1OP(C)(=O)OC(C)C.CC(C)OCC1CC([BaH])CCC1OP(C)(=O)OC(C)C.[H]OC1CC(C)CC(COC(C)C)C1OP(C)(=O)OC(C)C ZATWMXKSVOIIOF-UHFFFAOYSA-N 0.000 description 1
- XOZSPYLYLNFILM-UHFFFAOYSA-N CC(C)OC1CCC([BaH])C1OP(C)(=O)OC(C)C.CC(C)OC1COC([BaH])C1OP(C)(=O)OC(C)C Chemical compound CC(C)OC1CCC([BaH])C1OP(C)(=O)OC(C)C.CC(C)OC1COC([BaH])C1OP(C)(=O)OC(C)C XOZSPYLYLNFILM-UHFFFAOYSA-N 0.000 description 1
- IGLMPHLBEBUPHJ-UHFFFAOYSA-N CC(C)OC1COC(C)C(O)C1OP(C)(=O)OC(C)C.CC(C)OC1COC([BaH])C(O)C1OP(C)(=O)OC(C)C Chemical compound CC(C)OC1COC(C)C(O)C1OP(C)(=O)OC(C)C.CC(C)OC1COC([BaH])C(O)C1OP(C)(=O)OC(C)C IGLMPHLBEBUPHJ-UHFFFAOYSA-N 0.000 description 1
- SBKNSAAPTIZKMP-UHFFFAOYSA-N CC(C)OC1COC([BaH])C(OP(C)(=O)OC(C)C)C1.CC(C)OC1COC([BaH])C(OP(C)(=O)OC(C)C)C1.CC(C)OC1COC([BaH])CC1OP(C)(=O)OC(C)C.CC(C)OC1COC([BaH])CC1OP(C)(=O)OC(C)C.CC(C)OCC1OC([BaH])C(O)CC1OP(C)(=O)OC(C)C.CC(C)OCC1OC([BaH])C(O)CC1OP(C)(=O)OC(C)C.CC(C)OCC1OC([BaH])CC(O)C1OP(C)(=O)OC(C)C.CC(C)OCC1OC([BaH])CCC1OP(C)(=O)OC(C)C.[H]OC1CC(C)OC(COC(C)C)C1OP(C)(=O)OC(C)C Chemical compound CC(C)OC1COC([BaH])C(OP(C)(=O)OC(C)C)C1.CC(C)OC1COC([BaH])C(OP(C)(=O)OC(C)C)C1.CC(C)OC1COC([BaH])CC1OP(C)(=O)OC(C)C.CC(C)OC1COC([BaH])CC1OP(C)(=O)OC(C)C.CC(C)OCC1OC([BaH])C(O)CC1OP(C)(=O)OC(C)C.CC(C)OCC1OC([BaH])C(O)CC1OP(C)(=O)OC(C)C.CC(C)OCC1OC([BaH])CC(O)C1OP(C)(=O)OC(C)C.CC(C)OCC1OC([BaH])CCC1OP(C)(=O)OC(C)C.[H]OC1CC(C)OC(COC(C)C)C1OP(C)(=O)OC(C)C SBKNSAAPTIZKMP-UHFFFAOYSA-N 0.000 description 1
- DOWXRKKHQGUKDI-UHFFFAOYSA-N CC(C)OC1COC([BaH])C(OP(C)(=O)OC(C)C)C1O.CC(C)OC1COC([BaH])C(OP(C)(=O)OC(C)C)C1O.CC(C)OC1COC([BaH])C(OP(C)(=O)OC(C)C)C1O.[H]OC1C(OC(C)C)COC([BaH])C1OP(C)(=O)OC(C)C Chemical compound CC(C)OC1COC([BaH])C(OP(C)(=O)OC(C)C)C1O.CC(C)OC1COC([BaH])C(OP(C)(=O)OC(C)C)C1O.CC(C)OC1COC([BaH])C(OP(C)(=O)OC(C)C)C1O.[H]OC1C(OC(C)C)COC([BaH])C1OP(C)(=O)OC(C)C DOWXRKKHQGUKDI-UHFFFAOYSA-N 0.000 description 1
- YLABRIFBJBDLFO-MUTXJXMQSA-N CC([C@@H](CN)O[C@H]1O)C1N Chemical compound CC([C@@H](CN)O[C@H]1O)C1N YLABRIFBJBDLFO-MUTXJXMQSA-N 0.000 description 1
- YDANLVWNESOVQT-PLAPECPESA-N CC/C=C\COC(=O)C(C)(C)C.CC/C=C\CSSCCN1CCOCC1.CCCOC(=O)C(C)(C)C.CSS(C)(=O)=O Chemical compound CC/C=C\COC(=O)C(C)(C)C.CC/C=C\CSSCCN1CCOCC1.CCCOC(=O)C(C)(C)C.CSS(C)(=O)=O YDANLVWNESOVQT-PLAPECPESA-N 0.000 description 1
- ZTJCYNLJDKVGFB-ZPCNYNOLSA-N CC1=CN([C@H]2CC(O)[C@@H](COP(=O)(OC3C[C@H](N4C=C(C)C(=O)NC4=O)O[C@@H]3CO)SCCSSCCN3CCOCC3)O2)C(=O)NC1=O.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)SCCSSCCN1CCOCC1.[3H]SCCCSP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)OC1C[C@H](N2C=C(C)C(=O)NC2=O)O[C@@H]1CC Chemical compound CC1=CN([C@H]2CC(O)[C@@H](COP(=O)(OC3C[C@H](N4C=C(C)C(=O)NC4=O)O[C@@H]3CO)SCCSSCCN3CCOCC3)O2)C(=O)NC1=O.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)SCCSSCCN1CCOCC1.[3H]SCCCSP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)OC1C[C@H](N2C=C(C)C(=O)NC2=O)O[C@@H]1CC ZTJCYNLJDKVGFB-ZPCNYNOLSA-N 0.000 description 1
- QEMXDNUEXSQENB-RSYVZYGNSA-N CC1=CN([C@H]2CC(O)[C@@H](COP(=O)(OC3C[C@H](N4C=C(C)C(=O)NC4=O)O[C@@H]3CO)SCSSCCN3CCOCC3)O2)C(=O)NC1=O.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)SCSSCCN1CCOCC1.[3H]SCCSP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)OC1C[C@H](N2C=C(C)C(=O)NC2=O)O[C@@H]1CC Chemical compound CC1=CN([C@H]2CC(O)[C@@H](COP(=O)(OC3C[C@H](N4C=C(C)C(=O)NC4=O)O[C@@H]3CO)SCSSCCN3CCOCC3)O2)C(=O)NC1=O.CC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)SCSSCCN1CCOCC1.[3H]SCCSP(=O)(OC[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)CC1OC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1)OC1C[C@H](N2C=C(C)C(=O)NC2=O)O[C@@H]1CC QEMXDNUEXSQENB-RSYVZYGNSA-N 0.000 description 1
- GGZMUGFCBUEGOQ-UHFFFAOYSA-M CCC(=O)OC.CCC(C)(C)CSC(=O)CCN1CCOCC1.CCC1=C(OC(=O)C(C)(C)C)C=CC=C1.CCCN12CCC(CC1)CC2.CCCOC(=O)C(C)(C)C.CCOC(=O)C(C)(C)C.[Br-] Chemical compound CCC(=O)OC.CCC(C)(C)CSC(=O)CCN1CCOCC1.CCC1=C(OC(=O)C(C)(C)C)C=CC=C1.CCCN12CCC(CC1)CC2.CCCOC(=O)C(C)(C)C.CCOC(=O)C(C)(C)C.[Br-] GGZMUGFCBUEGOQ-UHFFFAOYSA-M 0.000 description 1
- YPIOSQVARYBYMH-UHFFFAOYSA-N CCOC(COC(C)C)COP(C)(=O)OCC(COP(C)(=O)OC(C)C)OC[BaH] Chemical compound CCOC(COC(C)C)COP(C)(=O)OCC(COP(C)(=O)OC(C)C)OC[BaH] YPIOSQVARYBYMH-UHFFFAOYSA-N 0.000 description 1
- ZMRWFHBJPSTFRE-UHFFFAOYSA-O CN(CCS)CSCC[N+](C)(C)C Chemical compound CN(CCS)CSCC[N+](C)(C)C ZMRWFHBJPSTFRE-UHFFFAOYSA-O 0.000 description 1
- GKXASWWKVLIZQU-UHFFFAOYSA-N CN1CCN(CCS)CC1 Chemical compound CN1CCN(CCS)CC1 GKXASWWKVLIZQU-UHFFFAOYSA-N 0.000 description 1
- JVGGQLLNQPHZBJ-UHFFFAOYSA-N COC(C1N(CCS)CCC1)=O Chemical compound COC(C1N(CCS)CCC1)=O JVGGQLLNQPHZBJ-UHFFFAOYSA-N 0.000 description 1
- VNMBNSSUMLBKKI-UHFFFAOYSA-N O=C(Cc1ccccc1CI)S Chemical compound O=C(Cc1ccccc1CI)S VNMBNSSUMLBKKI-UHFFFAOYSA-N 0.000 description 1
- YZVWMFBVTTUSAW-UHFFFAOYSA-N SCCN1CCOCC1 Chemical compound SCCN1CCOCC1 YZVWMFBVTTUSAW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
Definitions
- Oligonucleotides are useful in therapeutic, diagnostic, research and nanomaterials applications.
- the use of natural sequences of DNA or RNA for therapeutics is limited because of their instability against extra and intracellular nucleases, poor cell penetration and distribution.
- in vitro studies have shown that the properties of antisense nucleotides such as binding affinity, sequence specific binding to the complementary RNA (Cosstick and Eckstcin, 1985; LaPlanche et al., 1986; Latimer et al., 1989; Hacia et al., 1994; Mesmaeker et al., 1995), stability to nucleases are affected by the configurations of the phosphorous atoms Therefore, there is a need for modified oligonucleotides to impart stability towards ubiquitous nucleases, increase binding affinity towards complementary RNA and increase cell penetration and bio-distribution for a number of in-vitro and in-vivo applications.
- nucleic acids comprise chiral phosphorous moieties.
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIa, wherein W is O.
- R 1 is selected from:
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein the silylating reagent is selected from
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein W is O.
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein R 1 is selected from:
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein the silylating reagent is selected from
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- Another embodiment provides the process wherein the phosphorothiotriesters of structure IIIb comprise non-stereorandom phosphorous linkages and the H-phosphonate of structure Ic comprise non-stereorandom phosphorous linkages; and W is independently selected from O, NH, or CH 2 . Another embodiment provides the process wherein W is O.
- Another embodiment provides the process wherein R 6 is methyl.
- bis(thiosulfonate) reagent of structure IVc is selected from:
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein the silylating reagent is selected from
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- FIG. 1 provides the 31 P NMR spectrum of Compound 100S in CD 3 CN as described in Example 6;
- FIG. 2 provides the 31 P NMR spectrum of Compound 100S in CD 3 CN after adding BSTFA as described in Example 6;
- FIG. 3 provides the 31 P NMR spectrum of Compound 100S in CD 3 CN after adding BSTFA, TEA and MTS as described in Example 6;
- FIG. 4 provides the 31 P NMR spectrum of Compound 100R in CD 3 CN as described in Example 6;
- FIG. 5 provides the 31 P NMR spectrum of Compound 100R in CD 3 CN as described in Example 6;
- FIG. 6 provides the 31 P NMR spectrum of Compound 100R in CD 3 CN after adding BSTFA, TEA and MTS as described in Example 6.
- C 1 -C x includes C 1 -C 2 , C 1 -C 3 . . . C 1 -C x .
- a group designated as “C 1 -C 4 ” indicates that there are one to four carbon atoms in the moiety, i.e. groups containing 1 carbon atom, 2 carbon atoms, 3 carbon atoms or 4 carbon atoms, as well as the ranges C 1 -C 2 and C 1 -C 3 .
- C 1 -C 4 alkyl indicates that there are one to four carbon atoms in the alkyl group, i.e., the alkyl group is selected from among methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.
- a numerical range such as “1 to 10” refers to each integer in the given range; e.g., “1 to 10 carbon atoms” means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, 6 carbon atoms, 7 carbon atoms, 8 carbon atoms, 9 carbon atoms, or 10 carbon atoms.
- heteroatom or “hetero” as used herein, alone or in combination, refer to an atom other than carbon or hydrogen. Heteroatoms are may be independently selected from among oxygen, nitrogen, sulfur, phosphorous, silicon, selenium and tin but are not limited to these atoms. In embodiments in which two or more heteroatoms are present, the two or more heteroatoms can be the same as each another, or some or all of the two or more heteroatoms can each be different from the others.
- alkyl refers to a straight-chain or branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, or one to six carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n
- C 1 -C 6 alkyl or “C 1-6 alkyl” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms.
- the “alkyl” is substituted. Unless otherwise indicated, the “alkyl” is unsubstituted.
- alkenyl refers to a straight-chain or branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, or two to about six carbon atoms.
- the group may be in either the cis or trans conformation about the double bond(s), and should be understood to include both isomers. Examples include, but are not limited to ethenyl (—CH ⁇ CH 2 ), 1-propenyl (—CH 2 CH ⁇ CH 2 ), isopropenyl [—C(CH 3 ) ⁇ CH 2 ], butenyl, 1,3-butadienyl and the like.
- C 2 -C 6 alkenyl or “C 2-6 alkenyl”
- alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms.
- the “alkenyl” is substituted. Unless otherwise indicated, the “alkenyl” is unsubstituted.
- alkynyl refers to a straight-chain or branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, or from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl and the like.
- the “alkynyl” is substituted. Unless otherwise indicated, the “alkynyl” is unsubstituted.
- heteroalkyl refers to alkyl, alkenyl and alkynyl structures respectively, as described above, in which one or more of the skeletal chain carbon atoms (and any associated hydrogen atoms, as appropriate) are each independently replaced with a heteroatom (i.e.
- an atom other than carbon such as though not limited to oxygen, nitrogen, sulfur, silicon, phosphorous, tin or combinations thereof
- heteroatomic group such as though not limited to —O—O—, —S—S—, —O—S—, —S—O—, ⁇ N—N ⁇ , —N ⁇ N—, —N ⁇ N—NH—, —P(O) 2 —, —O—P(O) 2 —, —P(O) 2 —O—, —S(O) 2 —, —S(O) 2 —, —SnH 2 — and the like.
- haloalkyl refers to alkyl, alkenyl and alkynyl groups respectively, as defined above, in which one or more hydrogen atoms is replaced by fluorine, chlorine, bromine or iodine atoms, or combinations thereof.
- two or more hydrogen atoms may be replaced with halogen atoms that are the same as each another (e.g. difluoromethyl); in other embodiments two or more hydrogen atoms may be replaced with halogen atoms that are not all the same as each other (e.g. 1-chloro-1-fluoro-1-iodoethyl).
- Non-limiting examples of haloalkyl groups are fluoromethyl, chloromethyl and bromoethyl.
- a non-limiting example of a haloalkenyl group is bromoethenyl.
- a non-limiting example of a haloalkynyl group is chloroethynyl.
- carbon chain refers to any alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl or heteroalkynyl group, which is linear, cyclic, or any combination thereof. If the chain is part of a linker and that linker comprises one or more rings as part of the core backbone, for purposes of calculating chain length, the “chain” only includes those carbon atoms that compose the bottom or top of a given ring and not both, and where the top and bottom of the ring(s) are not equivalent in length, the shorter distance shall be used in determining the chain length. If the chain contains heteroatoms as part of the backbone, those atoms are not calculated as part of the carbon chain length.
- cycloalkyl refers to a saturated, hydrocarbon monoradical ring, containing from three to about fifteen ring carbon atoms or from three to about ten ring carbon atoms, though may include additional, non-ring carbon atoms as substituents (e.g. methylcyclopropyl).
- a numerical range such as “C 3 -C 6 cycloalkyl” or “C 3-6 cycloalkyl”, means that the cycloalkyl group may consist of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, i.e., is cyclopropyl, cyclobutyl, cyclopentyl or cyclohepty, although the present definition also covers the occurrence of the term “cycloalkyl” where no numerical range is designated.
- the term includes fused, non-fused, bridged and spiro radicals.
- a fused cycloalkyl may contain from two to four fused rings where the ring of attachment is a cycloalkyl ring, and the other individual rings may be alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof. Examples include, but are not limited to cyclopropyl, cyclopentyl, cyclohexyl, decalinyl, and bicyclo [2.2.1] heptyl and adamantyl ring systems. Illustrative examples include, but are not limited to the following moieties:
- the “cycloalkyl” is substituted. Unless otherwise indicated, the “cycloalkyl” is unsubstituted.
- non-aromatic heterocyclyl and “heteroalicyclyl” as used herein, alone or in combination, refer to a saturated, partially unsaturated, or fully unsaturated nonaromatic ring monoradicals containing from three to about twenty ring atoms, where one or more of the ring atoms are an atom other than carbon, independently selected from among oxygen, nitrogen, sulfur, phosphorous, silicon, selenium and tin but are not limited to these atoms.
- the two or more heteroatoms can be the same as each another, or some or all of the two or more heteroatoms can each be different from the others.
- fused, non-fused, bridged and spiro radicals include fused, non-fused, bridged and spiro radicals.
- a fused non-aromatic heterocyclic radical may contain from two to four fused rings where the attaching ring is a non-aromatic heterocycle, and the other individual rings may be alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof.
- Fused ring systems may be fused across a single bond or a double bond, as well as across bonds that are carbon-carbon, carbon-hetero atom or hetero atom-hetero atom.
- the terms also include radicals having from three to about twelve skeletal ring atoms, as well as those having from three to about ten skeletal ring atoms.
- Attachment of a non-aromatic heterocyclic subunit to its parent molecule can be via a heteroatom or a carbon atom.
- additional substitution can be via a heteroatom or a carbon atom.
- an imidazolidine non-aromatic heterocycle may be attached to a parent molecule via either of its N atoms (imidazolidin-1-yl or imidazolidin-3-yl) or any of its carbon atoms (imidazolidin-2-yl, imidazolidin-4-yl or imidazolidin-5-yl).
- non-aromatic heterocycles contain one or more carbonyl or thiocarbonyl groups such as, for example, oxo- and thio-containing groups.
- Examples include, but are not limited to pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2-
- the terms also include all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides.
- the “non-aromatic heterocyclyl” or “heteroalicyclyl” is substituted. Unless otherwise indicated, the “non-aromatic heterocyclyl” or “heteroalicyclyl” is unsubstituted.
- aryl refers to an aromatic hydrocarbon radical of six to about twenty ring carbon atoms, and includes fused and non-fused aryl rings.
- a fused aryl ring radical contains from two to four fused rings where the ring of attachment is an aryl ring, and the other individual rings may be alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof.
- aryl includes fused and non-fused rings containing from six to about twelve ring carbon atoms, as well as those containing from six to about ten ring carbon atoms.
- a non-limiting example of a single ring aryl group includes phenyl; a fused ring aryl group includes naphthyl, phenanthrenyl, anthracenyl, azulenyl; and a non-fused bi-aryl group includes biphenyl.
- the “aryl” is substituted. Unless otherwise indicated, the “aryl” is unsubstituted.
- heteroaryl refers to an aromatic monoradicals containing from about five to about twenty skeletal ring atoms, where one or more of the ring atoms is a heteroatom independently selected from among oxygen, nitrogen, sulfur, phosphorous, silicon, selenium and tin but not limited to these atoms and with the proviso that the ring of said group does not contain two adjacent O or S atoms.
- the two or more heteroatoms can be the same as each another, or some or all of the two or more heteroatoms can each be different from the others.
- heteroaryl includes fused and non-fused heteroaryl radicals having at least one heteroatom.
- heteroaryl also includes fused and non-fused heteroaryls having from five to about twelve skeletal ring atoms, as well as those having from five to about ten skeletal ring atoms. Bonding to a heteroaryl group can be via a carbon atom or a heteroatom.
- an imidazole group may be attached to a parent molecule via any of its carbon atoms (imidazol-2-yl, imidazol-4-yl or imidazol-5-yl), or its nitrogen atoms (imidazol-1-yl or imidazol-3-yl).
- a heteroaryl group may be further substituted via any or all of its carbon atoms, and/or any or all of its heteroatoms.
- a fused heteroaryl radical may contain from two to four fused rings where the ring of attachment is a heteroaromatic ring and the other individual rings may be alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof.
- a non-limiting example of a single ring heteroaryl group includes pyridyl; fused ring heteroaryl groups include benzimidazolyl, quinolinyl, acridinyl; and a non-fused bi-heteroaryl group includes bipyridinyl.
- heteroaryls include, without limitation, furanyl, thienyl, oxazolyl, acridinyl, phenazinyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, benzoxadiazolyl, benzotriazolyl, imidazolyl, indolyl, isoxazolyl, isoquinolinyl, indolizinyl, isothiazolyl, isoindolyloxadiazolyl, indazolyl, pyridyl, pyridazyl, pyrimidyl, pyrazinyl, pyrrolyl, pyrazinyl, pyrazolyl, purinyl, phthalazinyl, pteridinyl, quinolinyl, quinazolinyl, quinoxalinyl, triazolyl,
- the “heteroaryl” is substituted. Unless otherwise indicated, the “heteroaryl” is unsubstituted.
- heterocyclyl refers collectively to heteroalicyclyl and heteroaryl groups.
- the number of carbon atoms in a heterocycle is indicated (e.g., C 1 -C 6 heterocycle)
- at least one non-carbon atom must be present in the ring.
- Designations such as “C 1 -C 6 heterocycle” refer only to the number of carbon atoms in the ring and do not refer to the total number of atoms in the ring.
- 4-6 membered heterocycle refers to the total number of atoms that are contained in the ring (i.e., a four, five, or six membered ring, in which at least one atom is a carbon atom, at least one atom is a heteroatom and the remaining two to four atoms are either carbon atoms or heteroatoms).
- a four, five, or six membered ring in which at least one atom is a carbon atom, at least one atom is a heteroatom and the remaining two to four atoms are either carbon atoms or heteroatoms.
- those two or more heteroatoms can be the same or different from one another.
- Non-aromatic heterocyclic groups include groups having only three atoms in the ring, while aromatic heterocyclic groups must have at least five atoms in the ring. Bonding (i.e.
- heterocycle attachment to a parent molecule or further substitution) to a heterocycle can be via a heteroatom or a carbon atom.
- heterocyclyl is substituted.
- heterocycyl is unsubstituted.
- halogen halo or halide as used herein, alone or in combination refer to fluoro, chloro, bromo and/or iodo.
- the compounds, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, such as (R)- or (S)-.
- the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both Z and E geometric isomers (e.g., cis or trans).
- Z and E geometric isomers e.g., cis or trans
- all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included.
- stereoisomer refers to the relationship between two or more compounds made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not superimposable.
- enantiomer refers to two stereoisomers that are nonsuperimposeable mirror images of one another. It is contemplated that the various stereoisomers of the compounds disclosed herein, and mixtures thereof, are within the scope of the present disclosure and specifically includes enantiomers.
- a “tautomer” refers to a compound wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible.
- the compounds presented herein may exist as tautomers. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Some examples of tautomeric equilibrium are shown below.
- non-stereorandom phosphorous linkage(s) refers to a chiral phosphorous atom in the phosphodiester, or other isosteric linkage type, internucleotide linkage.
- the handedness of chirality at phosphorous is independently selected at each phosphorous atom.
- the oligonucleotide described herein is a pure diastereomer.
- the oligonucleotide is greater that 95% diastereomeric purity.
- the oligonucleotide is greater that 90% diastereomeric purity.
- “Optional” or “optionally” means that a subsequently described event or circumstance may or may not occur and that the description includes instances when the event or circumstance occurs and instances in which it does not.
- “optionally substituted alkyl” means that the alkyl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
- Natural nucleic acids have a phosphate backbone; artificial nucleic acids may contain other types of backbones, but contain the same bases.
- nucleotide refers to a monomeric unit of a polynucleotide that consists of a heterocyclic base, a sugar, and one or more phosphate groups.
- the naturally occurring bases (guanine, (G), adenine (A), cytosine (C), thymine (T), and uracil (U)) are derivatives of purine or pyrimidine, though it should be understood that naturally and non-naturally occurring base analogs are also included.
- the naturally occurring sugar is the pentose (five-carbon sugar) deoxyribose (which forms DNA) or ribose (which forms RNA), though it should be understood that naturally and non-naturally occurring sugar analogs are also included.
- Nucleic acids are linked via phosphate bonds to form nucleic acids, or polynucleotides, though many other linkages are known in the art (such as, though not limited to phosphorothioates, boranophosphates and the like).
- Artificial nucleic acids include PNAs (peptide nucleic acids), phosphothionates, and other variants of the phosphate backbone of native nucleic acids.
- nucleoside refers to a moiety wherein a nucleobase or a modified nucleobase is covalently bound to a sugar or modified sugar.
- sugar refers to a monosaccharide in closed and/or open form.
- Sugars include, but are not limited to, ribose, deoxyribose, pentofuranose, pentopyranose, and hexopyranose moieties.
- modified sugar refers to a moiety that can replace a sugar.
- the modified sugar mimics the spatial arrangement, electronic properties, or some other physicochemical property of a sugar.
- nucleic acid and “polynucleotide” as used herein refer to a polymeric form of nucleotides of any length, either ribonucleotides (RNA) or deoxyribonucleotides (DNA). These terms refer to the primary structure of the molecules and, thus, include double- and single-stranded DNA, and double- and single-stranded RNA. These terms include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs and modified polynucleotides such as, though not limited to, methylated and/or capped polynucleotides.
- RNA ribonucleotides
- DNA deoxyribonucleotides
- RNA poly- or oligo-ribonucleotides
- DNA poly- or oligo-deoxyribonucleotides
- RNA or DNA derived from N-glycosides or C-glycosides of nucleobases and/or modified nucleobases
- nucleic acids derived from sugars and/or modified sugars and nucleic acids derived from phosphate bridges and/or modified phosphorous-atom bridges.
- the term encompasses nucleic acids containing any combinations of nucleobases, modified nucleobases, sugars, modified sugars, phosphate bridges or modified phosphorous atom bridges.
- Examples include, and are not limited to, nucleic acids containing ribose moieties, the nucleic acids containing deoxy-ribose moieties, nucleic acids containing both ribose and deoxyribose moieties, nucleic acids containing ribose and modified ribose moieties.
- the prefix poly- refers to a nucleic acid containing about 1 to about 10,000 nucleotide monomer units and wherein the prefix oligo- refers to a nucleic acid containing about 1 to about 200 nucleotide monomer units.
- nucleobase refers to the parts of nucleic acids that are involved in the hydrogen-bonding that binds one nucleic acid strand to another complementary strand in a sequence specific manner.
- the most common naturally-occurring nucleobases are adenine (A), guanine (G), uracil (U), cytosine (C), and thymine (T).
- modified nucleobase refers to a moiety that can replace a nucleobase.
- the modified nucleobase mimics the spatial arrangement, electronic properties, or some other physicochemical property of the nucleobase and retains the property of hydrogen-bonding that binds one nucleic acid strand to another in a sequence specific manner.
- a modified nucleobase can pair with all of the five naturally occurring bases (uracil, thymine, adenine, cytosine, or guanine) without substantially affecting the melting behavior, recognition by intracellular enzymes or activity of the oligonucleotide duplex.
- chiral reagent refers to a compound that is chiral or enantiopure and can be used for asymmetric induction in nucleic acid synthesis.
- chiral ligand or “chiral auxiliary” refers to a moiety that is chiral or enantiopure and controls the stereochemical outcome of a reaction.
- condensation reagent refers to a reagent that activates a less reactive site and renders it more susceptible to attack by a nucleophile.
- blocking group refers to a group that transiently masks the reactivity of a functional group.
- the functional group can be subsequently unmasked by removal of the blocking group.
- moiety refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule.
- solid support refers to any support which enables synthetic mass production of nucleic acids and can be reutilized at need.
- the term refers to a polymer, that is insoluble in the media employed in the reaction steps performed to synthesize nucleic acids, and is derivatized to comprise reactive groups.
- linking moiety refers to any moiety optionally positioned between the terminal nucleoside and the solid support or between the terminal nucleoside and another nucleoside, nucleotide, or nucleic acid.
- a “DNA molecule” refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes.
- linear DNA molecules e.g., restriction fragments
- viruses e.g., plasmids, and chromosomes.
- sequences can be described herein according to the normal convention of giving only the sequence in the 5′ to 3′ direction along the non-transcribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).
- an “antisense” nucleic acid molecule comprises a nucleotide sequence which is complementary to a “sense” nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule, complementary to an mRNA sequence or complementary to the coding strand of a gene. Accordingly, an antisense nucleic acid molecule can hydrogen bond to a sense nucleic acid molecule.
- a “complementary DNA” or “cDNA” includes recombinant polynucleotides synthesized by reverse transcription of mRNA and from which intervening sequences (introns) have been removed.
- nucleic acids comprise chiral phosphorous moieties.
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein W is O.
- R 1 is selected from:
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein the silylating reagent is selected from
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein W is O.
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein R 1 is selected from:
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein the silylating reagent is selected from
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- Another embodiment provides the process wherein the phosphorothiotriesters of structure IIIb comprise non-stereorandom phosphorous linkages and the H-phosphonate of structure Ic comprise non-stereorandom phosphorous linkages; and W is independently selected from O, NH, or CH 2 . Another embodiment provides the process wherein W is O.
- Another embodiment provides the process wherein R 6 is methyl.
- bis(thiosulfonate) reagent of structure IVc is selected from:
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein the silylating reagent is selected from
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- Oligonucleotides have several pharmaceutical properties which can be improved through the application of prodrug strategies.
- oligonucleotides are rapidly degraded by nucleases and exhibit poor cellular uptake through the cytoplasmic cell membrane (Poijarvi-Virta et al., Curr. Med. Chem. (2006), 13(28); 3441-65; Wagner et al., Med. Res. Rev. (2000), 20(6):417-51; Peyrottes et al., Mini Rev. Med. Chem.
- the steps of reacting a molecule comprising an achiral H-phosphonate moiety and a nucleoside comprising a 5′-OH moiety to form a condensed intermediate can occur without isolating any intermediates.
- the steps of reacting a molecule comprising an achiral H-phosphonate moiety and a nucleoside comprising a 5′-OH moiety to form a condensed intermediate occurs is a one-pot reaction.
- a molecule comprising an achiral H-phosphonate moiety, condensing reagent, chiral reagent, and compound comprising a free nucleophilic moiety are added to the reaction mixture at different times.
- a molecule comprising an achiral H-phosphonate moiety, condensing reagent, and chiral reagent are present in the same reaction vessel or same pot.
- a molecule comprising an achiral H-phosphonate moiety, condensing reagent, chiral reagent, and compound comprising a free nucleophilic moiety are present in the same reaction or same pot. This allows the reaction to be performed without isolation of intermediates and eliminates time-consuming steps, resulting in an economical and efficient synthesis.
- the achiral H-phosphonate, condensing reagent, chiral amino alcohol, 5′-OH nucleoside are present at the same time in a reaction.
- the formation of the chiral intermediate for condensation is formed in situ and is not isolated prior to the condensation reaction.
- a molecule comprising an achiral H-phosphonate moiety has been activated by reaction with a condensing reagent, chiral reagent in a different reaction vessel from that used when reacting the chiral intermediate with the compound comprising a free 5′-OH moiety.
- the synthesis of the nucleic acid is performed in solution. In other embodiments, the synthesis of the nucleic acid is performed on solid phase.
- the reactive groups of a solid support may be unprotected or protected.
- oligonucleotide synthesis a solid support is treated with various reagents in several synthesis cycles to achieve the stepwise elongation of a growing oligonucleotide chain with individual nucleotide units.
- the nucleoside unit at the end of the chain which is directly linked to the solid support is termed “the first nucleoside” as used herein.
- the first nucleoside is bound to the solid support via a linker moiety, i.e.
- the linker stays intact during the synthesis cycles performed to assemble the oligonucleotide chain and is cleaved after the chain assembly to liberate the oligonucleotide from the support.
- Solid supports for solid-phase nucleic acid synthesis include the supports described in, e.g., U.S. Pat. Nos. 4,659,774, 5,141,813, 4,458,066; Caruthers U.S. Pat. Nos. 4,415,732, 4,458,066, 4,500,707, 4,668,777, 4,973,679, and 5,132,418; Andrus et al. U.S. Pat. Nos. 5,047,524, 5,262,530; and Koster U.S. Pat. No. 4,725,677 (reissued as Re34,069).
- the solid phase is an organic polymer support.
- the solid phase is an inorganic polymer support.
- the organic polymer support is polystyrene, aminomethyl polystyrene, a polyethylene glycol-polystyrene graft copolymer, polyacrylamide, polymethacrylate, polyvinylalcohol, highly cross-linked polymer (HCP), or other synthetic polymers, carbohydrates such as cellulose and starch or other polymeric carbohydrates, or other organic polymers and any copolymers, composite materials or combination of the above inorganic or organic materials.
- the inorganic polymer support is silica, alumina, controlled poreglass (CPG), which is a silica-gel support, or aminopropyl CPG.
- solid supports include fluorous solid supports (see e.g., WO/2005/070859), long chain alkylamine (LCAA) controlled pore glass (CPG) solid supports (sce e.g., S. P. Adams, K. S. Kavka, E. J. Wykes, S. B. Holder and G. R. Galluppi, J. Am. Chem. Soc., 1983, 105, 661-663; G. R. Gough, M. J. Bruden and P. T. Gilham, Tetrahedron Lett., 1981, 22, 4177-4180).
- Membrane supports and polymeric membranes see e.g.
- a membrane can be chemically functionalized for use in nucleic acid synthesis.
- a linker or spacer group attached to the membrane may be used to minimize steric hindrance between the membrane and the synthesized chain.
- suitable solid supports include those generally known in the art to be suitable for use in solid phase methodologies, including, for example, glass sold as PrimerTM 200 support, controlled pore glass (CPG), oxalyl-controlled pore glass (see, e.g., Alul, et al., Nucleic Acids Research, 1991, 19, 1527), TentaGel Support—an aminopolyethyleneglycol derivatized support (see, e.g., Wright, et al., Tetrahedron Lett., 1993, 34, 3373), and Poros-a copolymer of polystyrene/divinylbenzene.
- CPG controlled pore glass
- oxalyl-controlled pore glass see, e.g., Alul, et al., Nucleic Acids Research, 1991, 19, 1527
- TentaGel Support an aminopolyethyleneglycol derivatized support (see, e.g., Wright, et al., Tetrahe
- the solid support material can be any polymer suitably uniform in porosity, has sufficient amine content, and sufficiently flexible to undergo any attendant manipulations without losing integrity.
- suitable selected materials include nylon, polypropylene, polyester, polytetrafluoroethylene, polystyrene, polycarbonate, and nitrocellulose.
- Other materials can serve as the solid support, depending on the design of the investigator. In consideration of some designs, for example, a coated metal, in particular gold or platinum can be selected (see e.g., US publication No. 20010055761).
- a nucleoside is anchored to a solid support which is functionalized with hydroxyl or amino residues.
- the solid support is derivatized to provide an acid labile trialkoxytrityl group, such as a trimethoxytrityl group (TMT).
- TMT trimethoxytrityl group
- a diglycoate linker is optionally introduced onto the support.
- a linking moiety or linker is optionally used to connect the solid support to the compound comprising a free nucleophilic moiety.
- Suitable linkers are known such as short molecules which serve to connect a solid support to functional groups (e.g., hydroxyl groups) of initial nucleosides molecules in solid phase synthetic techniques.
- the linking moiety is a succinamic acid linker, or a succinate linker (—CO—CH 2 —CH 2 —CO—), or an oxalyl linker (—CO—CO—).
- the linking moiety and the nucleoside are bonded together through an ester bond.
- the linking moiety and the nucleoside are bonded together through an amide bond.
- the linking moiety connects the nucleoside to another nucleotide or nucleic acid.
- Suitable linkers are disclosed in, for example, Oligonucleotides And Analogues A Practical Approach, Ekstein, F. Ed., IRL Press, N.Y., 1991, Chapter 1.
- a linker moiety is used to connect the compound comprising a free nucleophilic moiety to another nucleoside, nucleotide, or nucleic acid.
- the linking moiety is a phosphodiester linkage.
- the linking moiety is an H-phosphonate moiety.
- the linking moiety is an X-phosphonate moiety.
- the solvent is acetonitrile, pyridine, or NMP.
- the solvent is acetone, acetontrile, NMP, ethyl acetate, THF, dioxane, DMF, DMSO, DCM, chloroform, pyridine, 2,6-lutidine, HMPA, HMPT, DMA, glyme, diglyme, sulfone, methyl tert-butyl ether, or combinations thereof.
- the solvent is a polar, aprotic organic solvent.
- the solvent is anhydrous.
- Acidification to remove blocking groups is accomplished by a Br ⁇ nsted acid or Lewis acid. In some embodiments, acidification is used to remove R 1 blocking groups.
- Useful Br ⁇ nsted acids are carboxylic acids, alkylsulfonic acids, arylsulfonic acids, phosphoric acid and its derivatives, phosphonic acid and its derivatives, alkylphosphonic acids and their derivatives, arylphosphonic acids and their derivatives, phosphinic acid, dialkylphosphinic acids, and diarylphosphinic acids which have a pKa (25° C. in water) value of ⁇ 0.6 (trifluoroacetic acid) to 4.76 (acetic acid) in an organic solvent or water (in the case of 80% acetic acid).
- the concentration of the acid (1 to 80%) used in the acidification step depends on the acidity of the acid. Consideration to the acid strength must be taken into account as strong acid conditions will result in depurination/depyrimidination, wherein purinyl or pyrimidinyl bases are cleaved from ribose ring.
- acidification is accomplished by a Lewis acid in an organic solvent.
- Useful Lewis acids are ZnX 2 wherein X is Cl, Br, I, or CF 3 SO 3 .
- the acidifying comprises adding an amount of a Br ⁇ nsted or Lewis acid effective to convert the condensed intermediate into the compound of Formula 4 without removing purine moieties from the condensed intermediate.
- Acids that are useful in the acidifying step also include, but are not limited to 10% phosphoric acid in an organic solvent, 10% hydrochloric acid in an organic solvent, 1% trifluoroacetic acid in an organic solvent, 3% dichloroacetic acid in an organic solvent or 80% acetic acid in water.
- concentration of any Br ⁇ nsted or Lewis acid used in the process is selected such that the concentration of the acid does not exceed a concentration that causes cleavage of the nucleobase from the sugar moiety.
- acidification comprises adding 1% trifluoroacetic acid in an organic solvent. In some embodiments, acidification comprises adding about 0.1% to about 8% trifluoroacetic acid in an organic solvent. In other embodiments, acidification comprises adding 3% dichloroacetic acid in an organic solvent. In other embodiments, acidification comprises adding about 0.1% to about 10% dichloroacetic acid in an organic solvent. In yet other embodiments, acidification comprises adding 3% trichloroacetic acid in an organic solvent. In yet other embodiments, acidification comprises adding about 0.1% to about 10% trichloroacetic acid in an organic solvent. In some embodiments, acidification comprises adding 80% acetic acid in water.
- acidification comprises adding about 50% to about 90%, or about 50% to about 80%, about 50% to about 70%, about 50% to about 60%, about 70% to about 90% acetic acid in water.
- the acidification comprises the further addition of cation scavengers to the acidic solvent.
- the cation scavengers can be triethylsilane or triisopropylsilane.
- R 1 is deblocked prior to the step of acidifying the condensed intermediate.
- R 1 is deblocked by acidification, which comprises adding 1% trifluoroacetic acid in an organic solvent.
- R 1 is deblocked by acidification, which comprises adding 3% dichloroacetic acid in an organic solvent. In some embodiments, R 1 is deblocked by acidification, which comprises adding 3% trichloroacetic acid in an organic solvent.
- hydroxyl or amino moieties which are located on nucleobases or sugar moieties are routinely blocked with blocking (protecting) groups (moieties) during synthesis and subsequently deblocked.
- a blocking group renders a chemical functionality of a molecule inert to specific reaction conditions and can later be removed from such functionality in a molecule without substantially damaging the remainder of the molecule (see e.g., Green and Wuts, Protective Groups in Organic Synthesis, 2 nd Ed., John Wiley & Sons, New York, 1991).
- amino groups can be blocked with nitrogen blocking groups such as phthalimido, 9-fludrenylmethoxycarbonyl (FMOC), triphenylmethylsulfenyl, t-BOC, 4,4′-dimethoxytrityl (DMTr), 4-methoxytrityl (MMTr), 9-phenylxanthin-9-yl (Pixyl), trityl (Tr), or 9-(p-methoxyphenyl)xanthin-9-yl (MOX).
- Nitro blocking groups such as phthalimido, 9-fludrenylmethoxycarbonyl (FMOC), triphenylmethylsulfenyl, t-BOC, 4,4′-dimethoxytrityl (DMTr), 4-methoxytrityl (MMTr), 9-phenylxanthin-9-yl (Pixyl), trityl (Tr), or 9-(p-methoxyphenyl)xanthin
- Hydroxy groups can be protected such as tetrahydropyranyl (THP), t-butyldimethylsilyl (TBDMS), 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (Ctmp), 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp), 1-(2-chloroethoxy)ethyl, 3-methoxy-1,5-dicarbomethoxypentan-3-yl (MDP), bis(2-acetoxyethoxy)methyl (ACE), triisopropylsilyloxymethyl (TOM), 1-(2-cyanoethoxy)ethyl (CEE), 2-cyanoethoxymethyl (CEM), [4-(N-dichloroacetyl-N-methylamino)benzyloxy]methyl, 2-cyanoethyl (CN), pivaloyloxymethyl (PivOM), levunyloxymethyl (
- hydroxyl blocking groups are acid-labile groups, such as the trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl, 9-phenylxanthin-9-yl (Pixyl) and 9-(p-methoxyphenyl)xanthin-9-yl (MOX).
- Chemical functional groups can also be blocked by including them in a precursor form. Thus an azido group can be considered a blocked form of an amine as the azido group is easily converted to the amine.
- R 2 is a blocking group
- removal of the blocking group at R 2 is orthogonal to the removal of the blocking group at R 1 .
- the blocking groups at R 1 and R 2 remain intact during the synthesis steps and are collectively removed after the chain assembly.
- the R 2 blocking group are removed simultaneously with the cleavage of the nucleic acids from the solid support and with the removal of the nucleobase blocking groups.
- the blocking group at R 1 is removed while the blocking groups at R 2 and nucleobases remain intact.
- Blocking groups at R 1 are cleavable on solid supports with an organic base such as a primary amine, a secondary amine, or a mixture thereof. Deblocking of the R 1 position is commonly referred to as front end deprotection.
- the nucleobase blocking groups are cleavable after the assembly of the respective nucleic acid with an acidic reagent.
- one or more of the nucleobase blocking groups is cleavable under neither acidic nor basic conditions, e.g. cleavable with fluoride salts or hydrofluoric acid complexes.
- one or more of the nucleobase blocking groups are cleavable after the assembly of the respective nucleic acid in the presence of base or a basic solvent, and wherein the nucleobase blocking group is stable to the conditions of the front end deprotection step with amines.
- blocking groups for nucleobases are not required. In other embodiments, blocking groups for nucleobases are required. In yet other embodiments, certain nucleobases require blocking group while other nucleobases do not require blocking groups. In embodiments where the nucleobases are blocked, the blocking groups are either completely or partially removed under conditions appropriate to remove the blocking group at the front end.
- R 1 can denote OR a , wherein R a is acyl, and Ba denotes guanine blocked with an acyl group including, but not limited to isobutyryl, acetyl or 4-(tert-butylphenoxy)acetyl. The acyl groups at R 1 and Ba will be removed or partially removed during the same deblocking step.
- Oligonucleoside phosphorothioates have shown therapeutic potential (Stein et al., Science (1993), 261:1004-12; Agrawal et al., Antisence Res. and Dev. (1992), 2:261-66; Bayever et al., Antisense Res. and Dev. (1993), 3:383-390). Oligonucleoside phosphorothioates prepared without regard to the stereochemistry of the phosphorothioate exist as a mixture of 2 n diastereomers, where n is the number of internucleotide phosphorothioates linkages. The chemical and biological properties of these diastereomeric phosphorothioates can be distinct.
- the nucleobase Ba utilized in the compounds and methods described herein is a natural nucleobase or a modified nucleobase derived from natural nucleobases.
- examples include, but are not limited to, uracil, thymine, adenine, cytosine, and guanine having their respective amino groups protected by acyl protecting groups, 2-fluorouracil, 2-fluorocytosine, 5-bromouracil, 5-iodouracil, 2,6-diaminopurine, azacytosine, pyrimidine analogs such as pseudoisocytosine and pseudouracil and other modified nucleobases such as 8-substituted purines, xanthine, or hypoxanthine (the latter two being the natural degradation products).
- R 8 is a linear or branched alkyl, aryl, aralkyl, or aryloxylalkyl group having 1 to 15 carbon atoms, including, by way of example only, a methyl, isopropyl, phenyl, benzyl, or phenoxymethyl group; and each of R 9 and R 10 represents a linear or branched alkyl group having 1 to 4 carbon atoms.
- Modified nucleobases also include expanded-size nucleobases in which one or more benzene rings has been added. Nucleic base replacements described in the Glen Research catalog (www.glenresearch.com); Krueger A T et al, Acc. Chem. Res., 2007, 40, 141-150; Kool, E T, Acc. Chem. Res., 2002, 35, 936-943; Benner S. A., et al., Nat. Rev. Genet., 2005, 6, 553-543; Romesberg, F. E., et al., Curr. Opin. Chem. Biol., 2003, 7, 723-733; Hirao, I., Curr. Opin. Chem. Biol., 2006, 10, 622-627, are contemplated as useful for the synthesis of the nucleic acids described herein. Some examples of these expanded-size nucleobases are shown below:
- modified nucleobases also encompass structures that are not considered nucleobases but are other moieties such as, but not limited to, corrin- or porphyrin-derived rings.
- Porphyrin-derived base replacements have been described in Morales-Rojas, H and Kool, E T, Org. Lett., 2002, 4, 4377-4380. Shown below is an example of a porphyrin-derived ring which can be used as a base replacement:
- modified nucleobases also include base replacements such as those shown below:
- Modified nucleobases which are fluorescent are also contemplated.
- Non-limiting examples of these base replacements include phenanthrene, pyrene, stillbene, isoxanthine, isozanthopterin, terphenyl, terthiophene, benzoterthiophene, coumarin, lumazine, tethered stillbene, benzo-uracil, and naphtho-uracil, as shown below:
- modified nucleobases can be unsubstituted or contain further substitutions such as heteroatoms, alkyl groups, or linking moieties connected to fluorescent moieties, biotin or avidin moieties, or other protein or peptides.
- Modified nucleobases also include certain ‘universal bases’ that are not nucleobases in the most classical sense, but function similarly to nucleobases.
- One representative example of such a universal base is 3-nitropyrrole.
- nucleosides can also be used in the process disclosed herein and include nucleosides that incorporate modified nucleobases, or nucleobases covalently bound to modified sugars.
- nucleosides that incorporate modified nucleobases include 4-acetylcytidine; 5-(carboxyhydroxylmethyl)uridine; 2′-O-methylcytidine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyluridine; dihydrouridine; 2′-O-methylpseudouridine; beta,D-galactosylqueosine; 2′-O-methylguanosine; N 6 -isopentenyladenosine; 1-methyladenosine; 1-methylpseudouridine; 1-methylguanosine; 1-methylinosine; 2,2-dimethylguanosine; 2-methyladenosine; 2-methylguanosine; N 7 -methylguanosine; 3-methyl-cytidine
- nucleosides include 6′-modified bicyclic nucleoside analogs that have either (R) or (S)-chirality at the 6′-position and include the analogs described in U.S. Pat. No. 7,399,845.
- nucleosides include 5′-modified bicyclic nucleoside analogs that have either (R) or (S)-chirality at the 5′-position and include the analogs described in US Patent Application Publication No. 20070287831.
- the nucleobases or modified nucleobases comprises biomolecule binding moieties such as antibodies, antibody fragments, biotin, avidin, streptavidin, receptor ligands, or chelating moieties.
- Ba is 5-bromouracil, 5-iodouracil, or 2,6-diaminopurine.
- Ba is modified by substitution with a fluorescent or biomolecule binding moiety.
- the substituent on Ba is a fluorescent moiety.
- the substituent on Ba is biotin or avidin.
- nucleotides The most common naturally occurring nucleotides are ribose sugars linked to the nucleobases adenosine (A), cytosine (C), guanine (G), and thymine (T) or uracil (U). Also contemplated are modified nucleotides wherein the phosphate group or the modified phosphorous atom moieties in the nucleotides can be linked to various positions of the sugar or modified sugar. As non-limiting examples, the phosphate group or the modified phosphorous-atom moiety can be linked to the 2′, 3′, 4′ or 5′ hydroxyl moiety of a sugar or modified sugar. Nucleotides that incorporate the modified nucleobases described above can also be used in the process disclosed herein. In some embodiments, nucleotides or modified nucleotides comprising an unprotected —OH moiety are used in the process disclosed herein.
- modified sugars can also be incorporated in the nucleic acids disclosed herein.
- the modified sugars contain one or more substituents at the 2′ position including one of the following: F; CF 3 , CN, N 3 , NO, NO 2 , O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, O-alkyl-N-alkyl or N-alkyl-O-alkyl wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C 1 -C 10 alkyl or C 2 -C 10 alkenyl and alkynyl.
- substituents include, and are not limited to, O(CH 2 ) n OCH 3 , and O(CH 2 ) n NH 2 , wherein n is from 1 to about 10, MOE, DMAOE, DMAEOE. Also contemplated herein are modified sugars described in WO 2001/088198; and Martin et al., Helv. Chim. Acta, 1995, 78, 486-504.
- modified sugars comprise substituted silyl groups, an RNA cleaving group, a reporter group, a fluorescent label, an intercalator, a group for improving the pharmacokinetic properties of a nucleic acid, or a group for improving the pharmacodynamic properties of a nucleic acid, and other substituents having similar properties.
- the modifications may be made at the at the 2′, 3′, 4′, 5′, or 6′ positions of the sugar or modified sugar, including the 3′ position of the sugar on the 3′-terminal nucleotide or in the 5′ position of the 5′-terminal nucleotide.
- Modified sugars also include sugar mimetics such as cyclobutyl or cyclopentyl moieties in place of the pentofuranosyl sugar.
- Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; and 5,359,044.
- Some modified sugars that are contemplated include:
- modified sugars include glycerol, which form glycerol nucleic acid (GNA) analogues.
- GNA glycerol nucleic acid
- One example of a GNA analogue is shown below and is described in Zhang, R et al., J. Am. Chem. Soc., 2008, 130, 5846-5847; Zhang L, et al., J. Am. Chem. Soc., 2005, 127, 4174-4175 and Tsai C H et al., PNAS, 2007, 14598-14603:
- modified sugars include hexopyranosyl (6′ to 4′), pentopyranosyl (4′ to 2′), pentopyranosyl (4′ to 3′), or tetrofuranosyl (3′ to 2′) sugars.
- Hexopyranosyl (6′ to 4′) sugars contemplated include:
- Pentopyranosyl (4′ to 2′) sugars contemplated include:
- Pentopyranosyl (4′ to 3′) sugars contemplated include:
- Tetrofuranosyl (3′ to 2′) sugars contemplated include:
- X is selected from S, Se, CH 2 , N-Me, N-Et or N-iPr.
- modified sugars and sugar mimetics can be prepared by methods known in the art, including, but not limited to: A. Eschenmoser, Science (1999), 284:2118; M. Bohringer et al, Helv. Chim. Acta (1992), 75:1416-1477; M. Egli et al, J. Am. Chem. Soc. (2006), 128(33):10847-56; A. Eschenmoser in Chemical Synthesis: Gnosis to Prognosis, C. Chatgilialoglu and V. Sniekus, Ed., (Kluwer Academic, Netherlands, 1996), p. 293; K.-U. Schoning et al, Science (2000), 290:1347-1351; A.
- protective groups are used to block some or all reactive moieties and prevent such groups from participating in chemical reactions until the protective group is removed.
- each protective group is removable by a different means.
- Protective groups that are cleaved under totally disparate reaction conditions fulfill the requirement of differential removal.
- protective groups are removed by acid, base, and/or hydrogenolysis.
- Groups such as trityl, dimethoxytrityl, acetal and t-butyldimethylsilyl are acid labile and are used in certain embodiments to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected with Cbz groups, which are removable by hydrogenolysis, and/or Fmoc groups, which are base labile.
- carboxylic acid and hydroxy reactive moieties are blocked with base labile groups such as, but not limited to, methyl, ethyl, and acetyl in the presence of amines blocked with acid labile groups such as t-butylcarbamate or with carbamates that are both acid and base stable but hydrolytically removable.
- hydroxy reactive moieties are blocked with hydrolytically removable protective groups such as the benzyl group, while amine groups capable of hydrogen bonding with acids are blocked with base labile groups such as Fmoc.
- carboxylic acid reactive moieties are protected by conversion to simple ester compounds, or they are, in yet another embodiment, blocked with oxidatively-removable protective groups such as 2,4-dimethoxybenzyl, while co-existing amino groups are blocked with fluoride labile silyl or carbamate blocking groups.
- Allyl blocking groups are useful in the presence of acid- and base-protecting groups since the former are stable and can be subsequently removed by metal or pi-acid catalysts.
- an allyl-blocked hydroxy groups can be deprotected with a Pd(O)-catalyzed reaction in the presence of acid labile t-butylcarbamate or base-labile acetate amine protecting groups.
- Yet another form of protecting group is a resin to which a compound or intermediate is attached. As long as the residue is attached to the resin, that functional group is blocked and cannot react. Once released from the resin, the functional group is available to react.
- blocking/protecting groups useful in the synthesis of the compounds described herein are, by way of example only:
- protecting groups useful to protect nucleotides during synthesis include base labile protecting groups and acid labile protecting groups.
- Base labile protecting groups are used to protect the exocyclic amino groups of the heterocyclic nucleobases. This type of protection is generally achieved by acylation. Three commonly used acylating groups for this purpose are benzoyl chloride, phenoxyacetic anhydride, and isobutyryl chloride. These protecting groups are stable to the reaction conditions used during nucleic acid synthesis and are cleaved at approximately equal rates during the base treatment at the end of synthesis.
- the 5′-protecting group is trityl, monomethoxy trityl, dimethoxytrityl, trimethoxytrityl, 2-chlorotrityl, DATE, TBTr, 9-phenylxanthine-9-yl (Pixyl), or 9-(p-methoxyphenyl)xanthine-9-yl (MOX).
- thiol moieties are incorporated in the compounds described herein and are protected.
- the protecting groups include, but are not limited to, pixyl, trityl, benzyl, p-methoxybenzyl (PMB), or tert-butyl (t-Bu).
- Pivaloyl chloride (4.96 ml, 40.3 mmol) was added dropwise via syringe to an ice cold DCM solution (50 mL) of 2-(hydroxymethyl)phenol (5 g, 40.3 mmol) and triethylamine (5.61 ml, 40.3 mmol).
- An ice-cold solution of the crude pivalate ester was treated with triethylamine (6.74 ml, 48.4 mmol) and 50 mL DCM.
- Methanesulfonyl chloride (3.43 ml, 44.3 mmol) was then added slowly (5 min) via syringe and the resulting mixture was warmed to r.t. The mixture was poured onto ice and the organic layer was separated then washed with sat NaHCO 3 (aq), dried (MgSO 4 ), filtered and reduced to 10.5 g crude pale yellow oil.
- Compound 23 is prepared according to a literature method (Journal of Medicinal Chemistry, 50(23), 5568-5570; 2007.)
- Compound 30 is prepared according to a literature method (Tetrahedron, 42(2), 601-7; 1986.)
- Compound 31 is prepared from compound 30 according to a patent procedure (US 20090181444)
- Compound 33 is prepared from compound 32 according to a patent procedure (US 20090181444)
- compound 100 is converted to compound 107 by a procedure analogous to that described for compound 101.
- compound 100 is converted to compound 108 by a procedure analogous to that described for compound 101.
- compound 100 is converted to compound 109 by a procedure analogous to that described for compound 101.
- compound 100 is converted to compound 110 by a procedure analogous to that described for compound 101.
- Compound 110 is converted to compound 210 by a procedure analogous to that described for compound 201.
- compound 100 is converted to compound 111 by a procedure analogous to that described for compound 101.
- Compound 111 is converted to compound 211 by a procedure analogous to that described for compound 201.
- compound 100 is converted to compound 112 by a procedure analogous to that described for compound 101.
- Compound 112 is converted to compound 212 by a procedure analogous to that described for compound 201.
- compound 100 is converted to compound 113 by a procedure analogous to that described for compound 101.
- compound 100 is converted to compound 114 by a procedure analogous to that described for compound 101.
- compound 100 is converted to compound 115 by a procedure analogous to that described for compound 101.
- Compound 100 is converted to compound 152 by a procedure analogous to that described for compound 101.
- compound 152 is converted to compound 153 by a procedure analogous to that described for compound 151.
- Compound 100 is converted to compound 154 by a procedure analogous to that described for compound 101.
- Compound 303 is prepared by sulfurization of compound 300 on support followed by cleavage.
- ACN 450 ⁇ L
- BSTFA 50 ⁇ L
- compound 12 (20 mg) are added to compound 300 (1 ⁇ mol) which is shaken for 18 h.
- the CPG is collected by filtration resuspended in 20% PrNH 2 in dry CH 3 CN (2 mL) and shaken for 16 h at rt. Solvents were removed under reduced pressure and the residue is purified by RPHPLC to provide pure compound 303.
Abstract
Described herein are methods for the synthesis of derivatives of thiosulfonate reagents. Said reagents have utility for the synthesis of phosphorothiotriesters from H-phosphonates in a stereospecific fashion.
Description
- This application claims priority to U.S. provisional application Ser. No. 61/509,526, filed Jul. 19, 2011, the entirety of which is hereby incorporated herein by reference.
- Oligonucleotides are useful in therapeutic, diagnostic, research and nanomaterials applications. The use of natural sequences of DNA or RNA for therapeutics is limited because of their instability against extra and intracellular nucleases, poor cell penetration and distribution. Additionally, in vitro studies have shown that the properties of antisense nucleotides such as binding affinity, sequence specific binding to the complementary RNA (Cosstick and Eckstcin, 1985; LaPlanche et al., 1986; Latimer et al., 1989; Hacia et al., 1994; Mesmaeker et al., 1995), stability to nucleases are affected by the configurations of the phosphorous atoms Therefore, there is a need for modified oligonucleotides to impart stability towards ubiquitous nucleases, increase binding affinity towards complementary RNA and increase cell penetration and bio-distribution for a number of in-vitro and in-vivo applications.
- Described herein are methods for the synthesis of novel functionalized nucleic acids and nucleic acid prodrugs. In some embodiments, the nucleic acids comprise chiral phosphorous moieties.
- One embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa comprising the steps of:
-
- i) reacting an H-phosphonate of structure Ia with an silylating reagent to provide a silyloxyphosphonate; and
- ii) reacting the silyloxyphosphonate with a thiosulfonate reagent of structure IIa to provide a phosphorothiotriester of structure IIIa;
- wherein,
- the H-phosphonate of structure Ia has the following structure:
-
- wherein,
- W is independently selected from O, S, NH, or CH2;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
- Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
- n is between 1 and about 200; and
- the thiosulfonate reagent of structure IIa has the following structure:
- wherein,
-
- X is alkyl, cycloalkyl, or heteroaryl;
- R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
- R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-;
- R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
- and the phosphorothiotriester of structure IIIa has the following structure:
-
- wherein,
- W is independently selected from O, S, NH, or CH2;
- R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
- R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-;
- R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
- Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
- n is between 1 and about 200.
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIa, wherein W is O.
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein R1 is selected from:
-
- R2 is selected from:
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein the silylating reagent is selected from
-
- 1,1,3,3-tetramethyl-1,3-diphenyldisilazane;
- 1,3-dimethyl-1,1,3,3-tetraphenyldisilazane;
- 1-(trimethylsilyl)imidazole;
- N-trimethylsilyl-N-methyl trifluoroacetamide;
- bis(dimethylamino)dimethylsilane;
- bromotrimethylsilane;
- chlorodimethyl(pentafluorophenyl)silane;
- chlorotriethylsilane;
- chlorotriisopropylsilane;
- chlorotrimethylsilane;
- dichlorodimethylsilane;
- hexamethyldisilazane;
- N,N′-bis(trimethylsilyl)urea;
- N,N-bis(trimethylsilyl)methylamine;
- N,N-dimethyltrimethylsilylamine;
- N,O-bis(trimethylsilyl)acetamide;
- N,O-bis(trimethylsilyl)carbamate;
- N,O-bis(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-trimethylsilylacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- trimethylsilyltriflate;
- triethylsilyltriflate;
- triisopropylsilyltriflate; or
- tert-butyldimethylsilyltriflate.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- One embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb comprising the steps of:
-
- i) reacting a H-phosphonate comprising non-stereorandom phosphorous linkages of structure Ib with an silylating reagent to provide a silyloxyphosphonate; and
- ii) reacting the silyloxyphosphonate with a thiosulfonate reagent of structure IIb to provide a phosphorothiotriester comprising non-stereorandom phosphorous linkages of structure IIIb;
- wherein,
- the H-phosphonate comprising non-stereorandom phosphorous linkages of structure Ib has the following structure:
-
- wherein,
- W is independently selected from O, NH, or CH2;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
- Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRe, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
- n is between 1 and about 200; and
- the thiosulfonate reagent of structure IIb has the following structure:
- wherein,
-
- X is alkyl, cycloalkyl, aryl, or heteroaryl;
- R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
- R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-;
- R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
- and the chiral phosphorothiotriester comprising non-stereorandom phosphorous linkages of structure IIIb has the following structure:
-
- wherein,
- W is independently selected from O, NH, or CH2;
- R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
- R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-;
- R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Rc is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
- Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
- n is between 1 and about 200.
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein W is O.
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein R1 is selected from:
- and
-
- R2 is selected from:
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein the silylating reagent is selected from
-
- 1,1,3,3-tetramethyl-1,3-diphenyldisilazane;
- 1,3-dimethyl-1,1,3,3-tetraphenyldisilazane;
- 1-(trimethylsilyl)imidazole;
- N-trimethylsilyl-N-methyl trifluoroacetamide;
- bis(dimethylamino)dimethylsilane;
- bromotrimethylsilane;
- chlorodimethyl(pentafluorophenyl)silane;
- chlorotriethylsilane;
- chlorotriisopropylsilane;
- chlorotrimethylsilane;
- dichlorodimethylsilane;
- hexamethyldisilazane;
- N,N′-bis(trimethylsilyl)urea;
- N,N-bis(trimethylsilyl)methylamine;
- N,N-dimethyltrimethylsilylamine;
- N,O-bis(trimethylsilyl)acetamide;
- N,O-bis(trimethylsilyl)carbamate;
- N,O-bis(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-trimethylsilylacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- trimethylsilyltriflate;
- triethylsilyltriflate;
- triisopropylsilyltriflate; or
- tert-butyldimethylsilyltriflate.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- One embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIc comprising the steps of:
-
- i) reacting a H-phosphonate of structure Ic with an silylating reagent to provide a silyloxyphosphonate;
- ii) reacting the silyloxyphosphonate with a bis(thiosulfonate) reagent of structure IVc to provide a phosphorothiotriester comprising a thiosulfonate group of structure Vc;
- iii) reacting the phosphorothiotriester comprising a thiosulfonate group of structure Vc with a nucleophile of structure VIc to provide the phosphorothiotriesters of structure IIIc;
- wherein,
- the H-phosphonate of structure Ic has the following structure:
-
- wherein,
- W is independently selected from O, S, NH, or CH2;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
- Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
- n is between 1 and about 200; and
- the bis(thiosulfonate) reagent of structure IVc has the following structure:
- wherein,
-
- X is alkylene, alkenylene, arylene, or heteroarylene;
- each R6 is independently alkyl, cycloalkyl, aryl, or heteroaryl;
- the nucleophile of structure VIc has the following structure:
- R7—SH, wherein R7 is selected from alkyl, alkenyl, aryl, heterocyclo, aminoalkyl, or (heterocyclo)alkyl;
- and phosphorothiotriesters of structure IIIc has the following structure:
-
- wherein,
- W is independently selected from O, S, NH, or CH2;
- R is R7—S—S—X—
- R7 is alkyl, alkenyl, aryl, heterocyclo, aminoalkyl, or (heterocyclo)alkyl;
- X is alkylene, alkenylene, arylene, or heteroarylene;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, L+1, or K+1; Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid;
- n is between 1 and about 200; and
- wherein the phosphorous linkages of the H-phosphonate of structure Ic, the phosphorothiotriester comprising a thiosulfonate group of structure Vc, and the phosphorothiotriesters of structure IIIc may optionally comprise non-stereorandom phosphorous linkages.
- Another embodiment provides the process wherein the phosphorothiotriesters of structure IIIb comprise non-stereorandom phosphorous linkages and the H-phosphonate of structure Ic comprise non-stereorandom phosphorous linkages; and W is independently selected from O, NH, or CH2. Another embodiment provides the process wherein W is O.
- Another embodiment provides the process wherein R6 is methyl.
- Another embodiment provides the process wherein bis(thiosulfonate) reagent of structure IVc is selected from:
- Another embodiment provides the process wherein the nucleophile of structure VIc has the following structure:
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein the silylating reagent is selected from
-
- 1,1,3,3-tetramethyl-1,3-diphenyldisilazane;
- 1,3-dimethyl-1,1,3,3-tetraphenyldisilazane;
- 1-(trimethylsilyl)imidazole;
- N-trimethylsilyl-N-methyl trifluoroacetamide;
- bis(dimethylamino)dimethylsilane;
- bromotrimethylsilane;
- chlorodimethyl(pentafluorophenyl)silane;
- chlorotriethylsilane;
- chlorotriisopropylsilane;
- chlorotrimethylsilane;
- dichlorodimethylsilane;
- hexamethyldisilazane;
- N,N′-bis(trimethylsilyl)urea;
- N,N-bis(trimethylsilyl)methylamine;
- N,N-dimethyltrimethylsilylamine;
- N,O-bis(trimethylsilyl)acetamide;
- N,O-bis(trimethylsilyl)carbamate;
- N,O-bis(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-trimethylsilylacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- trimethylsilyltriflate;
- triethylsilyltriflate;
- triisopropylsilyltriflate; or
- tert-butyldimethylsilyltriflate.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
- The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
-
FIG. 1 provides the 31P NMR spectrum ofCompound 100S in CD3CN as described in Example 6; -
FIG. 2 provides the 31P NMR spectrum ofCompound 100S in CD3CN after adding BSTFA as described in Example 6; -
FIG. 3 provides the 31P NMR spectrum ofCompound 100S in CD3CN after adding BSTFA, TEA and MTS as described in Example 6; -
FIG. 4 provides the 31P NMR spectrum ofCompound 100R in CD3CN as described in Example 6; -
FIG. 5 provides the 31P NMR spectrum ofCompound 100R in CD3CN as described in Example 6; and -
FIG. 6 provides the 31P NMR spectrum ofCompound 100R in CD3CN after adding BSTFA, TEA and MTS as described in Example 6. - Unless otherwise stated, the following terms used in this application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms “a” “an” and “the” include plural referents unless the context clearly dictates otherwise. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology are employed. In this application, the use of “or” or “and” means “and/or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “include”, “includes” and “included” is not limiting.
- Unless otherwise noted, the use of general chemical terms, such as though not limited to “alkyl,” “amine,” “aryl,” are unsubstituted.
- As used herein, C1-Cx includes C1-C2, C1-C3 . . . C1-Cx. By way of example only, a group designated as “C1-C4” indicates that there are one to four carbon atoms in the moiety, i.e. groups containing 1 carbon atom, 2 carbon atoms, 3 carbon atoms or 4 carbon atoms, as well as the ranges C1-C2 and C1-C3. Thus, by way of example only, “C1-C4 alkyl” indicates that there are one to four carbon atoms in the alkyl group, i.e., the alkyl group is selected from among methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl. Whenever it appears herein, a numerical range such as “1 to 10” refers to each integer in the given range; e.g., “1 to 10 carbon atoms” means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, 6 carbon atoms, 7 carbon atoms, 8 carbon atoms, 9 carbon atoms, or 10 carbon atoms.
- The terms “heteroatom” or “hetero” as used herein, alone or in combination, refer to an atom other than carbon or hydrogen. Heteroatoms are may be independently selected from among oxygen, nitrogen, sulfur, phosphorous, silicon, selenium and tin but are not limited to these atoms. In embodiments in which two or more heteroatoms are present, the two or more heteroatoms can be the same as each another, or some or all of the two or more heteroatoms can each be different from the others.
- The term “alkyl” as used herein, alone or in combination, refers to a straight-chain or branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, or one to six carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl and hexyl, and longer alkyl groups, such as heptyl, octyl and the like. Whenever it appears herein, a numerical range such as “C1-C6 alkyl” or “C1-6 alkyl”, means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms. In one embodiment, the “alkyl” is substituted. Unless otherwise indicated, the “alkyl” is unsubstituted.
- The term “alkenyl” as used herein, alone or in combination, refers to a straight-chain or branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, or two to about six carbon atoms. The group may be in either the cis or trans conformation about the double bond(s), and should be understood to include both isomers. Examples include, but are not limited to ethenyl (—CH═CH2), 1-propenyl (—CH2CH═CH2), isopropenyl [—C(CH3)═CH2], butenyl, 1,3-butadienyl and the like. Whenever it appears herein, a numerical range such as “C2-C6 alkenyl” or “C2-6 alkenyl”, means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms. In one embodiment, the “alkenyl” is substituted. Unless otherwise indicated, the “alkenyl” is unsubstituted.
- The term “alkynyl” as used herein, alone or in combination, refers to a straight-chain or branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, or from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl and the like. Whenever it appears herein, a numerical range such as “C2-C6 alkynyl” or “C2-6 alkynyl”, means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms. In one embodiment, the “alkynyl” is substituted. Unless otherwise indicated, the “alkynyl” is unsubstituted.
- The terms “heteroalkyl”, “heteroalkenyl” and “heteroalkynyl” as used herein, alone or in combination, refer to alkyl, alkenyl and alkynyl structures respectively, as described above, in which one or more of the skeletal chain carbon atoms (and any associated hydrogen atoms, as appropriate) are each independently replaced with a heteroatom (i.e. an atom other than carbon, such as though not limited to oxygen, nitrogen, sulfur, silicon, phosphorous, tin or combinations thereof), or heteroatomic group such as though not limited to —O—O—, —S—S—, —O—S—, —S—O—, ═N—N═, —N═N—, —N═N—NH—, —P(O)2—, —O—P(O)2—, —P(O)2—O—, —S(O)—, —S(O)2—, —SnH2— and the like.
- The terms “haloalkyl”, “haloalkenyl” and “haloalkynyl” as used herein, alone or in combination, refer to alkyl, alkenyl and alkynyl groups respectively, as defined above, in which one or more hydrogen atoms is replaced by fluorine, chlorine, bromine or iodine atoms, or combinations thereof. In some embodiments two or more hydrogen atoms may be replaced with halogen atoms that are the same as each another (e.g. difluoromethyl); in other embodiments two or more hydrogen atoms may be replaced with halogen atoms that are not all the same as each other (e.g. 1-chloro-1-fluoro-1-iodoethyl). Non-limiting examples of haloalkyl groups are fluoromethyl, chloromethyl and bromoethyl. A non-limiting example of a haloalkenyl group is bromoethenyl. A non-limiting example of a haloalkynyl group is chloroethynyl.
- The term “carbon chain” as used herein, alone or in combination, refers to any alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl or heteroalkynyl group, which is linear, cyclic, or any combination thereof. If the chain is part of a linker and that linker comprises one or more rings as part of the core backbone, for purposes of calculating chain length, the “chain” only includes those carbon atoms that compose the bottom or top of a given ring and not both, and where the top and bottom of the ring(s) are not equivalent in length, the shorter distance shall be used in determining the chain length. If the chain contains heteroatoms as part of the backbone, those atoms are not calculated as part of the carbon chain length.
- The term “cycloalkyl” as used herein, alone or in combination, refers to a saturated, hydrocarbon monoradical ring, containing from three to about fifteen ring carbon atoms or from three to about ten ring carbon atoms, though may include additional, non-ring carbon atoms as substituents (e.g. methylcyclopropyl). Whenever it appears herein, a numerical range such as “C3-C6 cycloalkyl” or “C3-6 cycloalkyl”, means that the cycloalkyl group may consist of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, i.e., is cyclopropyl, cyclobutyl, cyclopentyl or cyclohepty, although the present definition also covers the occurrence of the term “cycloalkyl” where no numerical range is designated. The term includes fused, non-fused, bridged and spiro radicals. A fused cycloalkyl may contain from two to four fused rings where the ring of attachment is a cycloalkyl ring, and the other individual rings may be alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof. Examples include, but are not limited to cyclopropyl, cyclopentyl, cyclohexyl, decalinyl, and bicyclo [2.2.1] heptyl and adamantyl ring systems. Illustrative examples include, but are not limited to the following moieties:
- and the like.
- In one embodiment, the “cycloalkyl” is substituted. Unless otherwise indicated, the “cycloalkyl” is unsubstituted.
- The terms “non-aromatic heterocyclyl” and “heteroalicyclyl” as used herein, alone or in combination, refer to a saturated, partially unsaturated, or fully unsaturated nonaromatic ring monoradicals containing from three to about twenty ring atoms, where one or more of the ring atoms are an atom other than carbon, independently selected from among oxygen, nitrogen, sulfur, phosphorous, silicon, selenium and tin but are not limited to these atoms. In embodiments in which two or more heteroatoms are present in the ring, the two or more heteroatoms can be the same as each another, or some or all of the two or more heteroatoms can each be different from the others. The terms include fused, non-fused, bridged and spiro radicals. A fused non-aromatic heterocyclic radical may contain from two to four fused rings where the attaching ring is a non-aromatic heterocycle, and the other individual rings may be alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof. Fused ring systems may be fused across a single bond or a double bond, as well as across bonds that are carbon-carbon, carbon-hetero atom or hetero atom-hetero atom. The terms also include radicals having from three to about twelve skeletal ring atoms, as well as those having from three to about ten skeletal ring atoms. Attachment of a non-aromatic heterocyclic subunit to its parent molecule can be via a heteroatom or a carbon atom. Likewise, additional substitution can be via a heteroatom or a carbon atom. As a non-limiting example, an imidazolidine non-aromatic heterocycle may be attached to a parent molecule via either of its N atoms (imidazolidin-1-yl or imidazolidin-3-yl) or any of its carbon atoms (imidazolidin-2-yl, imidazolidin-4-yl or imidazolidin-5-yl). In certain embodiments, non-aromatic heterocycles contain one or more carbonyl or thiocarbonyl groups such as, for example, oxo- and thio-containing groups. Examples include, but are not limited to pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl. Illustrative examples of heterocycloalkyl groups, also referred to as non-aromatic heterocycles, include:
- and the like.
- The terms also include all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides. In one embodiment, the “non-aromatic heterocyclyl” or “heteroalicyclyl” is substituted. Unless otherwise indicated, the “non-aromatic heterocyclyl” or “heteroalicyclyl” is unsubstituted.
- The term “aryl” as used herein, alone or in combination, refers to an aromatic hydrocarbon radical of six to about twenty ring carbon atoms, and includes fused and non-fused aryl rings. A fused aryl ring radical contains from two to four fused rings where the ring of attachment is an aryl ring, and the other individual rings may be alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof. Further, the term aryl includes fused and non-fused rings containing from six to about twelve ring carbon atoms, as well as those containing from six to about ten ring carbon atoms. A non-limiting example of a single ring aryl group includes phenyl; a fused ring aryl group includes naphthyl, phenanthrenyl, anthracenyl, azulenyl; and a non-fused bi-aryl group includes biphenyl. In one embodiment, the “aryl” is substituted. Unless otherwise indicated, the “aryl” is unsubstituted.
- The term “heteroaryl” as used herein, alone or in combination, refers to an aromatic monoradicals containing from about five to about twenty skeletal ring atoms, where one or more of the ring atoms is a heteroatom independently selected from among oxygen, nitrogen, sulfur, phosphorous, silicon, selenium and tin but not limited to these atoms and with the proviso that the ring of said group does not contain two adjacent O or S atoms. In embodiments in which two or more heteroatoms are present in the ring, the two or more heteroatoms can be the same as each another, or some or all of the two or more heteroatoms can each be different from the others. The term heteroaryl includes fused and non-fused heteroaryl radicals having at least one heteroatom. The term heteroaryl also includes fused and non-fused heteroaryls having from five to about twelve skeletal ring atoms, as well as those having from five to about ten skeletal ring atoms. Bonding to a heteroaryl group can be via a carbon atom or a heteroatom. Thus, as a non-limiting example, an imidazole group may be attached to a parent molecule via any of its carbon atoms (imidazol-2-yl, imidazol-4-yl or imidazol-5-yl), or its nitrogen atoms (imidazol-1-yl or imidazol-3-yl). Likewise, a heteroaryl group may be further substituted via any or all of its carbon atoms, and/or any or all of its heteroatoms. A fused heteroaryl radical may contain from two to four fused rings where the ring of attachment is a heteroaromatic ring and the other individual rings may be alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof. A non-limiting example of a single ring heteroaryl group includes pyridyl; fused ring heteroaryl groups include benzimidazolyl, quinolinyl, acridinyl; and a non-fused bi-heteroaryl group includes bipyridinyl. Further examples of heteroaryls include, without limitation, furanyl, thienyl, oxazolyl, acridinyl, phenazinyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, benzoxadiazolyl, benzotriazolyl, imidazolyl, indolyl, isoxazolyl, isoquinolinyl, indolizinyl, isothiazolyl, isoindolyloxadiazolyl, indazolyl, pyridyl, pyridazyl, pyrimidyl, pyrazinyl, pyrrolyl, pyrazinyl, pyrazolyl, purinyl, phthalazinyl, pteridinyl, quinolinyl, quinazolinyl, quinoxalinyl, triazolyl, tetrazolyl, thiazolyl, triazinyl, thiadiazolyl and the like, and their oxides, such as for example pyridyl-N-oxide. Illustrative examples of heteroaryl groups include the following moieties:
- and the like.
- In one embodiment, the “heteroaryl” is substituted. Unless otherwise indicated, the “heteroaryl” is unsubstituted.
- The term “heterocyclyl” as used herein, alone or in combination, refers collectively to heteroalicyclyl and heteroaryl groups. Herein, whenever the number of carbon atoms in a heterocycle is indicated (e.g., C1-C6 heterocycle), at least one non-carbon atom (the heteroatom) must be present in the ring. Designations such as “C1-C6 heterocycle” refer only to the number of carbon atoms in the ring and do not refer to the total number of atoms in the ring. Designations such as “4-6 membered heterocycle” refer to the total number of atoms that are contained in the ring (i.e., a four, five, or six membered ring, in which at least one atom is a carbon atom, at least one atom is a heteroatom and the remaining two to four atoms are either carbon atoms or heteroatoms). For heterocycles having two or more heteroatoms, those two or more heteroatoms can be the same or different from one another. Non-aromatic heterocyclic groups include groups having only three atoms in the ring, while aromatic heterocyclic groups must have at least five atoms in the ring. Bonding (i.e. attachment to a parent molecule or further substitution) to a heterocycle can be via a heteroatom or a carbon atom. In one embodiment, the “heterocyclyl” is substituted. Unless otherwise indicated, the “heterocycyl” is unsubstituted.
- The terms “halogen”, “halo” or “halide” as used herein, alone or in combination refer to fluoro, chloro, bromo and/or iodo.
- The compounds, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, such as (R)- or (S)-. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both Z and E geometric isomers (e.g., cis or trans). Likewise, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included.
- A “stereoisomer” refers to the relationship between two or more compounds made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not superimposable. The term “enantiomer” refers to two stereoisomers that are nonsuperimposeable mirror images of one another. It is contemplated that the various stereoisomers of the compounds disclosed herein, and mixtures thereof, are within the scope of the present disclosure and specifically includes enantiomers.
- A “tautomer” refers to a compound wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible. The compounds presented herein may exist as tautomers. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Some examples of tautomeric equilibrium are shown below.
- The term “non-stereorandom phosphorous linkage(s)” as used herein refers to a chiral phosphorous atom in the phosphodiester, or other isosteric linkage type, internucleotide linkage. For embodiments comprising more than one phosphorous internucleotide linkage, the handedness of chirality at phosphorous is independently selected at each phosphorous atom. In one embodiment, the oligonucleotide described herein is a pure diastereomer. In another embodiment, the oligonucleotide is greater that 95% diastereomeric purity. In another embodiment, the oligonucleotide is greater that 90% diastereomeric purity.
- “Optional” or “optionally” means that a subsequently described event or circumstance may or may not occur and that the description includes instances when the event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means that the alkyl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
- Natural nucleic acids have a phosphate backbone; artificial nucleic acids may contain other types of backbones, but contain the same bases.
- The term “nucleotide” as used herein refers to a monomeric unit of a polynucleotide that consists of a heterocyclic base, a sugar, and one or more phosphate groups. The naturally occurring bases, (guanine, (G), adenine (A), cytosine (C), thymine (T), and uracil (U)) are derivatives of purine or pyrimidine, though it should be understood that naturally and non-naturally occurring base analogs are also included. The naturally occurring sugar is the pentose (five-carbon sugar) deoxyribose (which forms DNA) or ribose (which forms RNA), though it should be understood that naturally and non-naturally occurring sugar analogs are also included. Nucleic acids are linked via phosphate bonds to form nucleic acids, or polynucleotides, though many other linkages are known in the art (such as, though not limited to phosphorothioates, boranophosphates and the like). Artificial nucleic acids include PNAs (peptide nucleic acids), phosphothionates, and other variants of the phosphate backbone of native nucleic acids.
- The term “nucleoside” refers to a moiety wherein a nucleobase or a modified nucleobase is covalently bound to a sugar or modified sugar.
- The term “sugar” refers to a monosaccharide in closed and/or open form. Sugars include, but are not limited to, ribose, deoxyribose, pentofuranose, pentopyranose, and hexopyranose moieties.
- The term “modified sugar” refers to a moiety that can replace a sugar. The modified sugar mimics the spatial arrangement, electronic properties, or some other physicochemical property of a sugar.
- The terms “nucleic acid” and “polynucleotide” as used herein refer to a polymeric form of nucleotides of any length, either ribonucleotides (RNA) or deoxyribonucleotides (DNA). These terms refer to the primary structure of the molecules and, thus, include double- and single-stranded DNA, and double- and single-stranded RNA. These terms include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs and modified polynucleotides such as, though not limited to, methylated and/or capped polynucleotides. The terms encompass poly- or oligo-ribonucleotides (RNA) and poly- or oligo-deoxyribonucleotides (DNA); RNA or DNA derived from N-glycosides or C-glycosides of nucleobases and/or modified nucleobases; nucleic acids derived from sugars and/or modified sugars; and nucleic acids derived from phosphate bridges and/or modified phosphorous-atom bridges. The term encompasses nucleic acids containing any combinations of nucleobases, modified nucleobases, sugars, modified sugars, phosphate bridges or modified phosphorous atom bridges. Examples include, and are not limited to, nucleic acids containing ribose moieties, the nucleic acids containing deoxy-ribose moieties, nucleic acids containing both ribose and deoxyribose moieties, nucleic acids containing ribose and modified ribose moieties. The prefix poly- refers to a nucleic acid containing about 1 to about 10,000 nucleotide monomer units and wherein the prefix oligo- refers to a nucleic acid containing about 1 to about 200 nucleotide monomer units.
- The term “nucleobase” refers to the parts of nucleic acids that are involved in the hydrogen-bonding that binds one nucleic acid strand to another complementary strand in a sequence specific manner. The most common naturally-occurring nucleobases are adenine (A), guanine (G), uracil (U), cytosine (C), and thymine (T).
- The term “modified nucleobase” refers to a moiety that can replace a nucleobase. The modified nucleobase mimics the spatial arrangement, electronic properties, or some other physicochemical property of the nucleobase and retains the property of hydrogen-bonding that binds one nucleic acid strand to another in a sequence specific manner. A modified nucleobase can pair with all of the five naturally occurring bases (uracil, thymine, adenine, cytosine, or guanine) without substantially affecting the melting behavior, recognition by intracellular enzymes or activity of the oligonucleotide duplex.
- The term “chiral reagent” refers to a compound that is chiral or enantiopure and can be used for asymmetric induction in nucleic acid synthesis.
- The term “chiral ligand” or “chiral auxiliary” refers to a moiety that is chiral or enantiopure and controls the stereochemical outcome of a reaction.
- In a condensation reaction, the term “condensing reagent” refers to a reagent that activates a less reactive site and renders it more susceptible to attack by a nucleophile.
- The term “blocking group” refers to a group that transiently masks the reactivity of a functional group. The functional group can be subsequently unmasked by removal of the blocking group.
- The term “moiety” refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule.
- The term “solid support” refers to any support which enables synthetic mass production of nucleic acids and can be reutilized at need. As used herein, the term refers to a polymer, that is insoluble in the media employed in the reaction steps performed to synthesize nucleic acids, and is derivatized to comprise reactive groups.
- The term “linking moiety” refers to any moiety optionally positioned between the terminal nucleoside and the solid support or between the terminal nucleoside and another nucleoside, nucleotide, or nucleic acid.
- A “DNA molecule” refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences can be described herein according to the normal convention of giving only the sequence in the 5′ to 3′ direction along the non-transcribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).
- As used herein, an “antisense” nucleic acid molecule comprises a nucleotide sequence which is complementary to a “sense” nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule, complementary to an mRNA sequence or complementary to the coding strand of a gene. Accordingly, an antisense nucleic acid molecule can hydrogen bond to a sense nucleic acid molecule.
- As used herein, a “complementary DNA” or “cDNA” includes recombinant polynucleotides synthesized by reverse transcription of mRNA and from which intervening sequences (introns) have been removed.
- Described herein are methods for the synthesis of novel functionalized nucleic acids and nucleic acid prodrugs. In some embodiments, the nucleic acids comprise chiral phosphorous moieties.
- One embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa comprising the steps of:
-
- i) reacting an H-phosphonate of structure Ia with an silylating reagent to provide a silyloxyphosphonate; and
- ii) reacting the silyloxyphosphonate with a thiosulfonate reagent of structure IIa to provide a phosphorothiotriester of structure IIIa;
- wherein,
- the H-phosphonate of structure Ia has the following structure:
-
- wherein,
- W is independently selected from O, S, NH, or CH2;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Rc is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
- Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
- n is between 1 and about 200; and
- the thiosulfonate reagent of structure IIa has the following structure:
- wherein,
-
- X is alkyl, cycloalkyl, or heteroaryl;
- R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
- R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-;
- R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
- and the phosphorothiotriester of structure IIIa has the following structure:
-
- wherein,
- W is independently selected from O, S, NH, or CH2;
- R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
- R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-;
- R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
- Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
- n is between 1 and about 200.
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein W is O.
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein R1 is selected from:
- and
-
- R2 is selected from:
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein the silylating reagent is selected from
-
- 1,1,3,3-tetramethyl-1,3-diphenyldisilazane;
- 1,3-dimethyl-1,1,3,3-tetraphenyldisilazane;
- 1-(trimethylsilyl)imidazole;
- N-trimethylsilyl-N-methyl trifluoroacetamide;
- bis(dimethylamino)dimethylsilane;
- bromotrimethylsilane;
- chlorodimethyl(pentafluorophenyl)silane;
- chlorotriethylsilane;
- chlorotriisopropylsilane;
- chlorotrimethylsilane;
- dichlorodimethylsilane;
- hexamethyldisilazane;
- N,N′-bis(trimethylsilyl)urea;
- N,N-bis(trimethylsilyl)methylamine;
- N,N-dimethyltrimethylsilylamine;
- N,O-bis(trimethylsilyl)acetamide;
- N,O-bis(trimethylsilyl)carbamate;
- N,O-bis(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-trimethylsilylacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- trimethylsilyltriflate;
- triethylsilyltriflate;
- triisopropylsilyltriflate; or
- tert-butyldimethylsilyltriflate.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- One embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb comprising the steps of:
-
- i) reacting a H-phosphonate comprising non-stereorandom phosphorous linkages of structure Ib with an silylating reagent to provide a silyloxyphosphonate; and
- ii) reacting the silyloxyphosphonate with a thiosulfonate reagent of structure IIb to provide a phosphorothiotriester comprising non-stereorandom phosphorous linkages of structure IIb;
- wherein,
- the H-phosphonate comprising non-stereorandom phosphorous linkages of structure Ib has the following structure:
-
- wherein,
- W is independently selected from O, NH, or CH2;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+; Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
- n is between 1 and about 200; and
- the thiosulfonate reagent of structure IIb has the following structure:
- wherein,
-
- X is alkyl, cycloalkyl, aryl, or heteroaryl;
- R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
- R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-; R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
- and the chiral phosphorothiotriester comprising non-stereorandom phosphorous linkages of structure IIIb has the following structure:
-
- wherein,
- W is independently selected from O, NH, or CH2;
- R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
- R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-;
- R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
- Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
- n is between 1 and about 200.
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein W is O.
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein R1 is selected from:
-
- R2 is selected from:
- Another embodiment provides a process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb, wherein the silylating reagent is selected from
-
- 1,1,3,3-tetramethyl-1,3-diphenyldisilazane;
- 1,3-dimethyl-1,1,3,3-tetraphenyldisilazane;
- 1-(trimethylsilyl)imidazole;
- N-trimethylsilyl-N-methyl trifluoroacetamide;
- bis(dimethylamino)dimethylsilane;
- bromotrimethylsilane;
- chlorodimethyl(pentafluorophenyl)silane;
- chlorotriethylsilane;
- chlorotriisopropylsilane;
- chlorotrimethylsilane;
- dichlorodimethylsilane;
- hexamethyldisilazane;
- N,N′-bis(trimethylsilyl)urea;
- N,N-bis(trimethylsilyl)methylamine;
- N,N-dimethyltrimethylsilylamine;
- N,O-bis(trimethylsilyl)acetamide;
- N,O-bis(trimethylsilyl)carbamate;
- N,O-bis(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-trimethylsilylacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- trimethylsilyltriflate;
- triethylsilyltriflate;
- triisopropylsilyltriflate; or
- tert-butyldimethylsilyltriflate.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- One embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIc comprising the steps of:
-
- i) reacting a H-phosphonate of structure Ic with an silylating reagent to provide a silyloxyphosphonate;
- ii) reacting the silyloxyphosphonate with a bis(thiosulfonate) reagent of structure IVc to provide a phosphorothiotriester comprising a thiosulfonate group of structure Vc;
- iii) reacting the phosphorothiotriester comprising a thiosulfonate group of structure Vc with a nucleophile of structure VIc to provide the phosphorothiotriesters of structure IIIc;
- wherein,
- the H-phosphonate of structure Ic has the following structure:
-
- wherein,
- W is independently selected from O, S, NH, or CH2;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
- Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
- n is between 1 and about 200; and
- the bis(thiosulfonate) reagent of structure IVc has the following structure:
- wherein,
-
- X is alkylene, alkenylene, arylene, or heteroarylene;
- each R6 is independently alkyl, cycloalkyl, aryl, or heteroaryl;
- the nucleophile of structure VIc has the following structure:
- R7—SH, wherein R7 is selected from alkyl, alkenyl, aryl, heterocyclo, aminoalkyl, or (heterocyclo)alkyl;
- and phosphorothiotriesters of structure IIIc has the following structure:
-
- wherein,
- W is independently selected from O, S, NH, or CH2;
- R is R7—S—S—X—
- R7 is alkyl, alkenyl, aryl, heterocyclo, aminoalkyl, or (heterocyclo)alkyl;
- X is alkylene, alkenylene, arylene, or heteroarylene;
- R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
- Y1 is O, NRd, S, or Se;
- Ra is a blocking group;
- Rc is a blocking group;
- each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
- each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
- Y2 is O, NRd, or S;
- each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
- each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
- R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid;
- n is between 1 and about 200; and
- wherein the phosphorous linkages of the H-phosphonate of structure Ic, the phosphorothiotriester comprising a thiosulfonate group of structure Vc, and the phosphorothiotriesters of structure IIIc may optionally comprise non-stereorandom phosphorous linkages.
- Another embodiment provides the process wherein the phosphorothiotriesters of structure IIIb comprise non-stereorandom phosphorous linkages and the H-phosphonate of structure Ic comprise non-stereorandom phosphorous linkages; and W is independently selected from O, NH, or CH2. Another embodiment provides the process wherein W is O.
- Another embodiment provides the process wherein R6 is methyl.
- Another embodiment provides the process wherein bis(thiosulfonate) reagent of structure IVc is selected from:
- Another embodiment provides the process wherein the nucleophile of structure VIc has the following structure:
- Another embodiment provides a process for the preparation of phosphorothiotriesters of structure IIIa, wherein the silylating reagent is selected from
-
- 1,1,3,3-tetramethyl-1,3-diphenyldisilazane;
- 1,3-dimethyl-1, 1,3,3-tetraphenyldisilazane;
- 1-(trimethylsilyl)imidazole;
- N-trimethylsilyl-N-methyl trifluoroacetamide;
- bis(dimethylamino)dimethylsilane;
- bromotrimethylsilane;
- chlorodimethyl(pentafluorophenyl)silane;
- chlorotriethylsilane;
- chlorotriisopropylsilane;
- chlorotrimethylsilane;
- dichlorodimethylsilane;
- hexamethyldisilazane;
- N,N′-bis(trimethylsilyl)urea;
- N,N-bis(trimethylsilyl)methylamine;
- N,N-dimethyltrimethylsilylamine;
- N,O-bis(trimethylsilyl)acetamide;
- N,O-bis(trimethylsilyl)carbamate;
- N,O-bis(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-(trimethylsilyl)trifluoroacetamide;
- N-methyl-N-trimethylsilylacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide;
- N-methyl-N-trimethylsilylheptafluorobutyramide;
- trimethylsilyltriflate;
- triethylsilyltriflate;
- triisopropylsilyltriflate; or
- tert-butyldimethylsilyltriflate.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethylsilyl)imidazole.
- Another embodiment provides the process, wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
- Another embodiment provides the process, wherein the H-phosphonate is covalently linked to a solid phase.
- Oligonucleotides have several pharmaceutical properties which can be improved through the application of prodrug strategies. In particular, oligonucleotides are rapidly degraded by nucleases and exhibit poor cellular uptake through the cytoplasmic cell membrane (Poijarvi-Virta et al., Curr. Med. Chem. (2006), 13(28); 3441-65; Wagner et al., Med. Res. Rev. (2000), 20(6):417-51; Peyrottes et al., Mini Rev. Med. Chem. (2004), 4(4):395-408; Gosselin et al., (1996), 43(1):196-208; Bologna et al., (2002), Antisense & Nucleic Acid Drug Development 12:33-41). In one example, Vives et al., (Nucleic Acids Research (1999), 27(20):4071-76) found that tert-butyl SATE pro-oligonucleotides displayed markedly increased cellular penetration compared to the parent oligonucleotide. Described herein are methods for the synthesis of modified oligonucleotides or pronucleotides.
- The steps of reacting a molecule comprising an achiral H-phosphonate moiety and a nucleoside comprising a 5′-OH moiety to form a condensed intermediate can occur without isolating any intermediates. In some embodiments, the steps of reacting a molecule comprising an achiral H-phosphonate moiety and a nucleoside comprising a 5′-OH moiety to form a condensed intermediate occurs is a one-pot reaction. In an embodiment, a molecule comprising an achiral H-phosphonate moiety, condensing reagent, chiral reagent, and compound comprising a free nucleophilic moiety are added to the reaction mixture at different times. In another embodiment, a molecule comprising an achiral H-phosphonate moiety, condensing reagent, and chiral reagent are present in the same reaction vessel or same pot. In another embodiment, a molecule comprising an achiral H-phosphonate moiety, condensing reagent, chiral reagent, and compound comprising a free nucleophilic moiety are present in the same reaction or same pot. This allows the reaction to be performed without isolation of intermediates and eliminates time-consuming steps, resulting in an economical and efficient synthesis. In specific embodiments, the achiral H-phosphonate, condensing reagent, chiral amino alcohol, 5′-OH nucleoside are present at the same time in a reaction. In a further embodiment, the formation of the chiral intermediate for condensation is formed in situ and is not isolated prior to the condensation reaction. In another embodiment, a molecule comprising an achiral H-phosphonate moiety has been activated by reaction with a condensing reagent, chiral reagent in a different reaction vessel from that used when reacting the chiral intermediate with the compound comprising a free 5′-OH moiety.
- In some embodiments, the synthesis of the nucleic acid is performed in solution. In other embodiments, the synthesis of the nucleic acid is performed on solid phase. The reactive groups of a solid support may be unprotected or protected. During oligonucleotide synthesis a solid support is treated with various reagents in several synthesis cycles to achieve the stepwise elongation of a growing oligonucleotide chain with individual nucleotide units. The nucleoside unit at the end of the chain which is directly linked to the solid support is termed “the first nucleoside” as used herein. The first nucleoside is bound to the solid support via a linker moiety, i.e. a diradical with covalent bonds to both the polymer of the solid support and the nucleoside. The linker stays intact during the synthesis cycles performed to assemble the oligonucleotide chain and is cleaved after the chain assembly to liberate the oligonucleotide from the support.
- Solid supports for solid-phase nucleic acid synthesis include the supports described in, e.g., U.S. Pat. Nos. 4,659,774, 5,141,813, 4,458,066; Caruthers U.S. Pat. Nos. 4,415,732, 4,458,066, 4,500,707, 4,668,777, 4,973,679, and 5,132,418; Andrus et al. U.S. Pat. Nos. 5,047,524, 5,262,530; and Koster U.S. Pat. No. 4,725,677 (reissued as Re34,069). In some embodiments, the solid phase is an organic polymer support. In other embodiments, the solid phase is an inorganic polymer support. In some embodiments, the organic polymer support is polystyrene, aminomethyl polystyrene, a polyethylene glycol-polystyrene graft copolymer, polyacrylamide, polymethacrylate, polyvinylalcohol, highly cross-linked polymer (HCP), or other synthetic polymers, carbohydrates such as cellulose and starch or other polymeric carbohydrates, or other organic polymers and any copolymers, composite materials or combination of the above inorganic or organic materials. In other embodiments, the inorganic polymer support is silica, alumina, controlled poreglass (CPG), which is a silica-gel support, or aminopropyl CPG. Other useful solid supports include fluorous solid supports (see e.g., WO/2005/070859), long chain alkylamine (LCAA) controlled pore glass (CPG) solid supports (sce e.g., S. P. Adams, K. S. Kavka, E. J. Wykes, S. B. Holder and G. R. Galluppi, J. Am. Chem. Soc., 1983, 105, 661-663; G. R. Gough, M. J. Bruden and P. T. Gilham, Tetrahedron Lett., 1981, 22, 4177-4180). Membrane supports and polymeric membranes (see e.g. Innovation and Perspectives in Solid Phase Synthesis, Peptides, Proteins and Nucleic Acids, ch 21 pp 157-162, 1994, Ed. Roger Epton and U.S. Pat. No. 4,923,901) are also useful for the synthesis of nucleic acids. Once formed, a membrane can be chemically functionalized for use in nucleic acid synthesis. In addition to the attachment of a functional group to the membrane, the use of a linker or spacer group attached to the membrane may be used to minimize steric hindrance between the membrane and the synthesized chain.
- Other suitable solid supports include those generally known in the art to be suitable for use in solid phase methodologies, including, for example, glass sold as Primer™ 200 support, controlled pore glass (CPG), oxalyl-controlled pore glass (see, e.g., Alul, et al., Nucleic Acids Research, 1991, 19, 1527), TentaGel Support—an aminopolyethyleneglycol derivatized support (see, e.g., Wright, et al., Tetrahedron Lett., 1993, 34, 3373), and Poros-a copolymer of polystyrene/divinylbenzene.
- Surface activated polymers have been demonstrated for use in synthesis of natural and modified nucleic acids and proteins on several solid supports mediums. The solid support material can be any polymer suitably uniform in porosity, has sufficient amine content, and sufficiently flexible to undergo any attendant manipulations without losing integrity. Examples of suitable selected materials include nylon, polypropylene, polyester, polytetrafluoroethylene, polystyrene, polycarbonate, and nitrocellulose. Other materials can serve as the solid support, depending on the design of the investigator. In consideration of some designs, for example, a coated metal, in particular gold or platinum can be selected (see e.g., US publication No. 20010055761). In one embodiment of oligonucleotide synthesis, for example, a nucleoside is anchored to a solid support which is functionalized with hydroxyl or amino residues. Alternatively, the solid support is derivatized to provide an acid labile trialkoxytrityl group, such as a trimethoxytrityl group (TMT). Without being bound by theory, it is expected that the presence of the trialkoxytrityl protecting group will permit initial detritylation under conditions commonly used on DNA synthesizers. For a faster release of oligonucleotide material in solution with aqueous ammonia, a diglycoate linker is optionally introduced onto the support.
- A linking moiety or linker is optionally used to connect the solid support to the compound comprising a free nucleophilic moiety. Suitable linkers are known such as short molecules which serve to connect a solid support to functional groups (e.g., hydroxyl groups) of initial nucleosides molecules in solid phase synthetic techniques. In some embodiments, the linking moiety is a succinamic acid linker, or a succinate linker (—CO—CH2—CH2—CO—), or an oxalyl linker (—CO—CO—). In other embodiments, the linking moiety and the nucleoside are bonded together through an ester bond. In other embodiments, the linking moiety and the nucleoside are bonded together through an amide bond. In further embodiments, the linking moiety connects the nucleoside to another nucleotide or nucleic acid. Suitable linkers are disclosed in, for example, Oligonucleotides And Analogues A Practical Approach, Ekstein, F. Ed., IRL Press, N.Y., 1991, Chapter 1.
- A linker moiety is used to connect the compound comprising a free nucleophilic moiety to another nucleoside, nucleotide, or nucleic acid. In some embodiments, the linking moiety is a phosphodiester linkage. In other embodiments, the linking moiety is an H-phosphonate moiety. In yet other embodiments, the linking moiety is an X-phosphonate moiety.
- Synthesis of the nucleic acids is performed in an aprotic organic solvent. In some embodiments, the solvent is acetonitrile, pyridine, or NMP. In some embodiments, the solvent is acetone, acetontrile, NMP, ethyl acetate, THF, dioxane, DMF, DMSO, DCM, chloroform, pyridine, 2,6-lutidine, HMPA, HMPT, DMA, glyme, diglyme, sulfone, methyl tert-butyl ether, or combinations thereof. In some embodiments, the solvent is a polar, aprotic organic solvent. In some embodiments, the solvent is anhydrous.
- Acidification to remove blocking groups is accomplished by a Brønsted acid or Lewis acid. In some embodiments, acidification is used to remove R1 blocking groups. Useful Brønsted acids are carboxylic acids, alkylsulfonic acids, arylsulfonic acids, phosphoric acid and its derivatives, phosphonic acid and its derivatives, alkylphosphonic acids and their derivatives, arylphosphonic acids and their derivatives, phosphinic acid, dialkylphosphinic acids, and diarylphosphinic acids which have a pKa (25° C. in water) value of −0.6 (trifluoroacetic acid) to 4.76 (acetic acid) in an organic solvent or water (in the case of 80% acetic acid). The concentration of the acid (1 to 80%) used in the acidification step depends on the acidity of the acid. Consideration to the acid strength must be taken into account as strong acid conditions will result in depurination/depyrimidination, wherein purinyl or pyrimidinyl bases are cleaved from ribose ring.
- In some embodiments, acidification is accomplished by a Lewis acid in an organic solvent. Useful Lewis acids are ZnX2 wherein X is Cl, Br, I, or CF3SO3.
- In some embodiments, the acidifying comprises adding an amount of a Brønsted or Lewis acid effective to convert the condensed intermediate into the compound of Formula 4 without removing purine moieties from the condensed intermediate.
- Acids that are useful in the acidifying step also include, but are not limited to 10% phosphoric acid in an organic solvent, 10% hydrochloric acid in an organic solvent, 1% trifluoroacetic acid in an organic solvent, 3% dichloroacetic acid in an organic solvent or 80% acetic acid in water. The concentration of any Brønsted or Lewis acid used in the process is selected such that the concentration of the acid does not exceed a concentration that causes cleavage of the nucleobase from the sugar moiety.
- In some embodiments, acidification comprises adding 1% trifluoroacetic acid in an organic solvent. In some embodiments, acidification comprises adding about 0.1% to about 8% trifluoroacetic acid in an organic solvent. In other embodiments, acidification comprises adding 3% dichloroacetic acid in an organic solvent. In other embodiments, acidification comprises adding about 0.1% to about 10% dichloroacetic acid in an organic solvent. In yet other embodiments, acidification comprises adding 3% trichloroacetic acid in an organic solvent. In yet other embodiments, acidification comprises adding about 0.1% to about 10% trichloroacetic acid in an organic solvent. In some embodiments, acidification comprises adding 80% acetic acid in water. In some embodiments, acidification comprises adding about 50% to about 90%, or about 50% to about 80%, about 50% to about 70%, about 50% to about 60%, about 70% to about 90% acetic acid in water. In some embodiments, the acidification comprises the further addition of cation scavengers to the acidic solvent. In specific embodiments, the cation scavengers can be triethylsilane or triisopropylsilane. In some embodiments, R1 is deblocked prior to the step of acidifying the condensed intermediate. In some embodiments, R1 is deblocked by acidification, which comprises adding 1% trifluoroacetic acid in an organic solvent. In some embodiments, R1 is deblocked by acidification, which comprises adding 3% dichloroacetic acid in an organic solvent. In some embodiments, R1 is deblocked by acidification, which comprises adding 3% trichloroacetic acid in an organic solvent.
- Functional groups such as hydroxyl or amino moieties which are located on nucleobases or sugar moieties are routinely blocked with blocking (protecting) groups (moieties) during synthesis and subsequently deblocked. In general, a blocking group renders a chemical functionality of a molecule inert to specific reaction conditions and can later be removed from such functionality in a molecule without substantially damaging the remainder of the molecule (see e.g., Green and Wuts, Protective Groups in Organic Synthesis, 2nd Ed., John Wiley & Sons, New York, 1991). For example, amino groups can be blocked with nitrogen blocking groups such as phthalimido, 9-fludrenylmethoxycarbonyl (FMOC), triphenylmethylsulfenyl, t-BOC, 4,4′-dimethoxytrityl (DMTr), 4-methoxytrityl (MMTr), 9-phenylxanthin-9-yl (Pixyl), trityl (Tr), or 9-(p-methoxyphenyl)xanthin-9-yl (MOX). Carboxyl groups can be protected as acetyl groups. Hydroxy groups can be protected such as tetrahydropyranyl (THP), t-butyldimethylsilyl (TBDMS), 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (Ctmp), 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp), 1-(2-chloroethoxy)ethyl, 3-methoxy-1,5-dicarbomethoxypentan-3-yl (MDP), bis(2-acetoxyethoxy)methyl (ACE), triisopropylsilyloxymethyl (TOM), 1-(2-cyanoethoxy)ethyl (CEE), 2-cyanoethoxymethyl (CEM), [4-(N-dichloroacetyl-N-methylamino)benzyloxy]methyl, 2-cyanoethyl (CN), pivaloyloxymethyl (PivOM), levunyloxymethyl (ALE). Other representative hydroxyl blocking groups have been described (see e.g., Beaucage et al., Tetrahedron, 1992, 46, 2223). In some embodiments, hydroxyl blocking groups are acid-labile groups, such as the trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl, 9-phenylxanthin-9-yl (Pixyl) and 9-(p-methoxyphenyl)xanthin-9-yl (MOX). Chemical functional groups can also be blocked by including them in a precursor form. Thus an azido group can be considered a blocked form of an amine as the azido group is easily converted to the amine. Further representative protecting groups utilized in nucleic acid synthesis are known (see e.g. Agrawal et al., Protocols for Oligonucleotide Conjugates, Eds., Humana Press, New Jersey, 1994, Vol. 26, pp. 1-72).
- Various methods are known and used for removal of blocking groups from the nucleic acids. In some embodiments, all blocking groups are removed. In other embodiments, the blocking groups are partially removed. In yet other embodiments, reaction conditions can be adjusted to remove blocking groups on certain moieties. In certain embodiments where R2 is a blocking group, removal of the blocking group at R2 is orthogonal to the removal of the blocking group at R1. The blocking groups at R1 and R2 remain intact during the synthesis steps and are collectively removed after the chain assembly. In some embodiments, the R2 blocking group are removed simultaneously with the cleavage of the nucleic acids from the solid support and with the removal of the nucleobase blocking groups. In specific embodiments, the blocking group at R1 is removed while the blocking groups at R2 and nucleobases remain intact. Blocking groups at R1 are cleavable on solid supports with an organic base such as a primary amine, a secondary amine, or a mixture thereof. Deblocking of the R1 position is commonly referred to as front end deprotection.
- In an embodiment, the nucleobase blocking groups, if present, are cleavable after the assembly of the respective nucleic acid with an acidic reagent. In another embodiment, one or more of the nucleobase blocking groups is cleavable under neither acidic nor basic conditions, e.g. cleavable with fluoride salts or hydrofluoric acid complexes. In yet another embodiment, one or more of the nucleobase blocking groups are cleavable after the assembly of the respective nucleic acid in the presence of base or a basic solvent, and wherein the nucleobase blocking group is stable to the conditions of the front end deprotection step with amines.
- In some embodiments, blocking groups for nucleobases are not required. In other embodiments, blocking groups for nucleobases are required. In yet other embodiments, certain nucleobases require blocking group while other nucleobases do not require blocking groups. In embodiments where the nucleobases are blocked, the blocking groups are either completely or partially removed under conditions appropriate to remove the blocking group at the front end. For example, R1 can denote ORa, wherein Ra is acyl, and Ba denotes guanine blocked with an acyl group including, but not limited to isobutyryl, acetyl or 4-(tert-butylphenoxy)acetyl. The acyl groups at R1 and Ba will be removed or partially removed during the same deblocking step.
- Oligonucleoside phosphorothioates have shown therapeutic potential (Stein et al., Science (1993), 261:1004-12; Agrawal et al., Antisence Res. and Dev. (1992), 2:261-66; Bayever et al., Antisense Res. and Dev. (1993), 3:383-390). Oligonucleoside phosphorothioates prepared without regard to the stereochemistry of the phosphorothioate exist as a mixture of 2n diastereomers, where n is the number of internucleotide phosphorothioates linkages. The chemical and biological properties of these diastereomeric phosphorothioates can be distinct. For example, Wada et al (Nucleic Acids Symposium Series No. 51 p. 119-120; doi:10.1093/nass/nrm060) found that stereodefined-(Rp)-(Ups)9U/(Ap)9A duplex showed a higher Tm value than that of natural-(Up)9U/(Ap)9A and stereodefined-(Sp)-(Ups)9U did not form a duplex. In another example, in a study by Tang et al., (Nucleosides Nucleotides (1995), 14:985-990) stereopure Rp-oligodeoxyribonucleoside phosphorothioates were found to possess lower stability to nucleases endogenous to human serum that the parent oligodeoxyribonucleoside phosphorothioates with undefined phosphorous chirality.
- The nucleobase Ba utilized in the compounds and methods described herein is a natural nucleobase or a modified nucleobase derived from natural nucleobases. Examples include, but are not limited to, uracil, thymine, adenine, cytosine, and guanine having their respective amino groups protected by acyl protecting groups, 2-fluorouracil, 2-fluorocytosine, 5-bromouracil, 5-iodouracil, 2,6-diaminopurine, azacytosine, pyrimidine analogs such as pseudoisocytosine and pseudouracil and other modified nucleobases such as 8-substituted purines, xanthine, or hypoxanthine (the latter two being the natural degradation products). The modified nucleobases disclosed in Chiu and Rana, RNA, 2003, 9, 1034-1048, Limbach et al. Nucleic Acids Research, 1994, 22, 2183-2196 and Revankar and Rao, Comprehensive Natural Products Chemistry, vol. 7, 313, are also contemplated as Ba moieties of the compounds and methods described herein.
- Compounds represented by the following general formulae are also contemplated as modified nucleobases:
- In the formulae above, R8 is a linear or branched alkyl, aryl, aralkyl, or aryloxylalkyl group having 1 to 15 carbon atoms, including, by way of example only, a methyl, isopropyl, phenyl, benzyl, or phenoxymethyl group; and each of R9 and R10 represents a linear or branched alkyl group having 1 to 4 carbon atoms.
- Modified nucleobases also include expanded-size nucleobases in which one or more benzene rings has been added. Nucleic base replacements described in the Glen Research catalog (www.glenresearch.com); Krueger A T et al, Acc. Chem. Res., 2007, 40, 141-150; Kool, E T, Acc. Chem. Res., 2002, 35, 936-943; Benner S. A., et al., Nat. Rev. Genet., 2005, 6, 553-543; Romesberg, F. E., et al., Curr. Opin. Chem. Biol., 2003, 7, 723-733; Hirao, I., Curr. Opin. Chem. Biol., 2006, 10, 622-627, are contemplated as useful for the synthesis of the nucleic acids described herein. Some examples of these expanded-size nucleobases are shown below:
- Herein, modified nucleobases also encompass structures that are not considered nucleobases but are other moieties such as, but not limited to, corrin- or porphyrin-derived rings. Porphyrin-derived base replacements have been described in Morales-Rojas, H and Kool, E T, Org. Lett., 2002, 4, 4377-4380. Shown below is an example of a porphyrin-derived ring which can be used as a base replacement:
- Other modified nucleobases also include base replacements such as those shown below:
- Modified nucleobases which are fluorescent are also contemplated. Non-limiting examples of these base replacements include phenanthrene, pyrene, stillbene, isoxanthine, isozanthopterin, terphenyl, terthiophene, benzoterthiophene, coumarin, lumazine, tethered stillbene, benzo-uracil, and naphtho-uracil, as shown below:
- The modified nucleobases can be unsubstituted or contain further substitutions such as heteroatoms, alkyl groups, or linking moieties connected to fluorescent moieties, biotin or avidin moieties, or other protein or peptides. Modified nucleobases also include certain ‘universal bases’ that are not nucleobases in the most classical sense, but function similarly to nucleobases. One representative example of such a universal base is 3-nitropyrrole.
- Other nucleosides can also be used in the process disclosed herein and include nucleosides that incorporate modified nucleobases, or nucleobases covalently bound to modified sugars. Some examples of nucleosides that incorporate modified nucleobases include 4-acetylcytidine; 5-(carboxyhydroxylmethyl)uridine; 2′-O-methylcytidine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyluridine; dihydrouridine; 2′-O-methylpseudouridine; beta,D-galactosylqueosine; 2′-O-methylguanosine; N6-isopentenyladenosine; 1-methyladenosine; 1-methylpseudouridine; 1-methylguanosine; 1-methylinosine; 2,2-dimethylguanosine; 2-methyladenosine; 2-methylguanosine; N7-methylguanosine; 3-methyl-cytidine; 5-methylcytidine; N6-methyladenosine; 7-methylguanosine; 5-methylaminoethyluridine; 5-methoxyaminomethyl-2-thiouridine; beta,D-mannosylqueosine; 5-methoxycarbonylmethyluridine; 5-methoxyuridine; 2-methylthio-N6-isopentenyladenosine; N-((9-beta,D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine; N-((9-beta,D-ribofuranosylpurine-6-yl)-N-methylcarbamoyl)threonine; uridine-5-oxyacetic acid methylester; uridine-5-oxyacetic acid (v); pseudouridine; queosine; 2-thiocytidine; 5-methyl-2-thiouridine; 2-thiouridine; 4-thiouridine; 5-methyluridine; 2′-O-methyl-5-methyluridine; and 2′-O-methyluridine.
- In some embodiments, nucleosides include 6′-modified bicyclic nucleoside analogs that have either (R) or (S)-chirality at the 6′-position and include the analogs described in U.S. Pat. No. 7,399,845. In other embodiments, nucleosides include 5′-modified bicyclic nucleoside analogs that have either (R) or (S)-chirality at the 5′-position and include the analogs described in US Patent Application Publication No. 20070287831.
- In some embodiments, the nucleobases or modified nucleobases comprises biomolecule binding moieties such as antibodies, antibody fragments, biotin, avidin, streptavidin, receptor ligands, or chelating moieties. In other embodiments, Ba is 5-bromouracil, 5-iodouracil, or 2,6-diaminopurine. In yet other embodiments, Ba is modified by substitution with a fluorescent or biomolecule binding moiety. In some embodiments, the substituent on Ba is a fluorescent moiety. In other embodiments, the substituent on Ba is biotin or avidin.
- The most common naturally occurring nucleotides are ribose sugars linked to the nucleobases adenosine (A), cytosine (C), guanine (G), and thymine (T) or uracil (U). Also contemplated are modified nucleotides wherein the phosphate group or the modified phosphorous atom moieties in the nucleotides can be linked to various positions of the sugar or modified sugar. As non-limiting examples, the phosphate group or the modified phosphorous-atom moiety can be linked to the 2′, 3′, 4′ or 5′ hydroxyl moiety of a sugar or modified sugar. Nucleotides that incorporate the modified nucleobases described above can also be used in the process disclosed herein. In some embodiments, nucleotides or modified nucleotides comprising an unprotected —OH moiety are used in the process disclosed herein.
- In addition to the ribose moiety described in Schemes 1-4b, other modified sugars can also be incorporated in the nucleic acids disclosed herein. In some embodiments, the modified sugars contain one or more substituents at the 2′ position including one of the following: F; CF3, CN, N3, NO, NO2, O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, O-alkyl-N-alkyl or N-alkyl-O-alkyl wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C1-C10 alkyl or C2-C10 alkenyl and alkynyl. Examples of substituents include, and are not limited to, O(CH2)nOCH3, and O(CH2)nNH2, wherein n is from 1 to about 10, MOE, DMAOE, DMAEOE. Also contemplated herein are modified sugars described in WO 2001/088198; and Martin et al., Helv. Chim. Acta, 1995, 78, 486-504. In some embodiments, modified sugars comprise substituted silyl groups, an RNA cleaving group, a reporter group, a fluorescent label, an intercalator, a group for improving the pharmacokinetic properties of a nucleic acid, or a group for improving the pharmacodynamic properties of a nucleic acid, and other substituents having similar properties. The modifications may be made at the at the 2′, 3′, 4′, 5′, or 6′ positions of the sugar or modified sugar, including the 3′ position of the sugar on the 3′-terminal nucleotide or in the 5′ position of the 5′-terminal nucleotide.
- Modified sugars also include sugar mimetics such as cyclobutyl or cyclopentyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; and 5,359,044. Some modified sugars that are contemplated include:
- Other non-limiting examples of modified sugars include glycerol, which form glycerol nucleic acid (GNA) analogues. One example of a GNA analogue is shown below and is described in Zhang, R et al., J. Am. Chem. Soc., 2008, 130, 5846-5847; Zhang L, et al., J. Am. Chem. Soc., 2005, 127, 4174-4175 and Tsai C H et al., PNAS, 2007, 14598-14603:
-
- wherein X is as defined herein. Another example of a GNA derived analogue, flexible nucleic acid (FNA) based on the mixed acetal aminal of formyl glycerol, is described in Joyce G F et al., PNAS, 1987, 84, 4398-4402 and Heuberger B D and Switzer C, J. Am. Chem. Soc., 2008, 130, 412-413, and is shown below:
- Other non-limiting examples of modified sugars include hexopyranosyl (6′ to 4′), pentopyranosyl (4′ to 2′), pentopyranosyl (4′ to 3′), or tetrofuranosyl (3′ to 2′) sugars.
- Hexopyranosyl (6′ to 4′) sugars contemplated include:
- Pentopyranosyl (4′ to 2′) sugars contemplated include:
- Pentopyranosyl (4′ to 3′) sugars contemplated include:
- Tetrofuranosyl (3′ to 2′) sugars contemplated include:
- Other modified sugars contemplated include:
- Further contemplated are the sugar mimetics illustrated below wherein X is selected from S, Se, CH2, N-Me, N-Et or N-iPr.
- The modified sugars and sugar mimetics can be prepared by methods known in the art, including, but not limited to: A. Eschenmoser, Science (1999), 284:2118; M. Bohringer et al, Helv. Chim. Acta (1992), 75:1416-1477; M. Egli et al, J. Am. Chem. Soc. (2006), 128(33):10847-56; A. Eschenmoser in Chemical Synthesis: Gnosis to Prognosis, C. Chatgilialoglu and V. Sniekus, Ed., (Kluwer Academic, Netherlands, 1996), p. 293; K.-U. Schoning et al, Science (2000), 290:1347-1351; A. Eschenmoser et al, Helv. Chim. Acta (1992), 75:218; J. Hunziker et al, Helv. Chim. Acta (1993), 76:259; G. Otting et al, Helv. Chim. Acta (1993), 76:2701; K. Groebke et al, Helv. Chim. Acta (1998), 81:375; and A. Eschenmoser, Science (1999), 284:2118.
- In the reactions described, it is necessary in certain embodiments to protect reactive functional groups, for example hydroxy, amino, thiol or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Protecting groups are used to block some or all reactive moieties and prevent such groups from participating in chemical reactions until the protective group is removed. In one embodiment, each protective group is removable by a different means. Protective groups that are cleaved under totally disparate reaction conditions fulfill the requirement of differential removal. In some embodiments, protective groups are removed by acid, base, and/or hydrogenolysis. Groups such as trityl, dimethoxytrityl, acetal and t-butyldimethylsilyl are acid labile and are used in certain embodiments to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected with Cbz groups, which are removable by hydrogenolysis, and/or Fmoc groups, which are base labile. In other embodiments, carboxylic acid and hydroxy reactive moieties are blocked with base labile groups such as, but not limited to, methyl, ethyl, and acetyl in the presence of amines blocked with acid labile groups such as t-butylcarbamate or with carbamates that are both acid and base stable but hydrolytically removable.
- In another embodiment, hydroxy reactive moieties are blocked with hydrolytically removable protective groups such as the benzyl group, while amine groups capable of hydrogen bonding with acids are blocked with base labile groups such as Fmoc. In another embodiment, carboxylic acid reactive moieties are protected by conversion to simple ester compounds, or they are, in yet another embodiment, blocked with oxidatively-removable protective groups such as 2,4-dimethoxybenzyl, while co-existing amino groups are blocked with fluoride labile silyl or carbamate blocking groups.
- Allyl blocking groups are useful in the presence of acid- and base-protecting groups since the former are stable and can be subsequently removed by metal or pi-acid catalysts. For example, an allyl-blocked hydroxy groups can be deprotected with a Pd(O)-catalyzed reaction in the presence of acid labile t-butylcarbamate or base-labile acetate amine protecting groups. Yet another form of protecting group is a resin to which a compound or intermediate is attached. As long as the residue is attached to the resin, that functional group is blocked and cannot react. Once released from the resin, the functional group is available to react.
- Typically blocking/protecting groups useful in the synthesis of the compounds described herein are, by way of example only:
- Representative protecting groups useful to protect nucleotides during synthesis include base labile protecting groups and acid labile protecting groups. Base labile protecting groups are used to protect the exocyclic amino groups of the heterocyclic nucleobases. This type of protection is generally achieved by acylation. Three commonly used acylating groups for this purpose are benzoyl chloride, phenoxyacetic anhydride, and isobutyryl chloride. These protecting groups are stable to the reaction conditions used during nucleic acid synthesis and are cleaved at approximately equal rates during the base treatment at the end of synthesis.
- In some embodiments, the 5′-protecting group is trityl, monomethoxy trityl, dimethoxytrityl, trimethoxytrityl, 2-chlorotrityl, DATE, TBTr, 9-phenylxanthine-9-yl (Pixyl), or 9-(p-methoxyphenyl)xanthine-9-yl (MOX).
- In some embodiments, thiol moieties are incorporated in the compounds described herein and are protected. In some embodiments, the protecting groups include, but are not limited to, pixyl, trityl, benzyl, p-methoxybenzyl (PMB), or tert-butyl (t-Bu).
- Other protecting groups, plus a detailed description of techniques applicable to the creation of protecting groups and their removal are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, N.Y., 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, N.Y., 1994, which are incorporated herein by reference for such disclosure.
- The examples provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations.
-
- Compound 2:
- A solution of (Z)-but-2-ene-1,4-diol (0.93 ml, 11.3 mmol) and triethylamine (3.3 ml, 24 mmol) in DCM (50 mL) was added in a dropwise fashion to a stirring ice cold solution of methanesulfonyl chloride (1.9 ml, 24 mmol) in DCM (50 mL). After stirring for 0.5 h at r.t. the mixture was poured onto ice and extracted. The organic layer was collected, dried (MgSO4), filtered and reduced to 2.66 g, 96% of compound 2, which was judged by NMR to be sufficiently pure for direct use in the next step of the reaction.
- 1H NMR (399 MHz, CDCl3) δ 5.94 (ddd, J=5.4, 4.1, 1.3 Hz, 2H), 4.83 (dd, J=4.1, 1.3 Hz, 4H), 3.04 (s, 6H); 13C NMR 128.34, 64.38, 38.27; MS (ESI+ve): calc (M+NH4): 262.04. found: 262.05. Rf=0.3 (1:1 EtOAc/hexane).
- Compound 3:
- A solution of sodium methanesulfonothioate (1.51 g, 11.3 mmol) in MeOH (20 ml) was treated with neat (Z)-but-2-ene-1,4-diyl dimethanesulfonate (1.25 g, 5.12 mmol) at r.t. After 5 min, precipitation was observed to occur. After 36 h, the mixture was partitioned between water and DCM. The organic layer was separated, dried (MgSO4), filtered and reduced to afford a colorless oil. Column chromatography (ISCO) gave the pure product as a pale colorless oil. Column chromatography gave pure compound 3 (0.89 g, 63%) as a colorless oil.
- 1H NMR (399 MHz, CDCl3) δ 5.84 (ddd, J=6.6, 5.1, 1.5 Hz, 2H), 3.92 (dd, J=5.1, 1.5 HZ, 4H), 3.33 (s, 6H); 13C NMR 128.1, 51.47, 33.13; MS (ESI+ve): calc (M+NH4): 294.00. found: 294.04. Rf=0.4 (1:1 EtOAc/hexane).
- Compound 4:
- Under argon atmosphere, morpholine (10 g, 115 mmol) was added to ethylene sulfide (15 g, 250 mmol) in a round bottom flask. The reaction was stirred for 7 hrs and was directly loaded on to a silica gel column. The column was washed with DCM first and then 2% MeOH/DCM was used to obtain compound 4 (15.3 g, 91%) as colorless oil.
- 1H NMR (399 MHz, CDCl3) δ 3.67-3.59 (m, 4H), 2.63-2.52 (m, 2H), 2.51-2.45 (m, 2H), 2.44-2.34 (m, 4H); MS (ESI+ve): calc (M+H)+=148.07. found: 148.1.
- Compound 5:
- A DCM solution (1 mL) of 2-morpholinoethanethiol (0.21 g, 1.44 mmol) was added dropwise via syringe to a stirring solution compound 3 (0.40 g, 1.44 mmol) in DCM (10 mL) at r.t. Immediately after addition, the TLC was checked, to reveal rapid formation of product and some quantity of dimer. After 0.5 h, the mixture was partitioned by addition of water. Upon extraction, the organic layer was separated then dried (MgSO4), filtered and reduced in vacuo. Column chromatography gave compound 5 (0.29 g, 58%) as colorless oil.
- 1H NMR (399 MHz, CDCl3) δ 5.78 (m, 2H), 3.92 (d, J=7.3 Hz, 2H), 3.70 (t, J=4.7 Hz, 4H), 3.46 (d, J=5.5 Hz, 2H), 3.31 (s, 3H), 2.84 (dd, J=7.8, 6.7 Hz, 2H), 2.66 (dd, J=7.8, 6.7, 2H), 2.48 (t, J=4.6 Hz, 4H); 13C NMR 130.35, 126.27, 66.97, 58.20, 53.67, 51.52, 36.22, 35.16, 33.67; MS (ESI+ve): calc (M+H): 344.05. found: 344.06. Rf=0.3 (EtOAc).
- Compound 5b:
- A DCM solution (1 mL) of compound 4b (395 mg, 1.085 mmol) was added dropwise via syringe to a stirring DCM (15 mL) solution compound 3 (300 mg, 1.085 mmol) at r.t. After 1 h, the resulting solution was partitioned by addition of water. Upon extraction, the organic layer was separated then dried (MgSO4), filtered and reduced in vacuo. Column chromatography gave compound 5b as a colorless oil (0.35 g, 58%). 1H NMR (399 MHz, CDCl3) δ 5.83-5.70 (m, 2H), 5.35-5.21 (dt, J=26.0, 9.3 Hz, 2H), 5.16-5.07 (m, 1H), 4.59-4.54 (d, J=9.5 Hz, 1H), 4.29-4.23 (m, 1H), 4.23-4.18 (m, 1H), 3.99-3.88 (dd, J=6.7, 1.2 Hz, 2H), 3.80-3.72 (ddd, J=10.1, 4.6, 2.6 Hz, 1H), 3.64-3.56 (m, 1H), 3.50-3.43 (m, 1H), 3.31 (s, 3H), 2.09 (s, 3H), 2.03 (s, 6H), 2.00 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.68, 170.30, 169.51, 169.30, 129.43, 127.14, 87.73, 76.49, 73.89, 69.16, 67.99, 61.99, 51.64, 35.89, 33.58, 20.95, 20.80, 20.74, 20.71; MS (ESI+ve): calc (M+NH4 +): 578.07. found: 577.96. Rf=0.5 (1:1 EtOAc/hexane).
- Compound 6:
- An ice cold solution of (Z)-but-2-ene-1,4-diol (0.93 ml, 11.3 mmol) and triethylamine (1.6 mL, 11.5 mmol) in DCM (50 ml) was treated dropwise via syringe with pivaloyl chloride (1.4 ml, 11.4 mmol) over 2 min. After 1 h, TLC showed good reaction.
- The resulting mixture was partitioned by addition of water. Upon extraction, the organic layer was separated then dried (MgSO4), filtered and reduced in vacuo. This crude compound was found: by TLC (Rf=0.6, 1:1 EtOAc/hexane) to contain no starting diol and was used crude to prepare the mesylate. The crude material was taken up in DCM (50 ml) containing triethylamine (1.7 mL, 12 mmol) and cooled on an ice bath. Methanesulfonyl chloride (0.98 ml, 12.66 mmol) was added dropwise via syringe over 2 min. TLC immediately after addition indicated complete consumption of starting material. The resulting mixture was partioned by addition of water. Upon extraction, the organic layer was separated then dried (MgSO4), filtered and reduced in vacuo. Column chromatography gave pure compound 6, 1.48 g, 52%, as a colorless oil.
- 1H NMR (399 MHz, CDCl3) δ 5.89-5.75 (m, 2H), 4.89-4.84 (d, J=5.7 Hz, 2H), 4.68-4.63 (d, J=5.9 Hz, 2H), 3.03 (s, 3H), 1.19 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 178.28, 130.61, 126.11, 65.08, 59.65, 38.84, 38.21, 27.25; MS (ESI+ve): calc (M+NH4): 268.12. found: 268.20. Rf=0.3 (20% EtOAc/hexane).
- Compound 7:
- A MeOH (10 ml) solution of sodium methanesulfonothioate (0.63 g, 4.70 mmol) and (Z)-4-(methylsulfonyloxy)but-2-enyl pivalate (1.00 g, 4.00 mmol) was stirred at r.t. for 18 h with formation of a white precipitate (after 10 min). The resulting mixture was partitioned by addition of water and DCM. Upon extraction into DCM, the organic layer was separated then dried (MgSO4), filtered and reduced in vacuo. Column chromatography gave compound 7, 0.83 g, 78% as a colorless oil.
- 1H NMR (399 MHz, CDCl3) δ 5.82-5.73 (m, 2H), 4.73-4.66 (m, 2H), 3.95-3.87 (m, 2H), 3.32 (s, 3H), 1.19 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 178.35, 129.37, 127.32, 59.50, 51.44, 38.84, 33.61, 27.28; MS (ESI+ve): calc (M+NH4): 284.10. found: 284.19. Rf=0.4 (20% EtOAc/hexane).
- Compound 9:
- Pivaloyl chloride (0.60 g, 5.0 mmol) was added in a dropwise fashion to a stirring solution of S-2-hydroxyethyl methanesulfonothioate (0.65 g, 4.16 mmol) in DCM (20 ml). After 2 h at r.t. the resulting mixture with white precipitate was partitioned with water. The organic layer was separated, dried (Ns2SO4), filtered and reduced to an oil. Column gave compound 9 as a colorless oil (0.45 g, 45%). 1H NMR (399 MHz, CDCl3) δ 4.39-4.34 (t, J=6.3 Hz, 2H), 3.44-3.39 (t, J=6.3 Hz, 2H), 3.36 (s, 3H), 1.20 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 62.10, 51.11, 38.96, 35.19, 27.24; MS (ESI+ve): calc (M+NH4): 158.08. found: 158.04. Rf=0.3 (20% EtOAc/hexane).
- Compound 11:
- Pivaloyl chloride (4.96 ml, 40.3 mmol) was added dropwise via syringe to an ice cold DCM solution (50 mL) of 2-(hydroxymethyl)phenol (5 g, 40.3 mmol) and triethylamine (5.61 ml, 40.3 mmol). An ice-cold solution of the crude pivalate ester was treated with triethylamine (6.74 ml, 48.4 mmol) and 50 mL DCM. Methanesulfonyl chloride (3.43 ml, 44.3 mmol) was then added slowly (5 min) via syringe and the resulting mixture was warmed to r.t. The mixture was poured onto ice and the organic layer was separated then washed with sat NaHCO3 (aq), dried (MgSO4), filtered and reduced to 10.5 g crude pale yellow oil.
- Column (ISCO) gave pure 11 5.45 g, 47%.
- 1H NMR (399 MHz, CDCl3) δ 7.53-7.46 (dd, 7.7, 1.8 Hz, 1H), 7.46-7.40 (dt, 7.7, 1.8 Hz, 1H), 7.32-7.24 (t, 7.7 Hz, 1H), 7.13-7.06 (d, 7.7 Hz, 1H), 5.21 (s, 2H), 2.79 (s, 3H), 1.40 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 177.05, 150.06, 131.18, 131.07, 126.35, 125.94, 123.21, 66.88, 39.48, 38.82, 27.30, 27.26. MS (ESI+ve): calc (M+NH4): 304.12. found: 303.99. Rf=0.4 (20% EtOAc/hexane).
- Compound 12:
- A MeOH (20 mL) solution of sodium methanesulfonothioate (0.825 g, 6.15 mmol) was treated with 2-((methylsulfonyloxy)methyl)phenyl pivalate (1.76 g, 6.15 mmol) at r.t. and left to stir for 18 h. The mixture was partitioned between water and DCM. The organic layer was separated, dried (MgSO4), filtered and reduced to afford a colorless oil. Column chromatography gave pure compound 12 as a pale colorless oil, 0.754 g, 41%.
- 1H NMR (399 MHz, CDCl3) δ 7.48-7.44 (dd, J=7.7, 1.7 Hz, 1H), 7.39-7.34 (td, J=7.8, 1.7 Hz, 1H), 7.25-7.20 (td, J=7.6, 1.2 Hz, 1H), 7.10-7.06 (dd, J=8.2, 1.2 Hz, 1H), 4.29 (s, 2H), 2.90 (s, 3H), 1.39 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 176.69, 149.59, 131.17, 129.85, 127.41, 126.18, 123.40, 51.43, 39.47, 36.01, 27.30; MS (ESI+ve): calc (M+NH4): 320.10. found: 320.09. Rf=0.4 (20% EtOAc/hexane).
- Compound 14:
- Chloromethyl pivalate (0.478 ml, 3.32 mmol) was added to a stirring mixture of sodium iodide (0.050 g, 0.33 mmol) and sodium methanesulfonothioate (0.445 g, 3.32 mmol) in acetone (7 ml) at r.t. After 24 h, TLC showed good conversion to product. The solvent was removed, and the residue was partitioned between water and DCM. The organic layer was separated and dried (MgSO4), filtered and reduced to afford a colorless oil. Column chromatography gave pure 14 as a slightly pink solid, 0.41 g, 55%.
- 1H NMR (399 MHz, CDCl3) δ 5.67 (s, 2H), 3.39 (s, 3H), 1.24 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 177.35, 67.84, 52.20, 38.93, 27.05. Rf=0.5 (20% EtOAc/hexane).
- Compound 16:
- Prepared from 15 and NaMTS as described previously: U.S. Pat. No. 3,484,473 1H NMR (399 MHz, CDCl3) δ 4.86 (s, 2H), 3.45 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 52.15, 41.50.
- Compound 18:
- Prepared from 17 and NaMTS as described previously: Chem. Pharm. Bull. Vol. 12(11) p. 1271, 1964.
- 1H NMR (399 MHz, CDCl3) δ 3.55 (s, 4H), 3.40 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 50.67, 35.96.
- Compound 19:
- A DCM solution (1 mL) of 2-morpholinoethanethiol (0.17 g, 1.2 mmol) was added dropwise via syringe to a stirring solution of compound 18 (300 mg, 1.2 mmol) in DCM (10 mL) at r.t. Immediately after addition, the TLC was checked, to reveal rapid formation of product and some dimer. After 0.5 h, the mixture was partitioned by addition of NaHCO3. Upon extraction, the organic layer was separated then dried (MgSO4), filtered and reduced in vacuo. Column chromatography gave pure 19 (0.20 g, 53%) as a colorless oil. 1H NMR (399 MHz, CDCl3) δ 3.73-3.67 (t, J=4.7 Hz, 4H), 3.51-3.46 (m, 2H), 3.35 (s, 3H), 3.07-3.01 (m, 2H), 2.88-2.83 (m, 2H), 2.69-2.63 (m, 2H), 2.52-2.43 (t, J=4.6 Hz, 4H); 13C NMR (100 MHz, CDCl3) δ 66.96, 57.91, 53.58, 50.79, 37.66, 36.10, 35.52; MS (ESI+ve): calc (M+H): 318.03. found: 318.04. Rf=0.3 (EtOAc).
- Compound 21:
-
Compound 20 is converted to compound 21 by a procedure analogous to that described for compound 11. - Compound 22:
- Compound 21 is converted to compound 22 by a procedure analogous to that described for compound 12.
- Compound 23:
- Compound 23 is prepared according to a literature method (Journal of Medicinal Chemistry, 50(23), 5568-5570; 2007.)
- Compound 24:
- An ice-cold pyridine solution (10 mL) of compound 23 (1 mmol) is treated successively, in a dropwise fashion with acetyl chloride (1 mmol), then after 5 min with MsCl (1.1 mmol). The solution is warmed to room temperature then the solvent is removed. The residue is dissolved in EtOAc, washed with water, dried (MgSO4), filtered and reduced in vacuo. Purification by column chromatography affords pure compound 24.
- Compound 25:
- Compound 24 is converted to compound 25 by a procedure analogous to that described for compound 12.
- Compound 27:
- Compound 26 is converted to compound 27 by a procedure analogous to that described for compound 14.
- Compound 29:
- Compound 28 is converted to compound 29 by a procedure analogous to that described for compound 14.
- Compound 30:
-
Compound 30 is prepared according to a literature method (Tetrahedron, 42(2), 601-7; 1986.) - Compound 31:
-
Compound 31 is prepared fromcompound 30 according to a patent procedure (US 20090181444) - Compound 33:
- Compound 33 is prepared from compound 32 according to a patent procedure (US 20090181444)
- Compound 36:
- An ice-cold DCM (20 mL) solution of compound 34 (1 mmol) is treated with NEt3 (1 mmol) followed by the dropwise addition of TMS-Cl (1.1 mmol). After 1 h, the solution is washed with water, dried (MgSO4), filtered and reduced in vacuo. The crude TMS protected material is redissolved in THF (10 mL), whereon PPh3 (1.2 mmol), compound 35 (1.2 mmol), then DEAD (1.2 mmol, dropwise) are added in succession. After stirring at r.t. for 18 h, the solvent is removed under vacuum, the residue is redissolved in DCM, the solution of which is washed with water, dried (MgSO4), filtered and reduced in vacuo. Purification by column chromatography affords pure compound 36.
- Compound 37:
- A THF (10 mL) solution of compound 36 (0.5 mmol) is treated with TBAF (1 mmol of a 1M solution in THF), with monitoring by TLC. On completion of TMS cleavage, the solvent is removed under vacuum, the residue is redissolved in DCM, the solution of which is washed with water, dried (MgSO4), filtered and reduced in vacuo. The crude alcohol is redissolved in pyridine (5 mL), and TsCl (0.55 mmol) is added. After 18 h at r.t., the solvent is removed, the residue is redissolved in DCM, the solution of which is washed with water, dried (MgSO4), filtered and reduced in vacuo. Purification by column chromatography affords pure compound 37.
- Compound 38:
- Compound 37 is converted to compound 38 by a procedure analogous to that described for compound 12.
- Compound 40:
- An ice-cold DCM (20 mL) solution of compound 39 (1 mmol) is treated with NEt3 (1 mmol) followed by the dropwise addition of TMS-Cl (1.1 mmol). After 1 h, the solution is washed with water, dried (MgSO4), filtered and reduced in vacuo. The crude TMS protected material is redissolved in THF (10 mL), whereon PPh3 (1.2 mmol), potassium p-toluenethiosulfonate (KTTS, 1.2 mmol), anhydrous ZnCl2 (1 mmol) then DEAD (1.2 mmol, dropwise) are added in succession. After stirring at r.t. for 18 h, the solvent is removed under vacuum, the residue is redissolved in DCM, the solution of which is washed with water, dried (MgSO4), filtered and reduced in vacuo. Purification by column chromatography affords
pure compound 40. - Compound 41:
- A THF (10 mL) solution of compound 40 (0.5 mmol) is treated with TBAF (1 mmol of a 1M solution in THF), with monitoring by TLC. On completion of TMS cleavage, the solvent is removed under vacuum, the residue is redissolved in DCM, the solution of which is washed with water, dried (MgSO4), filtered and reduced in vacuo. The crude alcohol is redissolved in THF (10 mL), whereon PPh3 (1.2 mmol), compound 35 (1.2 mmol), then DEAD (1.2 mmol, dropwise) are added in succession. After stirring at r.t. for 18 h, the solvent is removed under vacuum, the residue is redissolved in DCM, the solution of which is washed with water, dried (MgSO4), filtered and reduced in vacuo. Purification by column chromatography affords
pure compound 40. - Compound 42:
- Compound 41 is converted to compound 42 by a procedure analogous to that described for compound 14.
-
- Compound 100:
- The synthetic procedure for Di-DMTr H-phosphonate TT dimer (100) has been previously described (Froehler, Brian C.; Ng, Peter G.; Matteucci, Mark D., Nucleic Acids Research (1986), 14(13), 5399-5407; Garegg, Per J.; Lindh, Ingvar; Regberg, Tor; Stawinski, Jacek; Stroemberg, Roger; Henrichson, Christina Tetrahedron Letters (1986), 27(34), 4051-4054).
- Compound 101:
-
Compound 100, mixture of diastereomers (200 mg, 0.176 mmol) was dissolved in ACN (6 mL) then trimethylsilyl 2,2,2-trifluoro-N-(trimethylsilyl)acetamidate (227 mg, 0.882 mmol) was added. A solution of (Z)—S-4-((2-morpholinoethyl)disulfanyl)but-2-enyl methanesulfonothioate (121 mg, 0.353 mmol) in ACN (2 mL) was then added, over the course of 1 h in 3 approximately equal portions, with monitoring by TLC and HPLC/MS. After 3 h, the resulting solution was partitioned by addition of water. Upon extraction, the organic layer was separated then dried (MgSO4), filtered and reduced in vacuo. Column chromatography gave compound 101 as a white foam, 225 mg, 91%. - 1H NMR (399 MHz, CDCl3) δ 9.72 (d, br, 1H), 9.27, (d, br, 1H), 7.53 (dd, J=25.0, 1 Hz, 1H), 7.42, (t, J=7.0 Hz, 2H), 7.37-7.16 (m, 17H), 6.83 (m, 8H), 6.43-6.28 (m, 2H), 5.63-5.42 (m, 2H), 5.21 (q, J=7.1 Hz, 1H), 4.27 (m, br, 1H), 3.94 (m, br, 2H), 3.77 (m, 12H), 3.74-3.60 (m, 6H), 3.51-3.22 (m, 5H), 2.82-2.76 (m, 2H), 2.68-2.60 (m, 2H), 2.59-2.46 (m, 5H), 2.44-2.33 (m, 2H), 2.03-1.88 (m, 1H), 1.84 (m, 3H), 1.75-1.66 (m, 1H), 1.48-1.32 (dd, J=11.8, 1.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 164.10, 164.07, 164.00, 163.94, 159.14, 159.10, 150.80, 150.78, 150.75, 150.63, 145.09, 144.30, 144.27, 136.31, 136.27, 136.22, 136.18, 135.95, 135.82, 135.43, 135.35, 135.33, 135.24, 135.22, 130.52, 130.43, 130.40, 129.49, 129.30, 128.54, 128.43, 128.39, 127.64, 127.57, 113.78, 113.76, 113.73, 113.67, 112.05, 111.56, 87.77, 87.66, 87.58, 85.77, 85.59, 84.63, 84.51, 74.42, 74.33, 67.02, 66.95, 63.63, 63.49, 58.27, 58.23, 55.60, 55.58, 53.69, 53.62, 39.48, 39.26, 39.18, 35.88, 35.61, 35.43, 35.36, 28.18, 12.83, 12.79, 12.02, 11.95.; 31P NMR (162 MHz, CDCl3) δ 29.25, 29.12; MS (ESI+ve): calc (M+H): 1398.46. found: 1398.64. Rf=0.4 (5% MeOH/DCM).
- Compound 201:
- Compound 101 (0.150 g, 0.107 mmol) was stirred with 3% TCA/DCM (10 mL) over 10 min. TLC and HPLC/MS showed that the reaction was complete. 10 mL of MeOH was added and stirring continued for 2 min. Solvents were evaporated and the residue was purified by column chromatography to give compound 201 (85 mg, 100%) as a white solid.
- 1H NMR (399 MHz, CD3OD) δ 7.78 (dd, J=7.2, 1.3 Hz, 1H), 7.53 (d, J=1.3 Hz, 1H), 6.33-6.27 (m, 2H), 5.83-5.70 (m, 2H), 5.25-5.19 (m, 1H), 4.47-4.30 (m, 3H), 4.27-4.22 (m, 1H), 4.11-4.05 (m, 1H), 3.89-3.82 (t, J=4.8 Hz, 4H), 3.85 (m, 2H), 3.76-3.70 (ddd, J=15.5, 7.2, 1.7 Hz, 2H), 3.52 (dd, J=7.3, 3.7 Hz, 2H), 3.28-3.19 (br, 2H), 3.16-3.05 (br, 4H), 3.05-2.98 (ddd, J=9.8, 5.5, 2.0 Hz, 2H), 2.62-2.52 (tdd, J=11.5, 5.7, 1.9 Hz, 1H), 2.47-2.36 (m, 1H), 2.33-2.28 (m, 2H), 1.92-1.87 (m, 6H); 31P NMR (162 MHz, CD3OD) δ 30.22, 30.19; MS (ESI+ve): calc (M+H): 794.20. found: 794.18. Rf=0.3 (10% MeOH/DCM).
- Compound 102:
- Compound 100 (400 mg, 0.352 mmol) was converted to compound 102 by a procedure analogous to that described for compound 101 (417 mg, 90%).
- 1H NMR (399 MHz, CDCl3) δ 9.17 (d, J=6.0 Hz, 1H), 9.13-9.00 (d, J=25.7 Hz, 1H), 7.58-7.49 (dd, J=26.3, 1.5 Hz, 1H), 7.45-7.40 (ddd, J=8.0, 5.2, 1.3 Hz, 2H), 7.40-7.18 (m, 17H), 6.87-6.81 (m, 8H), 6.44-6.30 (m, 2H), 5.65-5.53 (m, 1H), 5.53-5.44 (m, 1H), 5.26-5.16 (quintet, J=6.4 Hz, 1H), 4.61-4.54 (m, 2H), 4.30-4.24 (m, 1H), 4.19-4.13 (m, 1H), 3.97-3.88 (m, 2H), 3.80-3.72 (m, 12H), 3.69-3.57 (m, 1H), 3.54-3.30 (m, 5H), 2.61-2.49 (dt, J=14.4, 5.4 Hz, 1H), 2.44-2.32 (m, 1H), 2.02-1.91 (dt, J=12.5, 5.4 Hz, 1H), 1.85-1.80 (dd, J=5.0, 1.3 Hz, 3H), 1.76-1.63 (m, 1H), 1.43-1.36 (dd, J=10.2, 1.2 Hz, 3H), 1.19-1.14 (d, J=2.0 Hz, 8H); 13C NMR (100 MHz, CDCl3) δ 178.22, 178.17, 163.82, 163.80, 163.75, 158.92, 158.88, 150.52, 150.43, 144.90, 144.88, 144.10, 144.05, 136.11, 136.08, 136.05, 136.01, 135.59, 135.28, 135.16, 135.03, 135.01, 130.30, 130.23, 130.19, 130.16, 128.69, 128.64, 128.59, 128.39, 128.34, 128.23, 128.21, 128.17, 127.42, 127.34, 113.54, 113.45, 111.85, 111.82, 111.41, 111.36, 87.59, 87.43, 87.37, 85.47, 85.33, 84.43, 84.29, 84.08, 84.00, 83.92, 74.24, 67.36, 63.38, 63.26, 59.42, 55.37, 39.22, 38.77, 27.94, 27.24, 12.57, 11.80, 11.74; 31P NMR (162 MHz, CDCl3) δ 29.23, 28.97; MS (ESI+ve): calc (M+H): 1338.51. found: 1338.84. Rf=0.5 (5% MeOH/DCM).
- Compound 202:
- Compound 102 (200 mg, 0.151 mmol) was converted to compound 202 by a procedure analogous to that described for compound 101 (105 mg, 97%).
- 1H NMR (399 MHz, CD3OD) δ 7.81-7.75 (dd, J=8.2, 1.3 Hz, 1H), 7.57-7.51 (dd, J=8.2, 1.3 Hz, 1H), 6.33-6.23 (m, 2H), 5.85-5.75 (m, 1H), 5.75-5.66 (m, 1H), 5.26-5.19 (m, 1H), 4.72-4.66 (m, 2H), 4.47-4.30 (m, 3H), 4.27-4.20 (m, 1H), 4.11-4.04 (m, 1H), 3.83-3.76 (m, 2H), 3.74-3.64 (m, 2H), 2.62-2.51 (m, 1H), 2.45-2.35 (td, J=8.7, 6.5 Hz, 1H), 2.32-2.24 (m, 2H), 1.93-1.82 (m, 6H), 1.20-1.15 (d, J=2.1 Hz, 9H); 13C NMR (126 MHz, CD3OD) δ 179.65, 166.28, 152.30, 152.28, 152.22, 137.90, 137.81, 137.79, 130.07, 130.04, 129.26, 129.24, 111.93, 111.88, 111.87, 87.26, 87.22, 86.96, 86.90, 86.76, 86.54, 86.12, 86.07, 85.98, 85.92, 85.88, 85.82, 80.54, 80.49, 80.46, 80.41, 71.84, 71.67, 68.71, 68.66, 68.45, 68.40, 62.58, 62.50, 60.72, 40.51, 40.44, 39.70, 39.52, 39.48, 28.67, 28.64, 28.61, 27.53, 12.64, 12.48; 31P NMR (162 MHz, CDCl3) δ 29.23, 28.97; MS (ESI+ve): calc (M+H): 717.22. found: 717.23. Rf=0.5 (10% MeOH/DCM).
- Compound 103:
- Compound 100 (400 mg, 0.352 mmol) was converted to compound 103 by a procedure analogous to that described for compound 101 (379 mg, 83%).
- 1H NMR (399 MHz, CDCl3) δ 9.48 (s, 1H), 9.41-9.29 (m, 1H), 7.60-7.48 (dd, J=9.0, 1.0 Hz, 1H), 7.46-7.40 (dt, J=6.9, 1.2 Hz, 2H), 7.39-7.17 (m, 17H), 6.89-6.79 (m, 8H), 6.44-6.31 (m, 2H), 5.27-5.20 (t, J=6.5 Hz, 1H), 4.30-4.24 (t, J=6.1 Hz, 1H), 4.19-4.15 (m, 2H), 4.13-4.07 (t, J=7.1 Hz, 1H), 3.99-3.90 (m, 2H), 3.79-3.74 (m, 12H), 3.70-3.58 (m, 1H), 3.51-3.43 (td, J=8.8, 7.2, 2.3 Hz, 1H), 3.40-3.32 (m, 1H), 3.02-2.85 (m, 2H), 2.61-2.49 (dt, J=18.5, 7.0 Hz, 1H), 2.47-2.33 (m, 1H), 1.98-1.90 (dt, J=10.2, 5.0 Hz, 1H), 1.85-1.81 (m, 3H), 1.74-1.62 (td, J=14.2, 7.1 Hz, 1H), 1.42-1.36 (m, 3H), 1.19-1.13 (d, J=4.9 Hz, 9H); 31P NMR (162 MHz, CDCl3) δ 29.36, 29.18; 13C NMR (126 MHz, CDCl3) δ 177.97, 177.89, 163.94, 163.91, 163.90, 163.86, 158.91, 158.87, 150.63, 150.54, 150.53, 150.50, 144.88, 144.85, 144.10, 144.04, 136.09, 135.99, 135.52, 135.50, 135.24, 135.16, 135.12, 135.04, 135.00, 130.31, 130.29, 130.20, 130.16, 130.13, 128.34, 128.20, 128.18, 128.14, 127.39, 127.31, 124.89, 113.55, 113.52, 113.43, 111.84, 111.38, 87.58, 87.42, 87.36, 85.30, 84.98, 84.95, 84.40, 84.33, 84.27, 83.98, 83.91, 83.84, 79.31, 79.27, 78.88, 78.84, 74.16, 74.08, 67.56, 67.50, 67.46, 67.41, 63.33, 63.24, 62.79, 62.75, 55.34, 39.21, 39.16, 39.04, 39.00, 38.85, 38.82, 29.95, 29.92, 29.66, 29.63, 27.17, 12.53, 11.80, 11.72; MS (ESI+ve): calc (M+H): 1312.69. found: 1312.49. Rf=0.4 (5% MeOH/DCM).
- Compound 203:
- Compound 103 (200 mg, 0.154 mmol) was converted to compound 203 by a procedure analogous to that described for compound 201 (103 mg, 98%).
- 1H NMR (399 MHz, CD3OD) δ 7.80-7.76 (dd, J=8.2, 1.2 Hz, 1H), 7.55-7.51 (dd, 7.1, 1.2 Hz, 1H), 6.32-6.24 (m, 2H), 5.26-5.19 (m, 1H), 4.46-4.20 (m, 6H), 4.10-4.05 (m, 1H), 3.82-3.78 (dd, J=6.5, 3.2 Hz, 2H), 3.22-3.14 (ddd, J=16.6, 7.0, 5.8 Hz, 2H), 2.61-2.51 (tdd, J=13.0, 5.9, 2.1 Hz, 1H), 2.46-2.37 (ddd, J=14.3, 8.3, 6.0 Hz, 1H), 2.31-2.26 (t, J=5.8 Hz, 2H), 1.91-1.86 (dt, J=11.0, 1.2 Hz, 6H), 1.21-1.17 (m, 9H); 31P NMR (162 MHz, CD3OD) δ 30.15; 13C NMR (100 MHz, CD3OD) δ 179.45, 179.42, 166.29, 152.31, 152.29, 152.23, 137.82, 137.80, 137.78, 111.91, 111.88, 87.21, 87.17, 86.94, 86.87, 86.63, 86.52, 86.11, 86.06, 85.92, 85.84, 85.77, 80.67, 80.60, 80.49, 80.43, 71.79, 71.64, 68.80, 68.74, 68.58, 68.52, 64.11, 64.07, 64.02, 62.54, 62.44, 40.48, 40.43, 39.81, 39.71, 39.68, 39.52, 39.47, 30.74, 30.72, 30.68, 27.52, 12.65, 12.50; MS (ESI+ve): calc (M+H): 691.21. found: 691.09. Rf=0.5 (10% MeOH/DCM).
- Compound 104:
- Compound 100 (400 mg, 0.352 mmol) was converted to compound 104 by a procedure analogous to that described for compound 101 (451 mg, 94%).
- 1H NMR (399 MHz, CDCl3) δ 9.17-9.01 (m, 2H), 7.51-7.46 (dd, J=7.8, 1.5 Hz, 1H), 7.45-7.38 (m, 2H), 7.37-7.09 (m, 19H), 7.01-6.90 (m, 2H), 6.87-6.78 (m, 8H), 6.39-6.27 (m, 2H), 5.15-5.01 (m, 1H), 4.20-4.13 (m, 1H), 3.96-3.90 (m, 1H), 3.90-3.83 (m, 2H), 3.80-3.68 (m, 14H), 3.52-3.20 (m, 3H), 2.45-2.16 (m, 2H), 2.01-1.88 (ddd, J=23.3, 13.6, 5.6 Hz, 1H), 1.85-1.79 (dd, J=9.3, 1.2 Hz, 3H), 1.69-1.53 (m, 1H), 1.40-1.31 (m, 12H); 13C NMR (100 MHz, CDCl3) δ 176.46, 176.37, 163.84, 163.78, 158.90, 158.87, 150.52, 150.50, 150.43, 149.38, 149.28, 144.95, 144.88, 144.16, 144.10, 136.13, 136.11, 136.09, 136.03, 135.57, 135.49, 135.37, 135.26, 135.21, 135.08, 135.04, 130.83, 130.74, 130.29, 130.21, 130.16, 129.51, 129.49, 129.40, 129.36, 129.35, 129.31, 128.38, 128.35, 128.27, 128.23, 128.19, 128.14, 127.39, 127.33, 126.05, 125.94, 122.94, 122.86, 113.53, 113.42, 111.77, 111.73, 111.39, 111.28, 87.55, 87.52, 87.37, 87.32, 85.33, 84.95, 84.90, 84.29, 84.20, 84.00, 83.92, 83.87, 83.79, 79.05, 79.00, 74.29, 74.24, 67.31, 67.24, 67.17, 67.11, 63.37, 55.37, 55.35, 39.37, 39.32, 39.15, 39.10, 38.64, 30.51, 30.41, 30.36, 27.28, 27.24, 12.59, 12.51, 11.75, 11.67; 31P NMR (162 MHz, CDCl3) δ 29.12, 28.49; MS (ESI+ve): calc (M+NH4): 1374.51. found: 1374.74. Rf=0.4 (5% MeOH/DCM).
- Compound 204:
- Compound 104 (200 mg, 0.147 mmol) was converted to compound 204 by a procedure analogous to that described for compound 201 (98 mg, 88%).
- 1H NMR (399 MHz, CD3OD) δ 7.77-7.73 (m, 1H), 7.51-7.43 (m, 2H), 7.38-7.31 (m, 1H), 7.25-7.19 (ddd, J=9.2, 5.4, 1.6 Hz, 1H), 7.08-7.02 (ddd, J=8.0, 3.8, 1.3 Hz, 1H), 6.28-6.17 (m, 2H), 5.10-5.01 (m, 1H), 4.30-4.16 (m, 3H), 4.11-4.03 (m, 3H), 4.03-3.97 (d, J=5.3 Hz, 2H), 3.74-3.63 (m, 2H), 2.48-2.11 (m, 5H), 1.90-1.82 (m, 6H), 1.43-1.36 (d, J=3.4 Hz, 9H); 13C NMR (100 MHz, CD3OD) δ 178.05, 166.26, 152.25, 152.19, 150.78, 137.80, 137.76, 132.13, 132.09, 130.61, 130.56, 127.24, 124.10, 111.92, 111.84, 111.79, 87.14, 87.09, 86.80, 86.71, 86.50, 85.98, 85.95, 85.92, 85.87, 85.83, 85.75, 80.55, 80.48, 80.32, 80.27, 71.97, 71.73, 68.67, 68.61, 68.35, 68.29, 62.51, 62.42, 40.41, 40.36, 40.32, 39.66, 39.64, 39.35, 39.29, 31.08, 31.04, 27.61, 12.68, 12.65, 12.49; 31P NMR (162 MHz, CD3OD) δ 29.54, 29.29; MS (ESI+ve): calc (M+H): 753.22. found: 753.12. Rf=0.5 (10% MeOH/DCM).
- Compound 105:
- Compound 100 (200 mg, 0.176 mmol) was converted to compound 105 by using compound 14 in a procedure analogous to that described for compound 101 (158 mg, 70%).
- 1H NMR (400 MHz, CDCl3) δ 7.46-7.39 (m, 2H) 7.38-7.16 (m, 18H), 6.90-6.77 (m, 8H), 6.43-6.27 (m, 1H), 5.39-5.18 (m, 2H), 4.31-4.23 (dd, J=12.0, 6.2 Hz, 1H), 4.20-4.12 (m, 1H), 3.98-3.86 (m, 1H), 3.82-3.70 (m, 12H), 3.69-3.52 (m, 1H), 3.50-3.43 (td, J=9.9, 8.9, 2.7 Hz, 1H), 3.41-3.29 (ddd, J=17.2, 10.8, 2.5 Hz, 1H), 2.59-2.49 (m, 1H), 2.44-2.30 (m, 1H), 2.03-1.93 (m, 1H), 1.86-1.79 (d, J=2.9 Hz, 3H), 1.75-1.67 (m, 4H), 1.43-1.36 (d, 3H), 1.16-1.08 (d, J=9.3 Hz, 9H); 31P NMR (162 MHz, CDCl3) δ 28.14, 27.81 (two diastereomers). MS (ESI+ve): calc (M+H): 1281.4. found: 1281.1 (M+H)+ and 1298.6 (M+NH4)+.
- Compound 205:
- Compound 105 (137 mg, 0.107 mmol) was converted to compound 205 by a procedure analogous to that described for compound 201 (66 mg, 91%).
- 1H NMR (399 MHz, CD3OD) δ 7.83-7.76 (m, 1H), 7.56-7.50 (m, 1H), 6.34-6.22 (m, 2H), 5.51-5.43 (m, H), 5.28-5.20 (qt, 0.1=7.8, 1.8 Hz, 1H), 4.47-4.31 (m, 3H), 4.29-4.21 (m, 1H), 4.10-4.05 (m, 1H), 3.87-3.73 (dd, J=7.6, 3.1 Hz, 2H), 2.62-2.50 (tdd, J=16.9, 5.7, 1.9 Hz, 1H), 2.45-2.36 (m, 1H), 2.32-2.25 (ddd, J=6.9, 5.4, 1.5 Hz, 3H), 1.92-1.84 (m, 6H), 1.22-1.18 (d, J=5.3 Hz, 9H); 31P NMR (162 MHz, CD3OD) δ 28.71, 28.42 (two diastereomers). MS (ESI+ve): calc (M+H): 677.2. found: 677.2 (M+H)+, 694.2 (M+NH4)+.
- Compound 106:
- Compound 100 (405 mg, 0.357 mmol) was converted to compound 106 by using compound 19 and following a procedure analogous to that described for compound 101 (0.35 g, 71%). 1H NMR (399 MHz, CDCl3) δ 9.97-9.42 (m, 2H), 7.58-7.47 (m, 1H), 7.46-7.39 (m, 2H), 7.39-7.13 (m, 17H), 6.87-6.78 (m, 8H), 6.44-6.29 (dtd, J=20.4, 9.2, 4.7 Hz, 2H), 5.27-5.16 (dt, J=14.7, 7.3 Hz, 1H), 4.30-4.22 (m, 1H), 4.22-4.12 (m, 1H), 4.02-3.90 (q, J=3.8, 3.4 Hz, 2H), 3.80-3.73 (m, 12H), 3.72-3.65 (m, 5H), 3.51-3.43 (m, 1H), 3.40-3.31 (m, 1H), 3.14-2.93 (m, 2H), 2.85-2.72 (m, 4H), 2.67-2.59 (m, 2H), 2.57-2.34 (m, 6H), 1.97-1.87 (td, J=13.7, 13.1, 5.7 Hz, 1H), 1.84 (s, 3H), 1.73-1.61 (td, J=14.1, 6.8 Hz, 1H), 1.42-1.37 (d, J=6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 163.97, 163.94, 163.91, 158.88, 158.84, 150.64, 150.60, 150.52, 144.86, 144.83, 144.09, 144.04, 136.06, 136.04, 135.95, 135.93, 135.54, 135.19, 135.09, 135.03, 134.99, 130.28, 130.17, 130.13, 128.29, 128.17, 128.14, 127.38, 127.31, 113.51, 113.42, 111.82, 111.79, 111.44, 111.38, 87.53, 87.38, 87.33, 85.29, 85.26, 84.89, 84.85, 84.41, 84.36, 84.29, 84.25, 83.88, 83.85, 83.80, 83.76, 79.28, 79.23, 78.72, 78.67, 74.04, 67.53, 67.46, 67.37, 67.29, 66.77, 63.33, 63.21, 57.84, 55.34, 53.41, 53.34, 39.23, 39.09, 39.01, 38.92, 38.55, 38.51, 38.46, 38.42, 35.64, 35.59, 30.35, 30.30, 30.26, 12.60, 11.79, 11.74; 31P NMR (162 MHz, CDCl3) δ 29.30, 29.14; MS (ESI+ve): calc (M+H): 1372.44. found: 1372.79. Rf=0.4 (5% MeOH/DCM).
- Compound 206:
- Compound 106 (200 mg, 0.146 mmol) was converted to compound 206 by a procedure analogous to that described for compound 201 (110 mg, 98%).
- 1H NMR (399 MHz, CD3OD) δ 7.83-7.75 (dd, J=7.6, 1.4 Hz, 1H), 7.56-7.48 (d, J=1.6 Hz, 1H), 6.35-6.23 (m, 2H), 5.27-5.20 (m, 1H), 4.48-4.31 (m, 3H), 4.28-4.21 (dd, J=9.7, 2.1 Hz, 1H), 4.11-4.04 (t, J=4.0 Hz, 1H), 3.97-3.84 (br, 4H), 3.83-3.77 (dd, J=6.0, 3.2 Hz, 2H), 3.43-3.36 (m, 2H), 3.29-3.18 (m, 6H), 3.11-3.00 (m, 4H), 2.62-2.51 (tdd, J=11.7, 5.7, 1.7 Hz, 1H), 2.47-2.38 (ddd, J=14.3, 8.4, 6.0 Hz, 1H), 2.38-2.25 (q, J=5.3, 4.8 Hz, 2H), 1.91 (s, 3H), 1.88 (s, 3H); 31P NMR (162 MHz, CD3OD) δ 30.19, 30.12; 13C NMR (100 MHz, CD3OD) δ 166.28, 166.24, 166.23, 152.32, 152.27, 152.24, 138.05, 138.00, 137.77, 137.75, 112.08, 112.03, 111.97, 111.94, 87.28, 87.24, 87.01, 86.96, 86.62, 86.51, 86.10, 86.06, 85.76, 85.68, 71.73, 71.51, 68.91, 68.58, 68.51, 65.44, 62.60, 62.50, 57.50, 53.50, 40.25, 40.16, 39.64, 39.57, 39.20, 39.16, 39.06, 32.56, 32.55, 31.04, 31.00, 12.73, 12.69, 12.52; MS (ESI+ve): calc (M+H): 768.18. found: 768.14. Rf=0.3 (10% MeOH/DCM).
- Compound 107:
- Using compound 22 in place of compound 5,
compound 100 is converted to compound 107 by a procedure analogous to that described for compound 101. - Compound 207:
- Compound 107 is converted to compound 207 by a procedure analogous to that described for compound 201.
- Compound 108:
- Using
compound 25 in place of compound 5,compound 100 is converted to compound 108 by a procedure analogous to that described for compound 101. - Compound 208:
- Compound 108 is converted to compound 208 by a procedure analogous to that described for compound 201.
- Compound 109:
- Using compound 27 in place of compound 5,
compound 100 is converted to compound 109 by a procedure analogous to that described for compound 101. - Compound 209:
- Compound 109 is converted to compound 209 by a procedure analogous to that described for compound 201.
- Compound 110:
- Using compound 29 in place of compound 5,
compound 100 is converted to compound 110 by a procedure analogous to that described for compound 101. - Compound 210:
-
Compound 110 is converted to compound 210 by a procedure analogous to that described for compound 201. - Compound 111:
- Using
compound 31 in place of compound 5,compound 100 is converted to compound 111 by a procedure analogous to that described for compound 101. - Compound 211:
- Compound 111 is converted to compound 211 by a procedure analogous to that described for compound 201.
- Compound 112:
- Using compound 33 in place of compound 5,
compound 100 is converted to compound 112 by a procedure analogous to that described for compound 101. - Compound 212:
- Compound 112 is converted to compound 212 by a procedure analogous to that described for compound 201.
- Compound 113:
- Using compound 38 in place of compound 5,
compound 100 is converted to compound 113 by a procedure analogous to that described for compound 101. - Compound 213:
- Compound 113 is converted to compound 213 by a procedure analogous to that described for compound 201.
- Compound 114:
- Using compound 41 in place of compound 5,
compound 100 is converted to compound 114 by a procedure analogous to that described for compound 101. - Compound 214:
- Compound 114 is converted to compound 214 by a procedure analogous to that described for compound 201.
- Compound 115:
- Using compound 43 in place of compound 5,
compound 100 is converted to compound 115 by a procedure analogous to that described for compound 101. - Compound 215:
-
Compound 115 is converted to compound 215 by a procedure analogous to that described for compound 201. -
- Compound 150:
- Compound 100 (300 mg, 0.264 mmol) was converted to compound 150 by a procedure analogous to that described for compound 101 (170 mg, 50%).
- 1H NMR (399 MHz, CDCl3) δ 9.34-9.30 (s, 1H), 9.28-9.17 (d, J=30.6 Hz, 1H), 7.57-7.47 (m, 1H), 7.47-7.40 (m, 2H), 7.38-7.18 (m, 17H), 7.18-7.07 (d, =1.4 Hz, 1H), 6.88-6.77 (dd, J=9.0, 1.5 Hz, 8H), 6.44-6.34 (ddd, J=15.6, 8.9, 5.4 Hz, 1H), 6.32-6.21 (ddd, J=18.9, 8.5, 5.9 Hz, 1H), 5.27-5.19 (q, J=5.9 Hz, 1H), 4.46-4.33 (m, 2H), 4.31-4.16 (m, 2H), 4.03-3.91 (m, 2H), 3.81-3.67 (m, 12H), 3.54-3.46 (m, 1H), 3.42-3.34 (m, 1H), 3.34-3.25 (d, J=20.2 Hz, 3H), 2.64-2.53 (td, J=13.4, 5.4 Hz, 1H), 2.47-2.34 (dq, J=19.9, 6.5, 5.9 Hz, 1H), 1.99-1.91 (m, 1H), 1.85-1.80 (t, J=1.5 Hz, 3H), 1.78-1.65 (tt, J=14.1, 7.5 Hz, 111), 1.44-1.37 (dd, J=7.3, 1.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.27, 163.83, 163.80, 158.95, 158.93, 158.90, 150.64, 150.53, 150.46, 150.38, 144.91, 144.88, 144.09, 144.02, 136.00, 135.98, 135.94, 135.81, 135.11, 135.04, 134.98, 134.97, 130.34, 130.27, 130.20, 128.30, 128.23, 128.20, 127.46, 127.36, 113.59, 113.56, 113.48, 111.95, 111.38, 87.60, 87.47, 87.43, 86.03, 85.83, 84.44, 84.34, 83.81, 79.82, 79.58, 73.99, 73.91, 67.85, 67.78, 63.31, 63.20, 55.39, 51.77, 51.70, 39.16, 38.99, 38.90, 37.21, 37.16, 37.12, 37.05, 12.63, 12.57, 11.85, 11.80; 31P NMR (162 MHz, CDCl3) δ 26.15, 25.60; MS (ESI+ve): calc (M+H): 1308.37. found: 1308.70. Rf=0.5 (5% MeOH/DCM).
- Compound 151:
- A DCM (5 mL) solution of compound 150 (150 mg, 0.116 mmol) was treated with 2-morpholinoethanethiol (17 mg, 0.116 mmol) at r.t. with monitoring by TLC. After 0.5 h, the mixture was washed with NaHCO3, extracting 5× into DCM. The organic extracts were dried (MgSO4), filtered and reduced. Column chromatography gave compound 151 as a colorless solid foam (81 mg, 51%).
- 1H NMR (399 MHz, CDCl3) δ 9.68-9.54 (m, 1H), 9.44 (s, 1H), 7.59-7.48 (m, 1H), 7.47-7.40 (m, 2H), 7.40-7.13 (m, 17H), 6.90-6.76 (ddd, J=9.3, 4.4, 2.7 Hz, 8H), 6.45-6.27 (m, 2H), 5.32-5.22 (dd, J=8.5, 5.7 Hz, 1H), 4.34-4.25 (m, 1H), 4.23-4.14 (m, 1H), 4.07-3.89 (m, 2H), 3.79-3.74 (m, 12H), 3.74-3.65 (m, 6H), 3.51-3.33 (m, 2H), 2.90-2.79 (dd, J=14.2, 7.6 Hz, 2H), 2.73-2.55 (m, 3H), 2.55-2.34 (m, 6H), 2.02-1.91 (m, 1H), 1.87-1.81 (dd, J=4.9, 1.2 Hz, 3H), 1.77-1.66 (ddd, J=14.2, 8.7, 6.4 Hz, 1H), 1.41-1.35 (dd, J=6.6, 1.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 163.97, 163.93, 163.88, 158.90, 158.86, 158.71, 150.64, 150.59, 150.53, 150.50, 144.92, 144.88, 144.13, 144.08, 136.11, 136.07, 136.03, 136.00, 135.73, 135.60, 135.22, 135.14, 135.08, 135.04, 135.02, 130.32, 130.30, 130.23, 130.18, 128.33, 128.19, 128.17, 127.39, 127.33, 113.56, 113.52, 113.45, 111.85, 111.82, 111.38, 111.29, 87.56, 87.41, 87.38, 85.71, 85.35, 84.91, 84.38, 84.27, 84.22, 84.05, 83.97, 83.85, 83.78, 79.36, 79.11, 79.05, 74.25, 74.07, 67.39, 66.88, 66.79, 63.27, 57.80, 55.36, 53.55, 53.51, 53.40, 43.06, 40.72, 40.54, 39.25, 39.16, 39.01, 35.91, 12.64, 12.60, 11.78, 11.74; 31P NMR (162 MHz, CDCl3) δ 27.76, 27.46; MS (ESI+ve): calc (M+H): 1358.43. found: 1358.74. Rf=0.4 (5% MeOH/DCM).
- Compound 251:
- Compound 151 (75 mg, 0.055 mmol) was converted to compound 251 by a procedure analogous to that described for compound 201 (10 mg, 24%). MS (ESI+ve): calc (M+H): 754.17. found: 754.19. Rf=0.3 (10% MeOH/DCM).
- Compound 152:
-
Compound 100 is converted to compound 152 by a procedure analogous to that described for compound 101. - Compound 153:
- Using 1-Thio-β-D-glucose tetraacetate in place of compound 4, compound 152 is converted to compound 153 by a procedure analogous to that described for compound 151.
- Compound 253:
- Compound 153 is converted to compound 253 by a procedure analogous to that described for compound 201.
- Compound 154:
-
Compound 100 is converted to compound 154 by a procedure analogous to that described for compound 101. - Compound 155:
- Compound 154 is converted to compound 155 by a procedure analogous to that described for compound 151.
- Compound 255:
- Compound 155 is converted to compound 255 by a procedure analogous to that described for compound 201.
- Compound 300:
- Synthesis of (Rp)-CAGT-H-phosphonate-oxalyl linker-CPG was carried out on an Applied Biosystems 394 DNA/RNA synthesizer according to the reported methods (Journal of
American Chemical Society 2008, 130, 16031-16037; Angewandte Chemie International Edition 2009, 48, 496-499). - Compound 301:
- (Sp)-CAGT-phosphorothioate (R═H): (Rp)-CAGT-H-phosphonate-oxalyl linker-CPG was treated by 0.2 M Beaucage Reagent/CH3CN—BSA (9:1, v/v), stirred for 1 h at rt, then washed successively with CS2 and acetonitrile and dried under reduced pressure. The resultant CPG was treated with 2 mL of 28% aqueous NH3 and stirred for 18 h at rt. After removal of NH3 under reduced pressure, the resulting product was analyzed by LC/MS and HPLC.
- Compound 302:
- (Sp)-CAGT-S-methyl phosphorothiotriester (R=Me): BSTFA (50 μL, 188 μmol) and acetonitrile (500 μL) were added to (Rp)-CAGT-H-phosphonate-oxalyl linker-CPG (14.7 mg, 1 μmol) then the mixture was shaken for 20 min at rt. S-methyl methane sulfonothioate (20 μL, 212 μmol) and NEt3 (50 μL) were added and shaking was continued for 1 h at rt. The CPG was washed with CH3CN then dried in vacuo. 20% PrNH2 in dry CH3CN (2 mL) was added to the CPG and the mixture was stirred for 16 h at rt. Solvents were removed under reduced pressure and CH3CN was added to the mixture. The CPG was removed by filtration and the filtrate was concentrated under reduced pressure. CH3CN/DMSO/0.5 M AA buffer (1:1:1, v/v/v) was added, the mixture was stirred for 16 h at rt, then analyzed by LC/MS and HPLC.
- Compound 303:
- Compound 303 is prepared by sulfurization of compound 300 on support followed by cleavage. ACN (450 μL), BSTFA (50 μL) and compound 12 (20 mg) are added to compound 300 (1 μmol) which is shaken for 18 h. The CPG is collected by filtration resuspended in 20% PrNH2 in dry CH3CN (2 mL) and shaken for 16 h at rt. Solvents were removed under reduced pressure and the residue is purified by RPHPLC to provide pure compound 303.
-
- Compound 305:
- Compound 300 (0.5 μmol) was taken up in ACN (125 μL) then BSTFA (62 μL) was added and the mixture was shaken for 20 min. PrNH2 (125 μL) was added and the vial was rotated for 18 h. After filtration and washing with 1 mL ACN, the solvent was removed in vacuo and the residue was co-evaporated 3× with toluene to provide crude compound 304. The residue was redissolved in pyridine (375 μL) and treated with BSTFA for (16 μl, 60.0 μmol) followed by compound 9 (7.2 mg, 30.0 μmol) with stirring under Ar. After 2 h at r.t. the solvent was removed and the residue was treated with MeOH (0.125 mL) for 1 h, then AA (0.5 M, 0.125 mL) was added and the mixture was stirred at r.t. for 2 h. The product was purified by RPHPLC to provide compound 305.
- Compound 303:
- Substituting compound 12 for compound 9, compound 303 was prepared by a procedure analogous to that described for compound 305.
- Compound 306:
- Substituting compound 12 for compound 14, compound 306 was prepared by a procedure analogous to that described for compound 305.
- Compound 307:
- Substituting compound 12 for compound 29, compound 307 is prepared by a procedure analogous to that described for compound 305.
- Compound 308:
- Substituting compound 12 for
compound 31, compound 308 is prepared by a procedure analogous to that described for compound 305. - Compound 309:
- Substituting compound 12 for compound 38, compound 309 is prepared by a procedure analogous to that described for compound 305.
- Objective: To demonstrate that the reaction of MTS reagents to H-phosphonate to generate phosphorothio triester is stereospecific. 31P NMR was used to trace the changes during the course of the reaction.
- Experimental procedure: In an NMR tube was added
compound 100S 5′-O-(4,4′-dimethoxytrityl)thymidin-3′-yl 3′-O-(4,4′-dimethoxytrityl)thymidin-5′-yl H-phosphonate (20 mg, 18 mol) in 0.8 mL CD3CN and the 31P NMR spectrum was recorded. BSTFA (17 μL, 176 μmol) was added to same NMR tube and after 5 min 31P NMR spectrum was recorded again. Triethylamine (49 μL, 352 μmol) and S-methyl methanethiosulfonate (22 μL, 88 μmol) were added to same NMR tube and 31P NMR spectrum was recorded immediately. - The same procedure was repeated for Rp isomer (
compound 100R). The 31P NMR spectrum recorded for the starting material, intermediate and the product show that the stereochemistry at phosphorus atom is retained during the reaction. - While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (18)
1. A process for the preparation of phosphorothiotriesters of structure IIIa comprising the steps of:
i) reacting an H-phosphonate of structure Ia with an silylating reagent to provide a silyloxyphosphonate; and
ii) reacting the silyloxyphosphonate with a thiosulfonate reagent of structure IIa to provide a phosphorothiotriester of structure IIIa;
wherein,
the H-phosphonate of structure Ia has the following structure:
wherein,
W is independently selected from O, S, NH, or CH2;
R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
Y1 is O, NRd, S, or Se;
Ra is a blocking group;
Rc is a blocking group;
each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
Y2 is O, NRd, or S;
each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
n is between 1 and about 200; and
the thiosulfonate reagent of structure IIa has the following structure:
wherein,
X is alkyl, cycloalkyl, or heteroaryl;
R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-;
R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
and the phosphorothiotriester of structure IIIa has the following structure:
wherein,
W is independently selected from O, S, NH, or CH2;
R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-;
R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
Y1 is O, NRd, S, or Se;
Ra is a blocking group;
Rc is a blocking group;
each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
Y2 is O, NRd, or S;
each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
n is between 1 and about 200.
2. A process for the preparation of phosphorothiotriesters comprising non-stereorandom phosphorous linkages of structure IIIb comprising the steps of:
i) reacting a H-phosphonate comprising non-stereorandom phosphorous linkages of structure Ib with an silylating reagent to provide a silyloxyphosphonate; and
ii) reacting the silyloxyphosphonate with a thiosulfonate reagent of structure IIb to provide a phosphorothiotriester comprising non-stereorandom phosphorous linkages of structure IIIb;
wherein,
the H-phosphonate comprising non-stereorandom phosphorous linkages of structure Ib has the following structure:
wherein,
W is independently selected from O, NH, or CH2;
R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
Y1 is O, NRd, S, or Se;
Ra is a blocking group;
Rc is a blocking group;
each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
Y2 is O, NRd, or S;
each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
n is between 1 and about 200; and
the thiosulfonate reagent of structure IIb has the following structure:
wherein,
X is alkyl, cycloalkyl, aryl, or heteroaryl;
R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-;
R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
and the chiral phosphorothiotriester comprising non-stereorandom phosphorous linkages of structure IIIb has the following structure:
wherein,
W is independently selected from O, NH, or CH2;
R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or R1-R2;
R1 is selected from —S-alkenylene-, —S-alkylene-, —S-alkylene-aryl-alkylene-, —S—CO-aryl-alkylene-, or —S—CO-alkylene-aryl-alkylene-;
R2 is selected from heterocyclo-alkylene-S—, heterocyclo-alkenylene-S—, aminoalkyl-S—, or (alkyl)4N-alkylene-S—;
R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
Y1 is O, NRd, S, or Se;
Ra is a blocking group;
Rc is a blocking group;
each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
Y2 is O, NRd, or S;
each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
n is between 1 and about 200.
3. The process of claim 1 , wherein W is O.
5. The process of claim 1 , wherein the silylating reagent is selected from
1,1,3,3-tetramethyl-1,3-diphenyldisilazane;
1,3-dimethyl-1,1,3,3-tetraphenyldisilazane;
1-(trimethylsilyl)imidazole;
N-trimethylsilyl-N-methyl trifluoroacetamide;
bis(dimethylamino)dimethylsilane;
bromotrimethylsilane;
chlorodimethyl(pentafluorophenyl)silane;
chlorotriethyl silane;
chlorotriisopropylsilane;
chlorotrimethylsilane;
dichlorodimethylsilane;
hexamethyldisilazane;
N,N′-bis(trimethylsilyl)urea;
N,N-bis(trimethylsilyl)methylamine;
N,N-dimethyltrimethylsilylamine;
N,O-bis(trimethylsilyl)acetamide;
N,O-bis(trimethylsilyl)carbamate;
N,O-bis(trimethylsilyl)trifluoroacetamide;
N-methyl-N-(trimethylsilyl)trifluoroacetamide;
N-methyl-N-trimethylsilylacetamide;
N-methyl-N-trimethylsilylheptafluorobutyramide;
N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide;
N-methyl-N-trimethylsilylheptafluorobutyramide;
trimethylsilyltriflate;
triethylsilyltriflate;
triisopropylsilyltriflate; or
tert-butyldimethylsilyltriflate.
6. The process of claim 5 , wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethyl silyl)imidazole.
7. The process of claim 6 , wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
8. The process of claim 1 , wherein the H-phosphonate is covalently linked to a solid phase.
9. A process for the preparation of phosphorothiotriesters of structure IIIc comprising the steps of:
i) reacting a H-phosphonate of structure Ic with an silylating reagent to provide a silyloxyphosphonate;
ii) reacting the silyloxyphosphonate with a bis(thiosulfonate) reagent of structure IVc to provide a phosphorothiotriester comprising a thiosulfonate group of structure Vc;
iii) reacting the phosphorothiotriester comprising a thiosulfonate group of structure Vc with a nucleophile of structure VIc to provide the phosphorothiotriesters of structure IIIc;
wherein,
the H-phosphonate of structure Ic has the following structure:
wherein,
W is independently selected from O, S, NH, or CH2;
R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
Y1 is O, NRd, S, or Se;
Ra is a blocking group;
Rc is a blocking group;
each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
Y2 is O, NRd, or S;
each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; and
n is between 1 and about 200; and
the bis(thiosulfonate) reagent of structure IVc has the following structure:
wherein,
X is alkylene, alkenylene, arylene, or heteroarylene;
each R6 is independently alkyl, cycloalkyl, aryl, or heteroaryl;
the nucleophile of structure VIc has the following structure:
R7—SH, wherein R7 is selected from alkyl, alkenyl, aryl, heterocyclo, aminoalkyl, or (heterocyclo)alkyl;
and phosphorothiotriesters of structure IIIc has the following structure:
wherein,
W is independently selected from O, S, NH, or CH2;
R is R7—S—S—X—
R7 is alkyl, alkenyl, aryl, heterocyclo, aminoalkyl, or (heterocyclo)alkyl;
X is alkylene, alkenylene, arylene, or heteroarylene;
R3 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;
Y1 is O, NRd, S, or Se;
Ra is a blocking group;
Rc is a blocking group;
each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);
each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;
Y2 is O, NRd, or S;
each instance of R4 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, and Rb is a blocking group;
each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;
R5 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid;
n is between 1 and about 200; and
wherein the phosphorous linkages of the H-phosphonate of structure Ic, the phosphorothiotriester comprising a thiosulfonate group of structure Vc, and the phosphorothiotriesters of structure IIIc may optionally comprise non-stereorandom phosphorous linkages.
10. The process of claim 8 , wherein the phosphorothiotriesters of structure IIIb comprise non-stereorandom phosphorous linkages and the H-phosphonate of structure Ic comprise non-stereorandom phosphorous linkages; and W is independently selected from O, NH, or CH2.
11. The process of claim 9 , wherein W is O.
12. The process of claim 9 , wherein R6 is methyl.
15. The process of claim 9 , wherein the silylating reagent is selected from
1,1,3,3-tetramethyl-1,3-diphenyldisilazane;
1,3-dimethyl-1,1,3,3-tetraphenyldisilazane;
1-(trimethylsilyl)imidazole;
N-trimethylsilyl-N-methyl trifluoroacetamide;
bis(dimethylamino)dimethylsilane;
bromotrimethylsilane;
chlorodimethyl(pentafluorophenyl)silane;
chlorotriethyl silane;
chlorotriisopropylsilane;
chlorotrimethylsilane;
dichlorodimethylsilane;
hexamethyldisilazane;
N,N′-bis(trimethylsilyl)urea;
N,N-bis(trimethylsilyl)methylamine;
N,N-dimethyltrimethylsilylamine;
N,O-bis(trimethylsilyl)acetamide;
N,O-bis(trimethylsilyl)carbamate;
N,O-bis(trimethylsilyl)trifluoroacetamide;
N-methyl-N-(trimethylsilyl)trifluoroacetamide;
N-methyl-N-trimethylsilylacetamide;
N-methyl-N-trimethylsilylheptafluorobutyramide;
N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide;
N-methyl-N-trimethylsilylheptafluorobutyramide;
trimethylsilyltriflate;
triethylsilyltriflate;
triisopropylsilyltriflate; or
tert-butyldimethylsilyltriflate.
16. The process of claim 15 , wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide, trimethylsilyltriflate, chlorotrimethylsilane, or 1-(trimethyl silyl)imidazole.
17. The process of claim 16 , wherein the silylating reagent is selected from N,O-bis(trimethylsilyl)trifluoroacetamide.
18. The process of claim 17 , wherein the H-phosphonate is covalently linked to a solid phase.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/222,910 US20170029457A1 (en) | 2011-07-19 | 2016-07-28 | Methods for the synthesis of functionalized nucleic acids |
US15/941,494 US10280192B2 (en) | 2011-07-19 | 2018-03-30 | Methods for the synthesis of functionalized nucleic acids |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161509526P | 2011-07-19 | 2011-07-19 | |
PCT/US2012/046805 WO2013012758A1 (en) | 2011-07-19 | 2012-07-13 | Methods for the synthesis of functionalized nucleic acids |
US201414233579A | 2014-02-27 | 2014-02-27 | |
US15/222,910 US20170029457A1 (en) | 2011-07-19 | 2016-07-28 | Methods for the synthesis of functionalized nucleic acids |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/046805 Continuation WO2013012758A1 (en) | 2011-07-19 | 2012-07-13 | Methods for the synthesis of functionalized nucleic acids |
US14/233,579 Continuation US9605019B2 (en) | 2011-07-19 | 2012-07-13 | Methods for the synthesis of functionalized nucleic acids |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/941,494 Continuation US10280192B2 (en) | 2011-07-19 | 2018-03-30 | Methods for the synthesis of functionalized nucleic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170029457A1 true US20170029457A1 (en) | 2017-02-02 |
Family
ID=47558410
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/233,579 Active US9605019B2 (en) | 2011-07-19 | 2012-07-13 | Methods for the synthesis of functionalized nucleic acids |
US15/222,910 Abandoned US20170029457A1 (en) | 2011-07-19 | 2016-07-28 | Methods for the synthesis of functionalized nucleic acids |
US15/941,494 Active US10280192B2 (en) | 2011-07-19 | 2018-03-30 | Methods for the synthesis of functionalized nucleic acids |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/233,579 Active US9605019B2 (en) | 2011-07-19 | 2012-07-13 | Methods for the synthesis of functionalized nucleic acids |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/941,494 Active US10280192B2 (en) | 2011-07-19 | 2018-03-30 | Methods for the synthesis of functionalized nucleic acids |
Country Status (16)
Country | Link |
---|---|
US (3) | US9605019B2 (en) |
EP (2) | EP3248982A1 (en) |
JP (2) | JP6128529B2 (en) |
KR (1) | KR20140068884A (en) |
CN (2) | CN103796657B (en) |
AU (1) | AU2012284265B2 (en) |
BR (1) | BR112014001244A2 (en) |
CA (1) | CA2842358C (en) |
DK (1) | DK2734208T3 (en) |
ES (1) | ES2626488T3 (en) |
HK (1) | HK1198479A1 (en) |
IL (1) | IL230522B (en) |
MX (1) | MX347361B (en) |
RU (1) | RU2014105311A (en) |
SG (1) | SG10201700554VA (en) |
WO (1) | WO2013012758A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9982257B2 (en) | 2012-07-13 | 2018-05-29 | Wave Life Sciences Ltd. | Chiral control |
US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
US10149905B2 (en) | 2014-01-15 | 2018-12-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
US10160969B2 (en) | 2014-01-16 | 2018-12-25 | Wave Life Sciences Ltd. | Chiral design |
US10167309B2 (en) | 2012-07-13 | 2019-01-01 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
US10280192B2 (en) | 2011-07-19 | 2019-05-07 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
US10307434B2 (en) | 2009-07-06 | 2019-06-04 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
US10329318B2 (en) | 2008-12-02 | 2019-06-25 | Wave Life Sciences Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
US10450568B2 (en) | 2015-10-09 | 2019-10-22 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
US10479995B2 (en) | 2015-07-22 | 2019-11-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
US10724035B2 (en) | 2016-05-04 | 2020-07-28 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
US11407775B2 (en) | 2016-03-13 | 2022-08-09 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101141544B1 (en) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | Multi-conjugate of siRNA and preparing method thereof |
MX356830B (en) | 2012-07-13 | 2018-06-15 | Shin Nippon Biomedical Laboratories Ltd | Chiral nucleic acid adjuvant. |
AU2014346658A1 (en) * | 2013-11-06 | 2016-06-02 | Solstice Biologics, Ltd. | Polynucleotide constructs having disulfide groups |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
WO2015125845A1 (en) * | 2014-02-20 | 2015-08-27 | 塩野義製薬株式会社 | Phosphate site modification of nucleic acid containing nitrogen-containing non-aromatic heterocycle |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
RU2708237C2 (en) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Modified oligonucleotides and method for production thereof |
US10465188B2 (en) | 2014-08-22 | 2019-11-05 | Auckland Uniservices Limited | Channel modulators |
SG11201702682PA (en) | 2014-10-03 | 2017-04-27 | Cold Spring Harbor Lab | Targeted augmentation of nuclear gene output |
DK3234131T3 (en) | 2014-12-16 | 2020-06-29 | Roche Innovation Ct Copenhagen As | Method of screening for chiral toxicity |
CN108026527B (en) | 2015-06-15 | 2022-05-10 | Mpeg La有限责任公司 | Defined multiconjugated oligonucleotides |
JPWO2016208773A1 (en) * | 2015-06-26 | 2018-04-12 | 協和発酵キリン株式会社 | Oligonucleotide derivatives |
KR102422625B1 (en) | 2015-10-09 | 2022-07-20 | 유니버시티 오브 사우스앰톤 | Regulation of gene expression and screening of deregulated protein expression |
CA3005245A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of alagille syndrome |
US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
ES2903394T3 (en) | 2015-12-14 | 2022-04-01 | Cold Spring Harbor Laboratory | Compositions for the treatment of retinitis pigmentosa 13 |
CA3005246A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of central nervous system diseases |
EP3389672A4 (en) | 2015-12-14 | 2019-08-14 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of liver diseases |
SG11201804443UA (en) | 2015-12-14 | 2018-06-28 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
WO2017155058A1 (en) * | 2016-03-09 | 2017-09-14 | 学校法人東京理科大学 | Nucleic acid oligomer for rna hybrid formation |
PT3430141T (en) | 2016-03-14 | 2021-02-25 | Hoffmann La Roche | Oligonucleotides for reduction of pd-l1 expression |
MA45471A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | PHOSPHATIDYLINOSITOL-3-KINASE NUCLEIC ACIDS AND THEIR USES |
MA45469A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | BETA-CATENIN NUCLEIC ACIDS AND THEIR USES |
MA45470A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | KRAS NUCLEIC ACIDS AND THEIR USES |
MA45349A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | EGFR NUCLEIC ACIDS AND THEIR USES |
MA45328A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
SG11201906200WA (en) | 2017-01-06 | 2019-08-27 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
CN106667176A (en) * | 2017-03-01 | 2017-05-17 | 戴建华 | Drug pillow for treating acne |
JP7152408B2 (en) * | 2017-03-10 | 2022-10-12 | キアペグ ファーマシューティカルズ アクチエボラグ | releasable conjugate |
EP3630199A4 (en) | 2017-06-02 | 2021-11-10 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
JP2020524485A (en) | 2017-06-02 | 2020-08-20 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | Oligonucleotide composition and method of using the same |
EP3642182A4 (en) | 2017-06-21 | 2020-12-09 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
AU2018316159A1 (en) | 2017-08-08 | 2020-02-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
JP6827148B2 (en) | 2017-08-25 | 2021-02-10 | ストーク セラピューティクス,インク. | Antisense oligomers for the treatment of conditions and diseases |
JP2021500311A (en) | 2017-09-18 | 2021-01-07 | ウェーブ ライフ サイエンシーズ リミテッド | Techniques for oligonucleotide preparation |
WO2019071028A1 (en) | 2017-10-04 | 2019-04-11 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and uses thereof |
US11596646B2 (en) | 2017-10-12 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
AU2018378812A1 (en) | 2017-12-06 | 2020-07-09 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
KR102270138B1 (en) * | 2018-09-17 | 2021-06-28 | 삼성에스디아이 주식회사 | Composition for forming silica layer, method for manufacturing silica layer, and silica layer |
IL297818A (en) | 2018-12-21 | 2023-01-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
EP3980436A4 (en) | 2019-06-06 | 2023-12-20 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
CA3172111A1 (en) | 2020-03-19 | 2021-09-23 | Barbora MALECOVA | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
EP4126066A1 (en) | 2020-03-27 | 2023-02-08 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
WO2021231107A1 (en) | 2020-05-11 | 2021-11-18 | Stoke Therapeutics, Inc. | Opa1 antisense oligomers for treatment of conditions and diseases |
EP4153747A2 (en) | 2020-05-22 | 2023-03-29 | Wave Life Sciences Ltd. | Double stranded oligonucleotide compositions and methods relating thereto |
JPWO2022230990A1 (en) * | 2021-04-28 | 2022-11-03 | ||
AU2022345098A1 (en) | 2021-09-16 | 2024-04-04 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
WO2023220737A2 (en) * | 2022-05-13 | 2023-11-16 | Adarx Pharmaceuticals, Inc. | Oligonucleotides having a synthetic backbone and synthesis thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9605019B2 (en) * | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
Family Cites Families (688)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2878264A (en) | 1959-03-17 | Substituted amino alcohols | ||
CH372667A (en) | 1957-09-26 | 1963-10-31 | Robins Co Inc A H | Process for the preparation of 3-aryl-3-pyrrolidinols |
US3135766A (en) | 1961-10-03 | 1964-06-02 | Mead Johnson & Co | 3-substituted-3-pyrrolidinols |
US3484473A (en) * | 1967-05-12 | 1969-12-16 | Buckman Labor Inc | Methylene bisesters of thiolsulfonic acids |
DE1934150A1 (en) | 1968-07-10 | 1970-01-15 | Pennwalt Corp | New 1-alkanoyloxy-1,2,4,5-tetrahydro-3H, 3-benzazepine |
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US3745162A (en) | 1970-08-31 | 1973-07-10 | Robins Co Inc A H | 1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides |
GB1448437A (en) | 1973-02-24 | 1976-09-08 | Beecham Group Ltd | Diphenylpropylamines |
US4022791A (en) | 1975-06-03 | 1977-05-10 | Pfizer Inc. | 2-Aminomethyl-3,4-dihydronaphthalenes |
GB1504424A (en) | 1975-08-09 | 1978-03-22 | Beecham Group Ltd | Isoquinoline-derived aminoethers |
BR7807288A (en) | 1977-11-08 | 1979-06-12 | Genentech Inc | POLYNUCLEOTIDE SYNTHESIS PROCESS |
DD133885B1 (en) | 1978-01-04 | 1981-02-25 | Hans Lehmann | AGENTS FOR THE CONTROL OF PHYTOPATHOGENIC BACTERIA AND MUSHROOMS |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4542142A (en) | 1982-11-22 | 1985-09-17 | Roussel Uclaf | Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain |
USRE34069E (en) | 1983-08-18 | 1992-09-15 | Biosyntech Gmbh | Process for the preparation of oligonucleotides |
DE3329892A1 (en) | 1983-08-18 | 1985-03-07 | Köster, Hubert, Prof. Dr., 2000 Hamburg | METHOD FOR PRODUCING OLIGONUCLEOTIDES |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5643889A (en) | 1984-07-11 | 1997-07-01 | Temple University-Of The Commonwealth System Of Pennsylvania | Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof |
FR2567892B1 (en) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS |
US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
FR2575751B1 (en) | 1985-01-08 | 1987-04-03 | Pasteur Institut | NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS |
FR2576898B1 (en) | 1985-02-01 | 1988-01-08 | Lafon Labor | 3-PHENYL-TETRAHYDROPYRIDINE DERIVATIVES, METHOD OF PREPARATION AND THERAPEUTIC USE |
US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
US4735949A (en) | 1986-02-18 | 1988-04-05 | Warner-Lambert Company | Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents |
US4840956A (en) | 1986-02-18 | 1989-06-20 | Warner-Lambert Company | Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents |
IL83663A0 (en) | 1986-10-27 | 1988-01-31 | Robins Co Inc A H | Preparation of 3-pyrrolidinols |
EP0366685B1 (en) | 1987-06-24 | 1994-10-19 | Howard Florey Institute Of Experimental Physiology And Medicine | Nucleoside derivatives |
EP0302349B1 (en) | 1987-07-30 | 1993-09-29 | Bar Ilan University | Biologically active carboxylic acid esters |
US4923901A (en) | 1987-09-04 | 1990-05-08 | Millipore Corporation | Membranes with bound oligonucleotides and peptides |
US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
US4943629A (en) | 1988-08-12 | 1990-07-24 | American Cyanamid Company | Antidiabetic alpha-substituted phosphonates |
US4945158A (en) | 1988-08-12 | 1990-07-31 | American Cyanamid Company | Antidiabetic phosphonates |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
JP2794461B2 (en) | 1989-08-17 | 1998-09-03 | 有機合成薬品工業株式会社 | Phosphoramidite compounds and solid-phase synthesis of oligoribonucleotides using the same |
US5141813A (en) | 1989-08-28 | 1992-08-25 | Clontech Laboratories, Inc. | Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
CA2029273A1 (en) | 1989-12-04 | 1991-06-05 | Christine L. Brakel | Modified nucleotide compounds |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
AU658134B2 (en) | 1989-12-28 | 1995-04-06 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
US5852188A (en) | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
JP2580091B2 (en) | 1990-01-11 | 1997-02-12 | アイシス・ファーマシューティカルス・インコーポレーテッド | Compositions and methods for detecting and modulating RNA activity and gene expression |
US6339066B1 (en) | 1990-01-11 | 2002-01-15 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C |
US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5635488A (en) | 1991-10-15 | 1997-06-03 | Isis Pharmaceuticals, Inc. | Compounds having phosphorodithioate linkages of high chiral purity |
US5506212A (en) | 1990-01-11 | 1996-04-09 | Isis Pharmaceuticals, Inc. | Oligonucleotides with substantially chirally pure phosphorothioate linkages |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5620963A (en) | 1991-10-15 | 1997-04-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5212295A (en) | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
US5914396A (en) | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
US5457191A (en) | 1990-01-11 | 1995-10-10 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5292875A (en) | 1990-04-20 | 1994-03-08 | Lynx Therapeutics, Inc. | Method of synthesizing sulfurized oligonucleotide analogs |
DK0531447T3 (en) | 1990-05-23 | 2000-03-27 | Isis Pharmaceuticals Inc | Compositions and Methods for Modulating RNA Activity by Modifying the 5 'Cap Structure of RNA |
US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
ATE154246T1 (en) | 1990-07-27 | 1997-06-15 | Isis Pharmaceuticals Inc | NUCLEASE RESISTANT PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECTE AND MODULATE GENE EXPRESSION |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5792844A (en) | 1990-07-27 | 1998-08-11 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent nitrogen atoms |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5834607A (en) | 1990-07-27 | 1998-11-10 | Isis Pharmaceuticals, Inc. | Amines and methods of making and using the same |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US6087482A (en) | 1990-07-27 | 2000-07-11 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5223618A (en) | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
US6121433A (en) | 1990-07-27 | 2000-09-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having nitrogen-containing linkages |
WO1994022886A1 (en) | 1993-03-30 | 1994-10-13 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5783682A (en) | 1990-07-27 | 1998-07-21 | Isis Pharmaceuticals, Inc. | Oligonucleotide mimics having nitrogen-containing linkages |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5998603A (en) | 1994-09-29 | 1999-12-07 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analogs, and oligomers thereof |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
JPH04348044A (en) | 1991-02-21 | 1992-12-03 | Matsushita Electron Corp | Resin sealing device for semiconductor |
US5512668A (en) | 1991-03-06 | 1996-04-30 | Polish Academy Of Sciences | Solid phase oligonucleotide synthesis using phospholane intermediates |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US20020183502A1 (en) | 1991-05-21 | 2002-12-05 | Mesmaeker Alain De | Backbone-modified oligonucleotide analogs and methods for using same |
US6414112B1 (en) | 1991-05-24 | 2002-07-02 | Ole Buchardt | Peptide nucleic acids having 2,6-diaminopurine nucleobases |
JPH04348077A (en) | 1991-05-24 | 1992-12-03 | Nec Corp | Thin-film transistor |
WO1992022655A1 (en) | 1991-06-10 | 1992-12-23 | Lucky Limited | Hepatitis c diagnostics and vaccines |
US5359052A (en) | 1991-08-05 | 1994-10-25 | Polish Academy Of Sciences | Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates |
US5646267A (en) | 1991-08-05 | 1997-07-08 | Polish Academy Of Sciences | Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues |
US6369209B1 (en) | 1999-05-03 | 2002-04-09 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US7119184B2 (en) | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US5654284A (en) | 1991-10-15 | 1997-08-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity |
EP0655088B1 (en) | 1991-10-15 | 2002-07-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
US5661134A (en) | 1991-10-15 | 1997-08-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity |
US5607923A (en) | 1991-10-15 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity |
US5599797A (en) | 1991-10-15 | 1997-02-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
DE59208572D1 (en) | 1991-10-17 | 1997-07-10 | Ciba Geigy Ag | Bicyclic nucleosides, oligonucleotides, processes for their preparation and intermediates |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
JP3131222B2 (en) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | 2 'modified oligonucleotide having a gap |
GB9213601D0 (en) | 1992-06-26 | 1992-08-12 | Mastico Robert A | Protein based delivery system |
US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
US6005107A (en) | 1992-12-23 | 1999-12-21 | Biochem Pharma, Inc. | Antiviral compounds |
US6444656B1 (en) | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
DE69400208T2 (en) | 1993-01-25 | 1996-11-28 | Hybridon Inc | OLIONUCLEOTIDALKYLPHOSPHONATES AND PHOSPHONOTHIOATES |
WO1994022890A1 (en) | 1993-03-31 | 1994-10-13 | Sterling Winthop Inc. | Novel 5'-substituted nucleosides and oligomers produced therefrom |
HU9501978D0 (en) | 1993-03-31 | 1995-09-28 | Sterling Winthorp Inc | Bifunctional nucleosides, oligomers thereof, and methods of making and using the same |
US5955591A (en) | 1993-05-12 | 1999-09-21 | Imbach; Jean-Louis | Phosphotriester oligonucleotides, amidites and method of preparation |
US6015886A (en) | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
EP0628394B1 (en) | 1993-06-10 | 1998-08-26 | Idemitsu Petrochemical Co. Ltd. | Injection molding die |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5643989A (en) | 1993-10-29 | 1997-07-01 | Azdel, Inc. | Fiber reinforced functionalized polyolefin composites |
US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
DE4435728A1 (en) | 1994-01-19 | 1995-07-20 | Boehringer Mannheim Gmbh | Biotin silane compounds and binding matrix containing these compounds |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
EP0746618B1 (en) | 1994-02-22 | 2002-08-21 | Novozymes A/S | A method of preparing a variant of a lipolytic enzyme |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
AU2445795A (en) | 1994-05-11 | 1995-12-05 | Novo Nordisk A/S | An enzyme with endo-1,3(4)-beta -glucanase activity |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
DE69507197T2 (en) | 1994-05-31 | 1999-05-27 | Bayer Ag | Aminobenzofuryl and thienyl derivatives |
HRP950288A2 (en) | 1994-05-31 | 1997-08-31 | Bayer Ag | Oxalylamino-benzofuran- and benzothienyl-derivatives |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CA2560114A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
CA2199464A1 (en) | 1994-09-07 | 1996-03-14 | Radhakrishnan Iyer | Oligonucleotide prodrugs |
US5681940A (en) | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
CA2208528A1 (en) | 1994-12-22 | 1996-06-27 | Hybridon, Inc. | Synthesis of stereospecific oligonucleotide phosphorothioates |
GB9501465D0 (en) * | 1995-01-25 | 1995-03-15 | King S College London | Nucleoside phosphorothioate derivatives,synthesis and use thereof |
EP0813539B1 (en) | 1995-03-06 | 2006-05-24 | Isis Pharmaceuticals, Inc. | Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom |
US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
EP0739983B1 (en) | 1995-04-27 | 2009-12-30 | Takara Bio Inc. | Gene encoding lacto-n-biosidase |
EP0824588B1 (en) | 1995-05-11 | 2004-07-14 | Applied Research Systems ARS Holding N.V. | Il-6 activity inhibitor |
CA2221589A1 (en) | 1995-05-19 | 1996-11-21 | Glycomed Incorporated | Collection of activated glycoside compounds and their biological use |
DE69609511T2 (en) | 1995-05-23 | 2001-03-29 | Hybridon Inc | New synthons for stereoselective oligonucleotide synthesis |
AU5871196A (en) | 1995-05-23 | 1996-12-24 | Hybridon, Inc. | Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced |
WO1996039154A1 (en) | 1995-06-06 | 1996-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5932450A (en) | 1995-06-07 | 1999-08-03 | Gen-Probe Incorporated | Enzymatic synthesis of oligonucleotides using digestible templates |
US5795765A (en) | 1995-06-29 | 1998-08-18 | Takara Shuzo Co., Ltd. | Gene encoding endoglycoceramidase |
US5824503A (en) | 1995-06-29 | 1998-10-20 | Takara Shuzo Co, Ltd. | Gene encoding endoglycoceramidase activator |
US6017700A (en) | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
US5936080A (en) | 1996-05-24 | 1999-08-10 | Genta Incorporated | Compositions and methods for the synthesis of organophosphorus derivatives |
WO1997009443A1 (en) | 1995-09-05 | 1997-03-13 | Michigan State University | PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp |
US5734041A (en) | 1995-10-20 | 1998-03-31 | Mcgill University | Preparation of chiral phosphorothioate oligomers |
US6476216B1 (en) | 1995-10-20 | 2002-11-05 | Mcgill University | Preparation of phosphorothioate oligomers |
US6160109A (en) | 1995-10-20 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Preparation of phosphorothioate and boranophosphate oligomers |
US7018793B1 (en) | 1995-12-07 | 2006-03-28 | Diversa Corporation | Combinatorial screening of mixed populations of organisms |
CA2246503A1 (en) | 1996-02-15 | 1997-08-21 | National Institutes Of Health | Rnase l activators and antisense oligonucleotides effective to treat rsv infections |
US6214805B1 (en) | 1996-02-15 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
GB9604669D0 (en) | 1996-03-05 | 1996-05-01 | Ciba Geigy Ag | Chemical compounds |
US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
WO1997043409A2 (en) | 1996-05-10 | 1997-11-20 | Novo Nordisk A/S | Method of providing novel dna sequences |
US5856465A (en) | 1996-05-24 | 1999-01-05 | Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych | Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
DE19622783A1 (en) | 1996-06-07 | 1997-12-11 | Hoechst Ag | Isolation of the biosynthetic genes for pseudo-oligosaccharides from Streptomyces glaucescens GLA.O and their use |
JP2000514307A (en) | 1996-07-16 | 2000-10-31 | ジェン―プローブ・インコーポレーテッド | Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides with increased target specific T <M> |
AU717387B2 (en) | 1996-07-24 | 2000-03-23 | Rolf H. Berg | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
WO1998007734A1 (en) | 1996-08-21 | 1998-02-26 | Hybridon, Inc. | Oligonucleotide prodrugs |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
GB9621522D0 (en) | 1996-10-16 | 1996-12-04 | Biocompatibles Ltd | Synthesis of phosphorus compounds |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6639062B2 (en) | 1997-02-14 | 2003-10-28 | Isis Pharmaceuticals, Inc. | Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
US6369237B1 (en) | 1997-03-07 | 2002-04-09 | President And Fellows Of Harvard College | DNA glycosylase inhibitors, and uses related thereto |
US6015887A (en) | 1997-04-11 | 2000-01-18 | Isis Pharmaceuticals, Inc. | Chiral peptide nucleic acids and methods for preparing same |
US6468983B2 (en) | 1997-04-21 | 2002-10-22 | The Cleveland Clinic Foundation | RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies |
PL184612B1 (en) | 1997-04-25 | 2002-11-29 | Pan | Method of obtaining p-chiral analoques of nucleotides |
CA2291839A1 (en) | 1997-05-28 | 1998-12-03 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
WO1999000377A1 (en) | 1997-06-27 | 1999-01-07 | The Procter & Gamble Company | Pro-fragrance cyclic acetals |
WO1999005160A2 (en) | 1997-07-25 | 1999-02-04 | Hybridon, Inc. | Oligonuclotides having 3' terminal stereospecific phosphorothioates |
US6767739B2 (en) | 2001-07-30 | 2004-07-27 | Isis Pharmaceuticals Inc. | Antisense modulation of microsomal triglyceride transfer protein expression |
GB9717158D0 (en) | 1997-08-13 | 1997-10-22 | King S College London | Solution synthesis of oligonucleotides and their phosphorothioate analogues |
US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
US6750344B1 (en) | 1997-09-05 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Amine compounds and combinatorial libraries comprising same |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
DE19741715A1 (en) | 1997-09-22 | 1999-03-25 | Hoechst Ag | New pentopyranosyl nucleoside compounds |
US6232463B1 (en) | 1997-10-09 | 2001-05-15 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US6528640B1 (en) | 1997-11-05 | 2003-03-04 | Ribozyme Pharmaceuticals, Incorporated | Synthetic ribonucleic acids with RNAse activity |
US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
US6080543A (en) | 1997-12-08 | 2000-06-27 | E. & J. Gallo Winery | Detection of fungal pathogens |
US6582936B1 (en) | 1997-12-12 | 2003-06-24 | The Regents Of The University Of California | Methods for making nucleic acids |
US6248519B1 (en) | 1998-03-11 | 2001-06-19 | E & J Gallo Winery | Detection of fermentation-related microorganisms |
US7045610B2 (en) | 1998-04-03 | 2006-05-16 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
AU3884199A (en) | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
DE69927495T2 (en) | 1998-05-14 | 2006-07-06 | Coley Pharmaceutical Group, Inc., Wellesley | METHOD OF REGULATING HEMATOPOESIS BY USING CPG OLIGONUCLEOTIDES |
US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
EP1100807A1 (en) | 1998-07-27 | 2001-05-23 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
DE69929444T2 (en) | 1998-08-10 | 2006-09-28 | Antigenics Inc., Woburn | CPG COMPOSITIONS, SAPONIN ADJUVANTIES, AND METHOD OF USE THEREOF |
WO2000023444A1 (en) | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
US6451524B1 (en) | 1998-11-25 | 2002-09-17 | Isis Pharmaceuticals, Inc. | Identification of disease predictive nucleic acids |
WO2000031110A1 (en) | 1998-11-25 | 2000-06-02 | Isis Pharmaceuticals, Inc. | Identification of disease predictive nucleic acids |
CA2353789C (en) | 1998-12-21 | 2012-02-14 | Genencor International, Inc. | Chemically modified enzymes with multiple charged variants |
CA2702148C (en) | 1999-01-06 | 2014-03-04 | Genenews Inc. | Method of profiling gene expression in a human subject having an infectious disease |
US6265172B1 (en) | 1999-02-08 | 2001-07-24 | University Of Kentucky | Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases |
US6121437A (en) | 1999-03-16 | 2000-09-19 | Isis Pharmaceuticals, Inc. | Phosphate and thiophosphate protecting groups |
US6506594B1 (en) | 1999-03-19 | 2003-01-14 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
GB9907245D0 (en) | 1999-03-29 | 1999-05-26 | Goldsborough Andrew | Cleavage of nucleic acids from solid supports |
JP3072345B1 (en) | 1999-03-31 | 2000-07-31 | 農林水産省家畜衛生試験場長 | Swine erysipelas recombinant subunit vaccine |
US5998148A (en) | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US6300069B1 (en) | 1999-05-03 | 2001-10-09 | Qiagen Gmbh | Generation and amplification of nucleic acids from ribonucleic acids |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6066500A (en) | 1999-06-25 | 2000-05-23 | Isis Pharmaceuticals Inc. | Antisense modulation of Beta catenin expression |
US6271004B1 (en) | 1999-06-25 | 2001-08-07 | Display Systems Biotech A/S | Method for improved reverse transcription at high temperatures |
US6414135B1 (en) | 1999-07-07 | 2002-07-02 | Isis Pharmaceuticals, Inc. | C3′-methylene hydrogen phosphonate monomers and related compounds |
US20030092647A1 (en) | 2001-08-08 | 2003-05-15 | Crooke Rosanne M. | Antisense modulation of cholesteryl ester transfer protein expression |
US6147200A (en) | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US7264932B2 (en) | 1999-09-24 | 2007-09-04 | Applera Corporation | Nuclease inhibitor cocktail |
JP2003510282A (en) | 1999-09-25 | 2003-03-18 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Immunostimulatory nucleic acids |
ATE333284T1 (en) | 1999-09-27 | 2006-08-15 | Coley Pharm Group Inc | METHOD USING IMMUNOSTIMULATIVE INTERFERON INDUCED BY NUCLEIC ACIDS |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US20020082227A1 (en) | 1999-09-30 | 2002-06-27 | Scott Henry | Use of oligonucleotides for inhibition of complement activation |
US6309836B1 (en) * | 1999-10-05 | 2001-10-30 | Marek Kwiatkowski | Compounds for protecting hydroxyls and methods for their use |
AU7863200A (en) | 1999-10-06 | 2001-05-10 | Quark Biotech, Inc. | Method for enrichment of natural antisense messenger rna |
GB9924285D0 (en) | 1999-10-14 | 1999-12-15 | Avecia Ltd | Process |
US20010055761A1 (en) | 1999-10-29 | 2001-12-27 | Agilent Technologies | Small scale dna synthesis using polymeric solid support with functionalized regions |
FR2800750B1 (en) | 1999-11-05 | 2003-01-31 | Centre Nat Rech Scient | MEMBRANE PROTEINS CTL (CHOLINE TRANSPORTER LIKE) INVOLVED IN THE TRANSPORT OF CHOLINE |
AU1656601A (en) | 1999-11-12 | 2001-06-12 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6322985B1 (en) | 1999-12-27 | 2001-11-27 | Technion Research And Development Foundation Ltd. | Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing |
EP1244906A1 (en) | 1999-12-30 | 2002-10-02 | Cabot Corporation | Sensors with improved properties |
WO2001050349A1 (en) | 1999-12-30 | 2001-07-12 | Rutgers, The State University Of New Jersey | Electronic document customization and transformation utilizing user feedback |
US6649750B1 (en) | 2000-01-05 | 2003-11-18 | Isis Pharmaceuticals, Inc. | Process for the preparation of oligonucleotide compounds |
US6159697A (en) | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
US6936432B2 (en) | 2000-03-01 | 2005-08-30 | Message Pharmaceuticals | Bacterial RNase P proteins and their use in identifying antibacterial compounds |
GB0004889D0 (en) * | 2000-03-01 | 2000-04-19 | Avecia Ltd | Synthesis of oligonucleotides |
JP2003528068A (en) | 2000-03-17 | 2003-09-24 | コリクサ コーポレイション | New amphiphilic aldehydes and their use as adjuvants and immune effectors |
MXPA02010261A (en) | 2000-04-20 | 2003-04-25 | Hoffmann La Roche | Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders. |
DE10019756A1 (en) | 2000-04-20 | 2001-10-25 | Bayer Ag | Process for the production of superabsorbent polymers from polyacrylonitriles |
US20020013287A1 (en) | 2000-05-09 | 2002-01-31 | Reliable Biopharmaceuticals, Inc. St Louis Missouri | Polymeric compounds useful as prodrugs |
US6492171B2 (en) | 2000-05-16 | 2002-12-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of TERT expression |
US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
AU2001278517A1 (en) | 2000-08-03 | 2002-02-18 | F. Hoffman-La Roche Ag | Nucleic acid binding compounds containing pyrazolo(3,4-d)pyrimidine analogues of purin-2,6-diamine and their uses |
US6725412B1 (en) | 2000-08-15 | 2004-04-20 | Dolby Laboratories Licensing Corporation | Low latency data encoder |
US6809195B1 (en) | 2000-08-16 | 2004-10-26 | Isis Pharmaceuticals, Inc. | Process for the preparation of oligonucleotides |
US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
WO2002022809A2 (en) | 2000-09-15 | 2002-03-21 | Coley Pharmaceutical Gmbh | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
GB0024752D0 (en) | 2000-10-10 | 2000-11-22 | Univ Belfast | Oxidative halogenation of aromatic compounds |
AU2002244337B2 (en) | 2000-10-18 | 2005-08-11 | Glaxosmithkline Biologicals S.A. | Vaccines |
US6372492B1 (en) | 2000-10-30 | 2002-04-16 | Isis Pharmaceuticals, Inc. | Antisense modulation of talin expression |
US6682889B1 (en) | 2000-11-08 | 2004-01-27 | Becton, Dickinson And Company | Amplification and detection of organisms of the Chlamydiaceae family |
NL1016978C2 (en) | 2000-12-22 | 2002-06-25 | Robert Jan Colenbrander | Device and method for packaging and preparing food and method for manufacturing such a device. |
DK1355916T3 (en) | 2001-01-22 | 2007-05-07 | Merck & Co Inc | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US8008459B2 (en) | 2001-01-25 | 2011-08-30 | Evolva Sa | Concatemers of differentially expressed multiple genes |
US7838287B2 (en) | 2001-01-25 | 2010-11-23 | Evolva Sa | Library of a collection of cells |
WO2002059294A1 (en) | 2001-01-26 | 2002-08-01 | Commonwealth Scientific And Industrial Research O Rganisation | Methods and means for producing efficient silencing construct using recombinational cloning |
US20050277133A1 (en) | 2001-05-18 | 2005-12-15 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20030207804A1 (en) | 2001-05-25 | 2003-11-06 | Muthiah Manoharan | Modified peptide nucleic acids |
GB0113523D0 (en) | 2001-06-04 | 2001-07-25 | Torotrak Dev Ltd | An Hydraulic control circuit for a continuosly variable transmission |
US20030069410A1 (en) | 2001-06-14 | 2003-04-10 | Isis Pharmaceuticals, Inc. | Methods for preparing oligonucleotides having chiral phosphorothioate linkages |
US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
US20030138458A1 (en) | 2001-06-29 | 2003-07-24 | Michael Houghton | HCV E1E2 vaccine compositions |
CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
US7205399B1 (en) | 2001-07-06 | 2007-04-17 | Sirna Therapeutics, Inc. | Methods and reagents for oligonucleotide synthesis |
US6440739B1 (en) | 2001-07-17 | 2002-08-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of glioma-associated oncogene-2 expression |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US6455308B1 (en) | 2001-08-01 | 2002-09-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of serum amyloid A4 expression |
US7888324B2 (en) | 2001-08-01 | 2011-02-15 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
US7259150B2 (en) | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
AU2002361468A1 (en) | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
CA2458393A1 (en) | 2001-08-24 | 2003-03-06 | Massachusetts Institute Of Technology | Reagents that facilitate the purification of compounds synthesized on a solid support |
US7049122B2 (en) | 2001-09-21 | 2006-05-23 | Academia Sinica | Mutant-type lipases and applications thereof |
US6933288B2 (en) | 2002-02-04 | 2005-08-23 | Isis Pharmaceuticals, Inc. | Pyranosyl cytosines: pharmaceutical formulations and methods |
JP4348044B2 (en) | 2002-02-12 | 2009-10-21 | 株式会社キラルジェン | Method for producing highly stereoregular dinucleoside phosphorothioates |
US20030159938A1 (en) | 2002-02-15 | 2003-08-28 | George Hradil | Electroplating solution containing organic acid complexing agent |
US20040149587A1 (en) | 2002-02-15 | 2004-08-05 | George Hradil | Electroplating solution containing organic acid complexing agent |
US8232383B2 (en) | 2002-02-20 | 2012-07-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20050096284A1 (en) | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
JP2005525358A (en) | 2002-02-28 | 2005-08-25 | ビオタ インコーポレーティッド | Nucleotide mimetics and their prodrugs |
EP1485396A2 (en) | 2002-02-28 | 2004-12-15 | Biota, Inc. | Nucleoside 5'-monophosphate mimics and their prodrugs |
US7288376B2 (en) | 2002-03-22 | 2007-10-30 | Council Of Scientific And Industrial Research | Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis |
US20040102394A1 (en) | 2002-11-23 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of huntingtin interacting protein 2 expression |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
AU2003237875A1 (en) | 2002-05-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein b expression |
US20040014957A1 (en) | 2002-05-24 | 2004-01-22 | Anne Eldrup | Oligonucleotides having modified nucleoside units |
AU2003241621A1 (en) | 2002-05-24 | 2003-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
US7507808B2 (en) | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
WO2003106477A1 (en) | 2002-06-01 | 2003-12-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation |
WO2004000351A1 (en) | 2002-06-20 | 2003-12-31 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
WO2004003228A1 (en) | 2002-07-01 | 2004-01-08 | Unisearch Limited | Genotyping method |
CA2489174C (en) | 2002-07-10 | 2013-02-05 | Thomas Tuschl | Rna-interference by single-stranded rna molecules |
US20040023905A1 (en) | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of LAR expression |
US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
US20080274989A1 (en) | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
WO2004014933A1 (en) | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
AU2003259735A1 (en) | 2002-08-08 | 2004-02-25 | Sirna Therapeutics, Inc. | Small-mer compositions and methods of use |
AR040996A1 (en) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
US7414116B2 (en) | 2002-08-23 | 2008-08-19 | Illumina Cambridge Limited | Labelled nucleotides |
BR0314236A (en) | 2002-09-13 | 2005-08-09 | Replicor Inc | Oligonucleotide formulation, pharmaceutical composition, kit, antiviral compound, preparation of oligonucleotide and methods for selection of an antiviral oligonucleotide for use as an antiviral agent, for prophylaxis or treatment of a viral infection in a patient, for prophylactic treatment of cancer caused by oncoviruses. for identifying a compound that alters the binding of an oligonucleotide to at least one viral component, for purifying oligonucleotide binding to at least one viral component and for enriching oligonucleotides from an oligonucleotide cluster |
US7572604B2 (en) | 2002-10-07 | 2009-08-11 | Isis Innovation Limited | Modified carbohydrate processing enzyme |
US7030230B2 (en) | 2002-10-25 | 2006-04-18 | Isis Pharmaceuticals, Inc. | Process of purifying phosphoramidites |
CN1753687A (en) | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
US20040147020A1 (en) | 2002-11-01 | 2004-07-29 | The Regents Of The University Of Colorado, A Body Corporate | Dopamine neurons from human embryonic stem cells |
US7696345B2 (en) | 2002-11-05 | 2010-04-13 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
AU2003291721A1 (en) | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
CA2505090A1 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Conjugated oligomeric compounds and their use in gene modulation |
CA2504929C (en) | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US7381527B2 (en) | 2002-11-06 | 2008-06-03 | Council Of Scientific And Industrial Research | Method of detection of SP-A2 gene variants |
US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
JP4986109B2 (en) | 2002-11-13 | 2012-07-25 | ジェンザイム・コーポレーション | Antisense regulation of apolipoprotein B expression |
EP2314691A3 (en) | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
EP2216407B1 (en) | 2003-03-07 | 2016-01-13 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
WO2004080466A1 (en) | 2003-03-07 | 2004-09-23 | Ribapharm Inc. | Cytidine analogs and methods of use |
CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
GB0306657D0 (en) | 2003-03-24 | 2003-04-30 | Avecia Ltd | Process and compounds |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
RU2351362C2 (en) | 2003-03-26 | 2009-04-10 | Цитос Байотекнолоджи Аг | CONJUGATES OF PEPTIDE Melan-A, VIRUS-LIKE PARTICLE ANALOGUE |
ITRM20030149A1 (en) | 2003-04-02 | 2004-10-03 | Giuliani Spa | ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
US20050261237A1 (en) | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
BRPI0409680A (en) | 2003-04-25 | 2006-04-18 | Gilead Sciences Inc | anti-cancer phosphonate analogs |
US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
CN101410120A (en) | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | Anti-inflammatory phosphonate compounds |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
US20090247488A1 (en) | 2003-04-25 | 2009-10-01 | Carina Cannizzaro | Anti-inflammatory phosphonate compounds |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
WO2004096286A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US7045306B2 (en) | 2003-04-28 | 2006-05-16 | The General Hospital Corporation | Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein |
US7214491B2 (en) | 2003-05-07 | 2007-05-08 | E. I. Du Pont De Nemours And Company | Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts |
AU2004239114B2 (en) | 2003-05-14 | 2008-03-13 | Japan Science And Technology Agency | Inhibition of the expression of huntingtin gene |
AU2004253455B2 (en) | 2003-06-03 | 2011-03-03 | Eli Lilly And Company | Modulation of survivin expression |
KR20060016817A (en) | 2003-06-20 | 2006-02-22 | 콜리 파마슈티칼 게엠베하 | Small molecule toll-like receptor (tlr) antagonists |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
JP2005089441A (en) | 2003-08-08 | 2005-04-07 | Toudai Tlo Ltd | Manufacturing method of highly stereoregular phosphorus atom-modified nucleotide analogue |
JP2011088935A (en) | 2003-08-08 | 2011-05-06 | Chiralgen Ltd | Optically-active nucleoside 3'-phosphoroamidite for production of phosphorus atom modified nucleotide analog |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
MXPA06001976A (en) | 2003-08-21 | 2006-05-31 | Univ Griffith | Novel sulfenamides. |
RU2006108577A (en) | 2003-08-21 | 2007-09-27 | Гриффит Юниверсити (Au) | NEW SULFENAMIDES |
CN1863813B (en) | 2003-08-27 | 2011-03-30 | 生物区科学管理控股有限公司 | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
JP4731324B2 (en) | 2003-08-28 | 2011-07-20 | 武 今西 | N-O bond cross-linked novel artificial nucleic acid |
JP4616175B2 (en) | 2003-09-02 | 2011-01-19 | 株式会社キラルジェン | Method for producing 5'-phosphitylated monomer and H-phosphonate oligonucleotide derivative |
JP4580870B2 (en) | 2003-09-02 | 2010-11-17 | 株式会社キラルジェン | Method for producing ribonucleotide or ribonucleotide derivative |
US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
CN100393209C (en) | 2003-09-09 | 2008-06-11 | 杰龙公司 | Modified oligonucleotides for telomerase inhibition |
US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
ES2485848T3 (en) | 2003-09-12 | 2014-08-14 | University Of Massachusetts | RNA interference for the treatment of disorders related to function gain |
GB0323968D0 (en) | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239102A1 (en) | 2003-10-31 | 2005-10-27 | Verdine Gregory L | Nucleic acid binding oligonucleotides |
US7846436B2 (en) | 2003-11-28 | 2010-12-07 | Chemgenes Corporation | Oligonucleotides and related compounds |
WO2005063983A1 (en) | 2003-12-29 | 2005-07-14 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
WO2005070859A1 (en) | 2004-01-27 | 2005-08-04 | Takeshi Wada | Fluorous supports and processes for production of oligonucleotide derivatives with the same |
US20050176045A1 (en) | 2004-02-06 | 2005-08-11 | Dharmacon, Inc. | SNP discriminatory siRNA |
US20080221303A1 (en) | 2004-02-18 | 2008-09-11 | Jehoshua Katzhendler | Method for the Preparation of Peptide-Oligonucleotide Conjugates |
JP3976742B2 (en) | 2004-02-27 | 2007-09-19 | 江守商事株式会社 | Immunostimulatory oligonucleotides that induce interferon alpha |
WO2005085272A1 (en) | 2004-03-05 | 2005-09-15 | Takeshi Wada | Boranophosphate monomer and process for producing oligonucleotide derivative therefrom |
WO2005092909A1 (en) | 2004-03-25 | 2005-10-06 | Toudai Tlo, Ltd. | Processes for producing ribonucleotide analogue with high stereoregularity and deoxyribonucleotide analogue |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
AU2005230684B2 (en) | 2004-04-05 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Process and reagents for oligonucleotide synthesis and purification |
TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
EP1753881A2 (en) | 2004-05-27 | 2007-02-21 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Differential expression of molecules associated with acute stroke |
US7759318B1 (en) | 2004-05-28 | 2010-07-20 | Isis Pharmaceuticals, Inc. | Identification of novel pathways, genes and promoter motifs regulating adipogenesis |
AU2005252663B2 (en) | 2004-06-03 | 2011-07-07 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
EP2500430B1 (en) | 2004-06-28 | 2017-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
PT1786472E (en) | 2004-08-10 | 2013-03-06 | Genzyme Corp | Antisense modulation of apolipoprotein b expression |
ATE556085T1 (en) | 2004-08-26 | 2012-05-15 | Nippon Shinyaku Co Ltd | PHOSPHORAMIDITE COMPOUND AND METHOD FOR PRODUCING OLIGO-RNA |
US20070066551A1 (en) | 2004-09-07 | 2007-03-22 | Keefe Anthony D | Aptamer medicinal chemistry |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
WO2006031461A2 (en) | 2004-09-09 | 2006-03-23 | Isis Pharmaceuticals, Inc. | Pyrrolidinyl groups for attaching conjugates to oligomeric compounds |
EP2397563A3 (en) | 2004-09-17 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
US20060089325A1 (en) | 2004-10-13 | 2006-04-27 | Sanjay Bhanot | Antisense modulation of PTP1B expression |
US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
EP1807440B1 (en) | 2004-11-03 | 2020-02-19 | The University of Kansas | Novobiocin analogues as anticancer agents |
US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
KR100721928B1 (en) | 2004-11-05 | 2007-05-28 | 주식회사 바이오씨에스 | Pharmaceutical composition for treating or preventing dermatitis comprising CpG oligodeoxynucleotide |
EP1657307A1 (en) | 2004-11-16 | 2006-05-17 | Immunotech S.A. | Oligonucleotides that induce the secretion of GM-CSF |
AU2005313883B2 (en) | 2004-12-09 | 2011-03-31 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs |
US9809824B2 (en) | 2004-12-13 | 2017-11-07 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
WO2006066260A2 (en) | 2004-12-17 | 2006-06-22 | Thiosense, Inc. | Compositions of and methods for producing phosphorus-chiral monomers and oligomers |
US20070099851A1 (en) | 2004-12-30 | 2007-05-03 | Linn Gregory S | Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders |
US20060183763A1 (en) | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
KR100980898B1 (en) | 2005-01-28 | 2010-09-07 | 권형주 | Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell |
CA2598992A1 (en) | 2005-02-24 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
WO2006137953A1 (en) | 2005-04-01 | 2006-12-28 | The Regents Of The Univerisity Of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
SI1877070T1 (en) | 2005-05-05 | 2009-06-30 | Antisense Pharma Gmb H | Therapeutic use of tgf-beta2 antisense oligonucleotides |
US20060257912A1 (en) | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US7902352B2 (en) | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
DK1910395T3 (en) | 2005-06-23 | 2013-02-04 | Isis Pharmaceuticals Inc | Compositions and Methods for Modulating SMN2 Splicing |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
EP2316967A1 (en) | 2005-06-28 | 2011-05-04 | Medtronic, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin gene. |
EP1948600B1 (en) | 2005-07-05 | 2014-04-16 | The President & Fellows Of Harvard College | Liver targeted conjugates |
JP4984634B2 (en) | 2005-07-21 | 2012-07-25 | ソニー株式会社 | Physical information acquisition method and physical information acquisition device |
WO2007016379A2 (en) | 2005-07-28 | 2007-02-08 | Id-Fish Technology, Inc. | Method for improving cell permeability to foreign particles |
EP2338991B1 (en) | 2005-08-29 | 2017-01-18 | Regulus Therapeutics Inc. | Methods for use in modulating MIR-122a |
EP1937312B1 (en) | 2005-08-30 | 2016-06-29 | Ionis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US20070077993A1 (en) | 2005-09-30 | 2007-04-05 | Midgley Timothy M | Method and apparatus for collecting user game play data and crediting users in a gaming environment |
AU2006304205C1 (en) | 2005-10-12 | 2012-11-15 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
US9308252B2 (en) | 2005-10-27 | 2016-04-12 | Cook Biotech, Inc. | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins |
CA2627134A1 (en) | 2005-10-28 | 2007-05-03 | Tosoh Corporation | Method of preparing carotenoid synthesizing microorganism and method of producing carotenoids |
CA2627025A1 (en) | 2005-10-28 | 2007-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
KR20080075107A (en) | 2005-11-11 | 2008-08-14 | 화이자 인코포레이티드 | Combinations and methods of using an immunomodulatory oligodeoxynucleotide |
WO2007064291A1 (en) | 2005-11-30 | 2007-06-07 | Jyoti Chattopadhyaya | Method and compounds for rna synthesis |
EP1957507B1 (en) | 2005-12-02 | 2018-10-24 | Ionis Pharmaceuticals, Inc. | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
CA2634381C (en) | 2005-12-21 | 2011-03-08 | Pfizer Products Inc. | Carbonylamino pyrrolopyrazoles, potent kinase inhibitors |
SI2161038T1 (en) | 2006-01-26 | 2014-05-30 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
DE602007009487D1 (en) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGUE |
DK1991678T4 (en) | 2006-02-15 | 2020-10-19 | Rechtsanwalt Thomas Beck | COMPOSITIONS AND PROCEDURES FOR OLIGONUCLEOTIDE FORMULATIONS |
JP4713514B2 (en) | 2006-02-20 | 2011-06-29 | エフ.ホフマン−ラ ロシュ アーゲー | Improved labeling reagent |
US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
US9040674B2 (en) | 2006-03-31 | 2015-05-26 | Applied Biosystems, Llc | Reagents useful for synthesizing rhodamine-labeled oligonucleotides |
WO2007118222A2 (en) | 2006-04-06 | 2007-10-18 | Ibis Biosciences, INC | Compositions for the use in identification of fungi |
KR101176697B1 (en) | 2006-04-20 | 2012-08-23 | 에프. 호프만-라 로슈 아게 | Diazepan derivatives modulators of chemokine receptors |
ES2396453T3 (en) | 2006-04-24 | 2013-02-21 | Sigma Alimentos, S.A. De C.V. | Method for multiple and simultaneous detection and quantification of pathogens by polymerase chain reaction in real time |
EP2018436A2 (en) | 2006-04-25 | 2009-01-28 | Immune Disease Institute Inc. | Targeted delivery to leukocytes using non-protein carriers |
GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
EP2015758B1 (en) | 2006-05-05 | 2014-04-02 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression apob |
WO2007131232A2 (en) | 2006-05-05 | 2007-11-15 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to ptpr alpha |
US20090012120A1 (en) | 2006-05-10 | 2009-01-08 | Board Of Trustees Of Michigan State University | Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines |
CN101490074B (en) | 2006-05-11 | 2013-06-26 | Isis制药公司 | 5'-modified bicyclic nucleic acid analogs |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
WO2007139190A1 (en) | 2006-05-31 | 2007-12-06 | Toray Industries, Inc. | Immunostimulatory oligonucleotide and pharmaceutical application thereof |
US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
EP2046993A4 (en) | 2006-07-07 | 2010-11-17 | Univ Massachusetts | Rna silencing compositions and methods for the treatment of huntington's disease |
CN101506368B (en) | 2006-07-12 | 2017-02-08 | 加利福尼亚大学董事会 | Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups |
CA2659155A1 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1 |
GB0614947D0 (en) | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
AU2007281082A1 (en) | 2006-08-04 | 2008-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of JNK proteins |
AT504194B1 (en) | 2006-09-07 | 2008-07-15 | Oesterr Rotes Kreuz | BACTERIA DETECTION |
US8138330B2 (en) | 2006-09-11 | 2012-03-20 | Sigma-Aldrich Co. Llc | Process for the synthesis of oligonucleotides |
MX2009003398A (en) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity. |
ES2526295T5 (en) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Antisense compounds |
CA2667816A1 (en) | 2006-10-23 | 2008-05-02 | Irm Llc | Compositions and methods for inhibiting cathepsin proteases |
EP2104738A2 (en) | 2006-10-26 | 2009-09-30 | Coley Pharmaceuticals GmbH | Oligoribonucleotides and uses thereof |
FR2908414B1 (en) | 2006-11-13 | 2012-01-20 | Centre Nat Rech Scient | IMMOBILIZATION OF MEMBRANE PROTEINS ON A SUPPORT THROUGH AN AMPHIPHILE MOLECULE |
US8754107B2 (en) | 2006-11-17 | 2014-06-17 | Abbvie Inc. | Aminopyrrolidines as chemokine receptor antagonists |
EP2102340A2 (en) | 2006-11-27 | 2009-09-23 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
CA2671883A1 (en) | 2006-12-12 | 2008-06-19 | Idera Pharmaceuticals, Inc. | Synthetic agonists of tlr9 |
UY30892A1 (en) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | AKT ACTIVITY INHIBITORS |
EP2125852B1 (en) | 2007-02-15 | 2016-04-06 | Ionis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
AU2008230886B9 (en) | 2007-03-24 | 2014-09-04 | Kastle Therapeutics, Llc | Administering antisense oligonucleotides complementary to human apolipoprotein B |
US7960353B2 (en) | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
CA2723672C (en) | 2007-05-11 | 2019-09-03 | Adynxx, Inc. | Gene expression and pain |
WO2008143343A1 (en) * | 2007-05-24 | 2008-11-27 | Kyorin Pharmaceutical Co., Ltd. | Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position |
GB0710186D0 (en) | 2007-05-29 | 2007-07-04 | Texas Instr Denmark | PWM loop with minimum allasing error property |
CA2688321A1 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
RU2471781C2 (en) | 2007-06-05 | 2013-01-10 | НСАБ, Филиаль аф НьюроСёрч Свиден АБ, Сверийе | Novel disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
EP2164865A2 (en) | 2007-06-13 | 2010-03-24 | Hochschule Mannheim | Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds |
ATE462787T1 (en) | 2007-06-18 | 2010-04-15 | Commissariat Energie Atomique | REVERSIBLE SIRNA-SILENCING OF A MUTATED AND ENDOGENOUS HUNTINGTON WILD-TYPE AND ITS APPLICATION TO THE TREATMENT OF HUNTINGTON'S DISEASE |
GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
CA2692161C (en) | 2007-07-09 | 2015-09-29 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory rna (simra) compounds |
TWI413530B (en) | 2007-07-20 | 2013-11-01 | Kao Corp | Organopolysiloxane |
CA2694718A1 (en) | 2007-07-31 | 2009-02-05 | University Of Saskatchewan | Genetic variation in pro-melanin-concentrating hormone gene affects carcass traits in cattle |
US7812003B2 (en) | 2007-08-02 | 2010-10-12 | Safe Stephen H | Antisense microRNA and uses therefor |
AU2008286735A1 (en) | 2007-08-15 | 2009-02-19 | Idera Pharmaceuticals, Inc. | Toll like receptor modulators |
MX2010003606A (en) | 2007-10-01 | 2010-07-02 | Isis Pharmaceuticals Inc | Antisense modulation of fibroblast growth factor receptor 4 expression. |
KR100886139B1 (en) | 2007-11-13 | 2009-02-27 | 주식회사 삼천리제약 | Method for preparing oligonucleotide |
TW200930375A (en) | 2007-12-21 | 2009-07-16 | Exelixis Inc | Benzofuropyrimidinones |
TWI340765B (en) | 2007-12-26 | 2011-04-21 | Ind Tech Res Inst | Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof |
CN101911676A (en) | 2008-01-15 | 2010-12-08 | 联发科技股份有限公司 | Multimedia presenting system, multimedia processing apparatus thereof, and method for presenting video and audio signals |
WO2009089659A1 (en) | 2008-01-18 | 2009-07-23 | Shanghai Targetdrug Co., Ltd. | Pyrollidine-based compounds |
CA2711587A1 (en) | 2008-02-04 | 2009-08-13 | Galapagos Nv | Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases |
JP2009190983A (en) | 2008-02-12 | 2009-08-27 | Tokyo Institute Of Technology | Oligonucleotide derivative |
US8426378B2 (en) | 2008-03-21 | 2013-04-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising tricyclic nucelosides and methods for their use |
US20110130440A1 (en) | 2008-03-26 | 2011-06-02 | Alnylam Pharmaceuticals, Inc. | Non-natural ribonucleotides, and methods of use thereof |
GB2471806B (en) | 2008-04-03 | 2012-12-19 | Spring Bank Pharmaceuticals Inc | Compositions and methods for treating viral infections |
DE112009001327A5 (en) | 2008-04-04 | 2011-03-31 | Universität Hamburg | Process for the stereoselective synthesis of phosphorus compounds |
WO2009124238A1 (en) | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
WO2009135322A1 (en) | 2008-05-09 | 2009-11-12 | The Universtity Of British Columbia | Methods and compositions for the treatment of huntington's disease |
US8679750B2 (en) | 2008-05-09 | 2014-03-25 | The University Of British Columbia | Methods and compositions for the treatment of Huntington'S disease |
EP2300102B1 (en) | 2008-05-15 | 2014-01-08 | Dynavax Technologies Corporation | Immunostimulatory sequences containing CpG for use in the treatment of allergic rhinitis |
US8541387B2 (en) | 2008-05-22 | 2013-09-24 | Isis Pharmaceuticals, Inc. | Modulation of SMRT expression |
EP2291200A4 (en) | 2008-05-22 | 2012-05-30 | Isis Pharmaceuticals Inc | Methods for modulating expression of rbp4 |
WO2009143391A2 (en) | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc | Methods for modulation expression of creb |
WO2009148605A2 (en) | 2008-06-04 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
EP2320895A2 (en) | 2008-07-03 | 2011-05-18 | Exelixis, Inc. | Cdk modulators |
WO2010030849A1 (en) | 2008-09-12 | 2010-03-18 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating cancer,inhibiting proliferation, and inducing cell death |
WO2010030858A1 (en) | 2008-09-15 | 2010-03-18 | Enanta Pharmaceuticals, Inc. | 4'-allene-substituted nucleoside derivatives |
EP3067359A1 (en) | 2008-09-23 | 2016-09-14 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
EP2356129B1 (en) | 2008-09-24 | 2013-04-03 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
WO2010036696A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acid analogs |
AU2009302385B2 (en) | 2008-10-07 | 2015-12-03 | President And Fellows Of Harvard College | Telomerase inhibitors and methods of use thereof |
CA2738957A1 (en) | 2008-10-22 | 2010-04-29 | Quark Pharmaceuticals, Inc. | Methods for treating eye disorders |
US8987435B2 (en) | 2008-10-24 | 2015-03-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
CN102264374B (en) | 2008-10-24 | 2015-01-07 | Isis制药公司 | 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom |
US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
WO2010072831A1 (en) | 2008-12-23 | 2010-07-01 | Girindus America, Inc | Sulfurizing reagents and their use for oligonucleotides synthesis |
WO2010080953A1 (en) | 2009-01-08 | 2010-07-15 | Isis Pharmaceuticals, Inc. | Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease |
KR20100087540A (en) | 2009-01-28 | 2010-08-05 | 삼성전자주식회사 | Ink composition for inkjet recording |
WO2010091301A1 (en) | 2009-02-06 | 2010-08-12 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and excipients |
US8202974B2 (en) | 2009-02-10 | 2012-06-19 | Idera Pharmaceuticals, Inc. | Synthetic RNA-based agonists of TLR7 |
JP5766617B2 (en) | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | Novobiocin analogs having modified sugar moieties |
EP2403863B1 (en) | 2009-03-02 | 2013-08-28 | Alnylam Pharmaceuticals Inc. | Nucleic acid chemical modifications |
WO2010107838A1 (en) | 2009-03-16 | 2010-09-23 | Isis Pharmaceuticals, Inc. | Targeting apolipoprotein b for the reduction of apolipoprotein c-iii |
US8653254B2 (en) | 2009-03-31 | 2014-02-18 | Takeda Pharmaceutical Company Limited | Process for producing nucleoside |
WO2010118263A1 (en) | 2009-04-08 | 2010-10-14 | University Of Massachusetts | Single-nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease |
WO2010120262A1 (en) | 2009-04-14 | 2010-10-21 | Smith Holdings, Llc | Methods and compositions for the treatment of medical conditions involving cellular programming |
WO2010129853A2 (en) | 2009-05-07 | 2010-11-11 | The Regents Of The University Of California | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS |
EP2438079A4 (en) | 2009-06-01 | 2013-05-22 | Univ California | Nucleic acid delivery compositions and methods of use thereof |
EP2437753B1 (en) | 2009-06-05 | 2016-08-31 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them |
LT3449926T (en) | 2009-06-17 | 2020-01-27 | Biogen Ma Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
JP5670097B2 (en) | 2009-06-19 | 2015-02-18 | 花王株式会社 | Two-layer separated hair cosmetic |
US20120108800A1 (en) | 2009-06-23 | 2012-05-03 | Shumpei Murata | Method for synthesizing nucleic acid |
WO2011005761A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc | Novel nucleic acid prodrugs and methods use thereof |
WO2011005764A1 (en) | 2009-07-06 | 2011-01-13 | Ada Technologies, Inc. | Electrochemical device and method for long-term measurement of hypohalites |
WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
US20110009477A1 (en) | 2009-07-08 | 2011-01-13 | Idera Pharmaceuticals, Inc. | Oligonucleotide-based compounds as inhibitors of toll-like receptors |
EP2458005A1 (en) | 2009-07-23 | 2012-05-30 | Galaxy Pharma Inc. | Fgf21 cis-element binding substance |
WO2011015573A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
WO2011015572A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
US8927553B2 (en) | 2009-08-10 | 2015-01-06 | Daljit Singh Dhanoa | Deuterium-enriched alkyl sulfonamides and uses thereof |
NZ599032A (en) | 2009-09-11 | 2014-09-26 | Isis Pharmaceuticals Inc | Modulation of huntingtin expression |
EP2479182B8 (en) | 2009-09-16 | 2016-07-13 | Wave Life Sciences Japan, Inc. | Novel protecting group for synthesizing rna and derivative thereof |
WO2011038288A1 (en) | 2009-09-25 | 2011-03-31 | Isis Pharmaceuticals, Inc. | Modulation of ttc39 expression to increase hdl |
WO2011045702A1 (en) | 2009-10-15 | 2011-04-21 | Pfizer Inc. | Pyrrolo[2,3-d] pyrimidine compounds |
TWI475051B (en) | 2009-11-18 | 2015-03-01 | Kao Corp | Organic polysiloxane |
JP5809408B2 (en) | 2009-11-25 | 2015-11-10 | 花王株式会社 | Hair cosmetics |
WO2011075560A1 (en) | 2009-12-17 | 2011-06-23 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
JP2013515953A (en) | 2009-12-28 | 2013-05-09 | アチラ ラボズ プライベート リミテッド | Diagnostic gel composition and method for producing said diagnostic gel composition |
AU2011203986C1 (en) | 2010-01-08 | 2015-03-05 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
US8750507B2 (en) | 2010-01-25 | 2014-06-10 | Cisco Technology, Inc. | Dynamic group creation for managed key servers |
WO2011097643A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
AU2011213563B2 (en) | 2010-02-08 | 2015-12-24 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
SG182471A1 (en) | 2010-02-10 | 2012-08-30 | Glaxosmithkline Llc | 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate |
US8859755B2 (en) | 2010-03-05 | 2014-10-14 | Chiralgen, Ltd. | Method for preparing ribonucleoside phosphorothioate |
WO2011127175A1 (en) | 2010-04-06 | 2011-10-13 | Isis Pharmaceuticals, Inc. | Modulation of cd130 (gp130) expression |
JP2013527148A (en) | 2010-04-07 | 2013-06-27 | アイシス ファーマシューティカルズ, インコーポレーテッド | Regulation of CETP expression |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
EP2625186B1 (en) | 2010-04-28 | 2016-07-27 | Ionis Pharmaceuticals, Inc. | 5' modified nucleosides and oligomeric compounds prepared therefrom |
WO2011139702A2 (en) | 2010-04-28 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
EP2563921B1 (en) | 2010-04-30 | 2016-11-23 | Cellectis | Method for modulating double-strand break-induced homologous recombination |
GB201008902D0 (en) | 2010-05-27 | 2010-07-14 | Imp Innovations Ltd | Membrane enhanced polymer sythesis |
WO2012030683A2 (en) | 2010-08-31 | 2012-03-08 | Merck Sharp & Dohme Corp. | Novel single chemical entities and methods for delivery of oligonucleotides |
WO2012039448A1 (en) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | Asymmetric auxiliary group |
US9238812B2 (en) | 2010-09-30 | 2016-01-19 | Lsip, Llc | Agent for suppressing expression of dominant mutant gene |
KR101381048B1 (en) | 2010-10-20 | 2014-04-14 | 씨제이제일제당 (주) | A microorganism producing O-phosphoserine and the method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same |
EP3327125B1 (en) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
AU2011325956B2 (en) | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
US8822671B2 (en) | 2010-11-30 | 2014-09-02 | The University Of Tokyo | 2'-O-modified RNA |
US20140050778A1 (en) | 2010-12-28 | 2014-02-20 | University Of Rochester | Nucleic acid binding compounds, methods of making, and use thereof |
WO2012109395A1 (en) | 2011-02-08 | 2012-08-16 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
CA2827380C (en) | 2011-02-12 | 2020-08-25 | University Of Iowa Research Foundation | Therapeutic nucleic acids |
US9353371B2 (en) | 2011-05-02 | 2016-05-31 | Ionis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with usher syndrome |
FR2975600B1 (en) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | AGENTS FOR THE TREATMENT OF TUMORS |
AU2012283994A1 (en) | 2011-07-19 | 2014-03-06 | University Of Idaho | Embodiments of a probe and method for targeting nucleic acids |
DK2742136T3 (en) | 2011-08-11 | 2017-11-20 | Ionis Pharmaceuticals Inc | GAPMER COMPOUNDS INCLUDING 5 'MODIFIED DEOXYRIBONUCLEOSIDES IN GAP AND APPLICATIONS THEREOF |
WO2013033223A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
US20140080896A1 (en) | 2011-08-30 | 2014-03-20 | The Regents Of The University Of California | Identification of small molecules that facilitate therapeutic exon skipping |
WO2013030588A1 (en) | 2011-08-31 | 2013-03-07 | The University Of Manchester | Method for diagnosing a neurodegenerative disease |
US20140255936A1 (en) | 2011-09-09 | 2014-09-11 | Mayo Foundation For Medical Education And Research | Detecting frontotemporal dementia and amyotrophic lateral sclerosis |
ES2832531T3 (en) | 2011-11-30 | 2021-06-10 | Sarepta Therapeutics Inc | Oligonucleotides for the treatment of repeat expansion diseases |
CA2895077A1 (en) | 2011-12-12 | 2013-06-20 | Beverly Packard | In vivo delivery of oligonucleotides |
AU2012353330B2 (en) | 2011-12-16 | 2018-04-19 | National University Corporation Tokyo Medical And Dental University | Chimeric double-stranded nucleic acid |
CN102675386B (en) | 2011-12-24 | 2014-07-02 | 河南科技大学 | Method for separating and purifying gentiamarin |
WO2013134558A1 (en) | 2012-03-07 | 2013-09-12 | The Texas A & M University System | Cancer treatment targeting non-coding rna overexpression |
CA2866381C (en) | 2012-03-13 | 2020-03-24 | Gilead Sciences, Inc. | 2'- substituted carba-nucleoside analogs for antiviral treatment |
KR20130114435A (en) | 2012-04-09 | 2013-10-17 | 삼성전자주식회사 | Biomolecule detection apparatus including a plurality of electrode |
DK2841578T3 (en) | 2012-04-23 | 2017-07-31 | Biomarin Tech Bv | RNA modulating oligonucleotides with improved properties for the treatment of neuromuscular diseases |
MX355708B (en) | 2012-05-22 | 2018-04-27 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease. |
SG11201407967TA (en) | 2012-05-30 | 2015-01-29 | Hokkaido System Science Co Ltd | Oligonucleotide synthesis method using highly dispersible liquid-phase support |
CN104684893B (en) | 2012-07-13 | 2016-10-26 | 日本波涛生命科学公司 | Asymmetric auxiliary group |
RU2015104762A (en) | 2012-07-13 | 2018-08-31 | Уэйв Лайф Сайенсес Лтд. | CHIRAL CONTROL |
MX356830B (en) | 2012-07-13 | 2018-06-15 | Shin Nippon Biomedical Laboratories Ltd | Chiral nucleic acid adjuvant. |
US10086081B2 (en) | 2012-08-06 | 2018-10-02 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
WO2014028739A1 (en) | 2012-08-15 | 2014-02-20 | Isis Pharmaceuticals, Inc. | Method of preparing oligomeric compounds using modified capping protocols |
EP3459549B1 (en) | 2012-10-12 | 2022-04-06 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
JP6570447B2 (en) | 2012-10-15 | 2019-09-04 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Composition for modulating C9ORF72 expression |
EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | Methods for monitoring c9orf72 expression |
ES2762326T5 (en) | 2012-10-15 | 2023-04-27 | Ionis Pharmaceuticals Inc | Methods to modulate the expression of C9ORF72 |
EP2725029A1 (en) | 2012-10-29 | 2014-04-30 | Laboratoire Biodim | New antibacterial compounds and biological applications thereof |
JP2015535261A (en) | 2012-10-29 | 2015-12-10 | コクリスタル ファーマ,インコーポレイテッド | Pyrimidine nucleotides and their monophosphate prodrugs for the treatment of viral infections and cancer |
WO2014069520A1 (en) | 2012-10-31 | 2014-05-08 | 武田薬品工業株式会社 | New modified nucleic acid |
EP2920307B1 (en) | 2012-11-15 | 2018-05-02 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
MX2015006289A (en) | 2012-11-26 | 2015-12-03 | Roche Innovation Ct Copenhagen As | Compositions and methods for modulation of fgfr3 expression. |
US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
RU2649367C2 (en) | 2013-01-30 | 2018-04-02 | Ф. Хоффманн-Ля Рош Аг | Lna oligonucleotide carbohydrate conjugates |
WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
EP2951304B1 (en) | 2013-02-04 | 2020-07-08 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
CA2900238A1 (en) | 2013-02-22 | 2014-08-28 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage |
CA2901983A1 (en) | 2013-03-01 | 2014-09-04 | National University Corporation Tokyo Medical And Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
CA2907511A1 (en) | 2013-03-28 | 2014-10-02 | Syngenta Participations Ag | Methods of controlling neonicotinoid resistant pests |
CA2907750A1 (en) | 2013-03-28 | 2014-10-02 | Syngenta Participations Ag | Methods of controlling neonicotinoid resistant pests |
BR112015027377B1 (en) | 2013-05-01 | 2023-01-10 | Ionis Pharmaceuticals, Inc | OLIGOMERIC COMPOUNDS WITH CONJUGATE GROUPS, COMPOSITIONS COMPRISING THE SAID COMPOUNDS AND USES THEREOF |
EP3015467A4 (en) | 2013-05-24 | 2016-11-02 | Ajinomoto Kk | Morpholino oligonucleotide manufacturing method |
WO2014188001A1 (en) | 2013-05-24 | 2014-11-27 | Santaris Pharma A/S | Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof |
ES2700277T3 (en) | 2013-05-30 | 2019-02-14 | Univ Nat Corp Tokyo Medical & Dental | Double chain agents for the delivery of therapeutic oligonucleotides |
WO2014203518A1 (en) | 2013-06-16 | 2014-12-24 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
US20160122761A1 (en) | 2013-06-21 | 2016-05-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
PL3013959T3 (en) | 2013-06-27 | 2020-05-18 | Roche Innovation Center Copenhagen A/S | Antisense oligomers and conjugates targeting pcsk9 |
TWI772856B (en) | 2013-07-19 | 2022-08-01 | 美商百健Ma公司 | Compositions for modulating tau expression |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10435430B2 (en) | 2013-07-31 | 2019-10-08 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
CN105579442A (en) | 2013-09-06 | 2016-05-11 | 先正达参股股份有限公司 | Insecticidal compounds |
WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
EA201690675A1 (en) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS |
WO2015051366A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
EP4166667A3 (en) | 2013-10-11 | 2023-08-02 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
US20160237432A1 (en) | 2013-10-14 | 2016-08-18 | Ionis Pharmaceuticals, Inc. | Methods for modulating expression of c9orf72 antisense transcript |
EP3058068B1 (en) | 2013-10-14 | 2019-04-24 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
NZ719477A (en) | 2013-11-11 | 2022-05-27 | Sangamo Therapeutics Inc | Methods and compositions for treating huntington’s disease |
CN105722980A (en) | 2013-11-14 | 2016-06-29 | 罗氏创新中心哥本哈根有限公司 | APOB antisense conjugate compounds |
US20150167017A1 (en) | 2013-12-13 | 2015-06-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
ES2917473T3 (en) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | chiral design |
WO2015143078A1 (en) | 2014-03-18 | 2015-09-24 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
EP3137476B1 (en) | 2014-04-28 | 2019-10-09 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
US9382540B2 (en) | 2014-05-01 | 2016-07-05 | Isis Pharmaceuticals, Inc | Compositions and methods for modulating angiopoietin-like 3 expression |
US11110154B2 (en) | 2014-05-08 | 2021-09-07 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's Disease |
EP3146051B8 (en) | 2014-05-20 | 2019-11-27 | University of Iowa Research Foundation | Huntington's disease therapeutic compounds |
US20160017327A1 (en) | 2014-07-11 | 2016-01-21 | The Johns Hopkins University | Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity |
JP2017524357A (en) | 2014-07-16 | 2017-08-31 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Chimeric polynucleotide |
EP2982758A1 (en) | 2014-08-04 | 2016-02-10 | Centre Hospitalier Universitaire Vaudois (CHUV) | Genome editing for the treatment of huntington's disease |
US10252974B2 (en) | 2014-08-07 | 2019-04-09 | Takeda Pharmaceutical Company Limited | Cationic lipid |
WO2016024205A1 (en) | 2014-08-15 | 2016-02-18 | Pfizer Inc. | Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene |
WO2016037191A1 (en) | 2014-09-05 | 2016-03-10 | Health Research, Inc. | Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic |
CN113846101A (en) | 2014-11-17 | 2021-12-28 | 阿尔尼拉姆医药品有限公司 | Apolipoprotein C3(APOC3) iRNA compositions and methods of use thereof |
EP3220921A1 (en) | 2014-11-19 | 2017-09-27 | Roche Innovation Center Copenhagen A/S | Lna chiral phosphorothioates |
DK3234131T3 (en) | 2014-12-16 | 2020-06-29 | Roche Innovation Ct Copenhagen As | Method of screening for chiral toxicity |
BR112017013573A2 (en) | 2014-12-24 | 2018-03-06 | Uniqure Ip Bv | double stranded rna, dna sequence, expression cassette, gene therapy vector, and host cell. |
US9688707B2 (en) | 2014-12-30 | 2017-06-27 | Ionis Pharmaceuticals, Inc. | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom |
WO2016112132A1 (en) | 2015-01-06 | 2016-07-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
WO2016127002A1 (en) | 2015-02-04 | 2016-08-11 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
JP6772156B2 (en) | 2015-02-04 | 2020-10-21 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | How to choose a therapeutic molecule |
EP3253875B1 (en) | 2015-02-04 | 2020-01-08 | H. Hoffnabb-La Roche Ag | Tau antisense oligomers and uses thereof |
SG10201907396XA (en) | 2015-02-10 | 2019-09-27 | Genzyme Corp | VARIANT RNAi |
CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
EP3262174A4 (en) | 2015-02-23 | 2018-10-17 | Ionis Pharmaceuticals, Inc. | Compounds and methods for increasing antisense activity |
WO2016141236A1 (en) | 2015-03-03 | 2016-09-09 | Ionis Pharmaceuticals, Inc. | Compositions for modulating mecp2 expression |
WO2016145142A1 (en) | 2015-03-10 | 2016-09-15 | Emory University | Nucleotide and nucleoside therapeutics compositions and uses related thereto |
WO2016154096A1 (en) | 2015-03-20 | 2016-09-29 | Ionis Pharmaceuticals, Inc. | Modulation of smggds expression |
RS60762B1 (en) | 2015-04-03 | 2020-10-30 | Univ Massachusetts | Oligonucleotide compounds for targeting huntingtin mrna |
WO2016164896A2 (en) | 2015-04-10 | 2016-10-13 | Ionis Pharmaceuticals, Inc. | Modulation of smn expression |
US10407678B2 (en) | 2015-04-16 | 2019-09-10 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
KR102104163B1 (en) | 2015-04-16 | 2020-04-23 | 아이오니스 파마수티컬즈, 인코포레이티드 | Composition for modulating C9ORF72 expression |
WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
EP3313989A4 (en) | 2015-06-29 | 2018-12-05 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
IL256622B2 (en) | 2015-07-10 | 2023-09-01 | Ionis Pharmaceuticals Inc | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
WO2017011286A1 (en) | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
CA2989970A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
MA43072A (en) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
US20180216114A1 (en) | 2015-07-27 | 2018-08-02 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
SG10201912341SA (en) | 2015-07-31 | 2020-02-27 | Alnylam Pharmaceuticals Inc | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES |
DK3341479T3 (en) | 2015-08-24 | 2020-02-24 | Roche Innovation Ct Copenhagen As | LNA-G Process |
KR20180054640A (en) | 2015-08-25 | 2018-05-24 | 알닐람 파마슈티칼스 인코포레이티드 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROGNOSTIC PROTEIN CONDUCTORS Subtilillocexcis (PCSK9) gene-related disorders |
US10889813B2 (en) | 2015-09-02 | 2021-01-12 | Alnylam Pharmaceuticals, Inc. | Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof |
EP3350328A1 (en) | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
WO2017059411A1 (en) | 2015-10-01 | 2017-04-06 | Memorial Sloan-Kettering Cancer Center | Inhibitors of menaquinone biosynthesis |
US10874686B2 (en) | 2015-10-01 | 2020-12-29 | Memorial Sloan-Kettering Cancer Center | Anthranilyl-adenosinemonosulfamate analogs and uses thereof |
KR20180073584A (en) | 2015-10-02 | 2018-07-02 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | Oligonucleotide joining method |
WO2017062862A2 (en) | 2015-10-09 | 2017-04-13 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
EP3183347A4 (en) | 2015-10-17 | 2018-04-18 | Lifesplice Pharma LLC | Splice modulating oligonucleotides and methods of use thereof |
WO2017068087A1 (en) | 2015-10-22 | 2017-04-27 | Roche Innovation Center Copenhagen A/S | Oligonucleotide detection method |
WO2017067970A1 (en) | 2015-10-22 | 2017-04-27 | Roche Innovation Center Copenhagen A/S | In vitro toxicity screening assay |
US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
EP3374498A1 (en) | 2015-11-12 | 2018-09-19 | H. Hoffnabb-La Roche Ag | Standardized neuronal cell assays from primate species |
MA43822A (en) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITE AND OLIGONUCLEOTIDES |
PT3430141T (en) | 2016-03-14 | 2021-02-25 | Hoffmann La Roche | Oligonucleotides for reduction of pd-l1 expression |
CN108779139A (en) | 2016-03-18 | 2018-11-09 | 罗氏创新中心哥本哈根有限公司 | The L-LNA- guanosine monomers of acyl group protection |
WO2017165489A1 (en) | 2016-03-23 | 2017-09-28 | Emory University | Antiviral agents for treating zika and dengue virus infections |
WO2017180835A1 (en) | 2016-04-13 | 2017-10-19 | Ionis Pharmaceuticals, Inc. | Methods for reducing c9orf72 expression |
KR102468177B1 (en) | 2016-04-14 | 2022-11-16 | 에프. 호프만-라 로슈 아게 | Trityl-mono-GalNAc Compounds and Uses Thereof |
MA45290A (en) | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | PROCESSES AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS |
MA45270A (en) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
CN109311925B (en) | 2016-05-12 | 2022-06-03 | 罗氏创新中心哥本哈根有限公司 | Enhanced coupling of sterically defined oxaazaphospholane phosphoramidite monomers to nucleosides or oligonucleotides |
CN109072234B (en) | 2016-05-13 | 2022-11-29 | 豪夫迈·罗氏有限公司 | Protein-based sample collection matrices and devices |
WO2017198775A1 (en) | 2016-05-18 | 2017-11-23 | Eth Zurich | Stereoselective synthesis of phosphorothioate oligoribonucleotides |
WO2017210647A1 (en) | 2016-06-03 | 2017-12-07 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
CN109310765A (en) | 2016-06-20 | 2019-02-05 | 领先基因生物技术股份有限公司 | Antibody-drug conjugates |
US20190264267A1 (en) | 2016-07-25 | 2019-08-29 | Wave Life Sciences Ltd. | Phasing |
MA46905A (en) | 2016-11-23 | 2019-10-02 | Wave Life Sciences Ltd | COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITES AND OLIGONUCLEOTIDES |
-
2012
- 2012-07-13 RU RU2014105311/04A patent/RU2014105311A/en unknown
- 2012-07-13 EP EP17158311.5A patent/EP3248982A1/en not_active Withdrawn
- 2012-07-13 MX MX2014000716A patent/MX347361B/en active IP Right Grant
- 2012-07-13 JP JP2014521681A patent/JP6128529B2/en active Active
- 2012-07-13 WO PCT/US2012/046805 patent/WO2013012758A1/en active Application Filing
- 2012-07-13 DK DK12814522.4T patent/DK2734208T3/en active
- 2012-07-13 CN CN201280041560.0A patent/CN103796657B/en active Active
- 2012-07-13 CN CN201710437875.1A patent/CN107365339A/en active Pending
- 2012-07-13 EP EP12814522.4A patent/EP2734208B1/en active Active
- 2012-07-13 AU AU2012284265A patent/AU2012284265B2/en active Active
- 2012-07-13 BR BR112014001244A patent/BR112014001244A2/en not_active Application Discontinuation
- 2012-07-13 US US14/233,579 patent/US9605019B2/en active Active
- 2012-07-13 KR KR1020147004108A patent/KR20140068884A/en not_active Application Discontinuation
- 2012-07-13 SG SG10201700554VA patent/SG10201700554VA/en unknown
- 2012-07-13 ES ES12814522.4T patent/ES2626488T3/en active Active
- 2012-07-13 CA CA2842358A patent/CA2842358C/en active Active
-
2014
- 2014-01-19 IL IL230522A patent/IL230522B/en active IP Right Grant
- 2014-11-26 HK HK14111931.3A patent/HK1198479A1/en unknown
-
2016
- 2016-07-28 US US15/222,910 patent/US20170029457A1/en not_active Abandoned
-
2017
- 2017-04-04 JP JP2017074528A patent/JP6490133B2/en active Active
-
2018
- 2018-03-30 US US15/941,494 patent/US10280192B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9605019B2 (en) * | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10329318B2 (en) | 2008-12-02 | 2019-06-25 | Wave Life Sciences Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
US10307434B2 (en) | 2009-07-06 | 2019-06-04 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
US10280192B2 (en) | 2011-07-19 | 2019-05-07 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
US10167309B2 (en) | 2012-07-13 | 2019-01-01 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
US9982257B2 (en) | 2012-07-13 | 2018-05-29 | Wave Life Sciences Ltd. | Chiral control |
US10590413B2 (en) | 2012-07-13 | 2020-03-17 | Wave Life Sciences Ltd. | Chiral control |
US10149905B2 (en) | 2014-01-15 | 2018-12-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
US10160969B2 (en) | 2014-01-16 | 2018-12-25 | Wave Life Sciences Ltd. | Chiral design |
US10479995B2 (en) | 2015-07-22 | 2019-11-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
US10450568B2 (en) | 2015-10-09 | 2019-10-22 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
US11407775B2 (en) | 2016-03-13 | 2022-08-09 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
US10724035B2 (en) | 2016-05-04 | 2020-07-28 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
Also Published As
Publication number | Publication date |
---|---|
CN103796657B (en) | 2017-07-11 |
US10280192B2 (en) | 2019-05-07 |
EP2734208A4 (en) | 2015-03-18 |
JP2017141272A (en) | 2017-08-17 |
CN107365339A (en) | 2017-11-21 |
EP3248982A1 (en) | 2017-11-29 |
MX2014000716A (en) | 2014-05-22 |
EP2734208B1 (en) | 2017-03-01 |
AU2012284265A1 (en) | 2014-02-06 |
KR20140068884A (en) | 2014-06-09 |
CA2842358C (en) | 2020-07-14 |
RU2014105311A (en) | 2015-08-27 |
ES2626488T3 (en) | 2017-07-25 |
CA2842358A1 (en) | 2013-01-24 |
WO2013012758A1 (en) | 2013-01-24 |
EP2734208A1 (en) | 2014-05-28 |
IL230522A0 (en) | 2014-03-31 |
IL230522B (en) | 2018-02-28 |
JP6128529B2 (en) | 2017-05-17 |
BR112014001244A2 (en) | 2017-02-21 |
CN103796657A (en) | 2014-05-14 |
US20140194610A1 (en) | 2014-07-10 |
US20180222936A1 (en) | 2018-08-09 |
SG10201700554VA (en) | 2017-03-30 |
JP6490133B2 (en) | 2019-03-27 |
ES2626488T8 (en) | 2017-08-14 |
JP2014522862A (en) | 2014-09-08 |
DK2734208T3 (en) | 2017-06-19 |
HK1198479A1 (en) | 2015-05-08 |
MX347361B (en) | 2017-04-12 |
US9605019B2 (en) | 2017-03-28 |
AU2012284265B2 (en) | 2017-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10280192B2 (en) | Methods for the synthesis of functionalized nucleic acids | |
US9695211B2 (en) | Method for the synthesis of phosphorus atom modified nucleic acids | |
KR101885383B1 (en) | Novel nucleic acid prodrugs and methods of use thereof | |
JP4865544B2 (en) | Method for producing highly stereoregular ribonucleotide analogs and deoxyribonucleotide analogs | |
CN103889999A (en) | Ionic tags for synthesis of oligoribonucleotides | |
AU2015255202B2 (en) | Novel nucleic acid prodrugs and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: WAVE LIFE SCIENCES LTD., SINGAPORE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VERDINE, GREGORY L.;., MEENA;IWAMOTO, NAOKI;AND OTHERS;SIGNING DATES FROM 20161213 TO 20161214;REEL/FRAME:041373/0649 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |